{
    "paper_id": "0b7554b66935a95270f6e8cd480e4ce82c09ceb7",
    "metadata": {
        "title": "The epidemiology, management, and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: Protocol for an observational study series",
        "authors": [
            {
                "first": "Matthew",
                "middle": [],
                "last": "Harries",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Abby",
                "middle": [
                    "E"
                ],
                "last": "Macbeth",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Norwich University Hospitals NHS Foundation Trust",
                    "location": {
                        "settlement": "Norwich",
                        "country": "UK"
                    }
                },
                "email": ""
            },
            {
                "first": "Susan",
                "middle": [],
                "last": "Holmes",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Elizabeth University Hospital",
                    "location": {
                        "settlement": "Glasgow",
                        "region": "Queen",
                        "country": "UK"
                    }
                },
                "email": ""
            },
            {
                "first": "Andrew",
                "middle": [
                    "R"
                ],
                "last": "Thompson",
                "suffix": "",
                "affiliation": {
                    "laboratory": "South Wales Clinical Psychology Training Programme",
                    "institution": "Cardiff University",
                    "location": {
                        "addrLine": "11th Floor, Tower Building, 70 Park Place Cardiff",
                        "postCode": "CF10 3AT, SE1 9RT",
                        "settlement": "London, London",
                        "country": "Wales, UK"
                    }
                },
                "email": ""
            },
            {
                "first": "William",
                "middle": [],
                "last": "Romero Gallardo",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Andrew",
                "middle": [
                    "G"
                ],
                "last": "Messenger",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Christos",
                "middle": [],
                "last": "Tziotzios",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Simon",
                "middle": [],
                "last": "De Lusignan",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Oxford",
                    "location": {
                        "settlement": "London",
                        "country": "UK; Royal, UK, UK"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "UK; the common in infections to be explored are all regularly monitored conditions within the network. \uf0b7 A limitation of the study is that a validated case definition of AA is not available for primary care databases; this will be mitigated by additional analysis to explore the sensitivity of findings when non-specific alopecia diagnostic codes (e.g. unspecified alopecia) are included.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "on the quality of infections recording the quality of recording of these infection events higher in this network than other data sources.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "An ontological approach to detecting cases of AA and associated comorbidities will improve accuracy compared to the use of diagnostic codes alone.(69) Exclusion of individuals with potentially confounding conditions (i.e. other causes of hair loss) will also improve the accuracy of our estimates. The algorithms used to detect common mental health conditions have been previously validated in UK primary care. The completeness of GP data coding for prescriptions, referrals and issue of Med 3 certificates will ensure that our findings on AA and comorbidity management are robust and reliable, and the \"episode typing\" functionality of the RCGP RSC database will ensure incident and prevalent cases are appropriately assigned. The RCGP RSC database has been shown to be a representative sample of",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Alopecia Areata (AA) is a common cause of immune-mediated non-scarring hair loss. Links between AA and common mental health, autoimmune and atopic conditions, and common infections have previously been described but remain incompletely elucidated and contemporary descriptions of the epidemiology of AA in the UK are lacking.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Retrospective study series using a large population-based cohort (5. In the epidemiology theme, we will describe the incidence and prevalence of AA overall and by age, sex, and sociodemographic factors. Healthcare utilisation (primary care visits and secondary care referrals) and treatments for AA will also be assessed. In the mental health theme, we will describe the prevalence and incidence of mental-health conditions (anxiety, depressive episodes, recurrent depressive disorder, adjustment disorder, agoraphobia, self-harm, and parasuicide) in people with AA compared with matched controls. We will also explore mental health treatment patterns ( ",
            "cite_spans": [
                {
                    "start": 652,
                    "end": 653,
                    "text": "(",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Methods and analysis:"
        },
        {
            "text": "\uf0b7 We will use a nationally representative primary care database of over 5.2 million people to explore the epidemiology of alopecia areata (AA), as well as associations of AA with mental health conditions, autoimmune and atopic conditions, and common infections. \uf0b7 As national guidelines recommend initial assessment and management of AA is undertaken in primary care, this study will provide an accurate contemporary analysis of AA epidemiology in England in both children and adults. \uf0b7 The Oxford-RCGP-RSC primary care dataset has a high level of completeness on sociodemographic and geographic data and therefore enables an assessment of variation in the incidence and prevalence of AA across England. \uf0b7 Oxford-RCGP-RSC is the primary infectious disease sentinel network for the (1) Clinical presentations of AA are heterogeneous, ranging from welldemarcated patches of hair loss on the scalp to total loss of hair on the scalp (alopecia areata totalis) or entire scalp and body (alopecia areata universalis). (2) Active AA is estimated to affect approximately 0.1-0.2% (2, 3) of the population worldwide, with a lifetime risk of 1.0-2.1%. (4) (5) (6) Following the initial episode, the majority of those with limited patchy AA will experience spontaneous remission, but over 80% will have subsequent relapses.(7) Spontaneous remission has been reported to occur in less than 10% of those with extensive AA.(7) A number of treatment options can induce hair growth in people with AA, but none have been shown to have a durable impact on remission. (8) AA has been associated with a number of autoimmune conditions, supporting the theory of an underlying autoimmune aetiology. (9) Atopic conditions and mental health disorders have also been demonstrated to be more common in people with AA, (9) (10) (11) although the temporal relationship between psychiatric conditions and AA remains poorly researched. (12) The association between AA and common infections is not well studied.",
            "cite_spans": [
                {
                    "start": 1012,
                    "end": 1015,
                    "text": "(2)",
                    "ref_id": null
                },
                {
                    "start": 1072,
                    "end": 1075,
                    "text": "(2,",
                    "ref_id": null
                },
                {
                    "start": 1076,
                    "end": 1078,
                    "text": "3)",
                    "ref_id": null
                },
                {
                    "start": 1142,
                    "end": 1145,
                    "text": "(4)",
                    "ref_id": null
                },
                {
                    "start": 1146,
                    "end": 1149,
                    "text": "(5)",
                    "ref_id": null
                },
                {
                    "start": 1150,
                    "end": 1153,
                    "text": "(6)",
                    "ref_id": null
                },
                {
                    "start": 1549,
                    "end": 1552,
                    "text": "(8)",
                    "ref_id": null
                },
                {
                    "start": 1677,
                    "end": 1680,
                    "text": "(9)",
                    "ref_id": null
                },
                {
                    "start": 1792,
                    "end": 1795,
                    "text": "(9)",
                    "ref_id": null
                },
                {
                    "start": 1796,
                    "end": 1800,
                    "text": "(10)",
                    "ref_id": null
                },
                {
                    "start": 1801,
                    "end": 1805,
                    "text": "(11)",
                    "ref_id": null
                },
                {
                    "start": 1906,
                    "end": 1910,
                    "text": "(12)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Strengths and limitations of this study"
        },
        {
            "text": "This study series, using a large contemporary population-based sample aims to explore and describe many important elements of AA over four key areas: i) the Clinic-based studies from around the world have estimated the incidence of AA to be in the region of 0.57-3.8%. (14) (15) (16) (17) (18) Worldwide, the majority of studies on AA have not found a significant difference in incidence between males and females. ",
            "cite_spans": [
                {
                    "start": 269,
                    "end": 273,
                    "text": "(14)",
                    "ref_id": null
                },
                {
                    "start": 274,
                    "end": 278,
                    "text": "(15)",
                    "ref_id": null
                },
                {
                    "start": 279,
                    "end": 283,
                    "text": "(16)",
                    "ref_id": null
                },
                {
                    "start": 284,
                    "end": 288,
                    "text": "(17)",
                    "ref_id": null
                },
                {
                    "start": 289,
                    "end": 293,
                    "text": "(18)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Strengths and limitations of this study"
        },
        {
            "text": "It is well-recognised by clinical experts in AA that the condition can have a profound psychological impact and a possible comorbid burden of mental health conditions. A recent USA cross-sectional database study comparing 5,605 patients with AA with matched controls found a higher prevalence of mental health diagnoses in the AA group (32.8% vs 20.0%). (19) In particular, higher rates of 59-15.35) were observed when compared with controls. (19) These findings concur with previous work and a similar pattern is seen in other countries. (20) (21) (22) (23) Recently a British study identified a bi-directional positive association between major depressive disorder and AA. (24) In a sample of over 400,000 participants, major depressive disorder was seen to increase the risk of incident AA by 90% [HR 1.90, 95%CI 1.67-2.15] and AA was found to increase the risk of incident major depressive disorder by 34% [HR 1.34, 95%CI 1. 23-1.46] . (24) The association of other common mental health conditions with AA however was not assessed. 2.08-12.51), psoriasis (HR 2.01; 95%CI 1.06-3.83) and rheumatoid arthritis (RA) (HR 1.79; 95%CI 1.07-3.00) were observed. (27) There was no relationship between AA and Hashimoto's thyroiditis or type 1 diabetes (T1DM). A recent systematic review and meta-analysis found AA to be significantly associated with Graves' Disease (OR 2.07, 95%CI 1.80-2.38) and Hashimoto's Thyroiditis (OR 2.15; 95%CI 1.71-2.72) but not with SLE, RA, Psoriasis or T1DM. (9) There has also been interest in the prevalence of co-morbid atopy in patients with AA. The prevalence of atopy in patients with AA has been reported to be in the range of 11-38.2% (5) representing cohorts from the USA, India and Singapore . (11, 14, 28, 29) A large meta-analysis found patients with AA had higher odds of having atopic dermatitis (OR 2.36; 95%CI 1.80-3.09) or allergic rhinitis (OR 1. conditions, and a genome-wide association study established that IL-13 is also susceptible loci for AA. (30) ",
            "cite_spans": [
                {
                    "start": 354,
                    "end": 358,
                    "text": "(19)",
                    "ref_id": null
                },
                {
                    "start": 390,
                    "end": 399,
                    "text": "59-15.35)",
                    "ref_id": null
                },
                {
                    "start": 443,
                    "end": 447,
                    "text": "(19)",
                    "ref_id": null
                },
                {
                    "start": 539,
                    "end": 543,
                    "text": "(20)",
                    "ref_id": null
                },
                {
                    "start": 544,
                    "end": 548,
                    "text": "(21)",
                    "ref_id": null
                },
                {
                    "start": 549,
                    "end": 553,
                    "text": "(22)",
                    "ref_id": null
                },
                {
                    "start": 554,
                    "end": 558,
                    "text": "(23)",
                    "ref_id": "BIBREF79"
                },
                {
                    "start": 675,
                    "end": 679,
                    "text": "(24)",
                    "ref_id": "BIBREF80"
                },
                {
                    "start": 929,
                    "end": 937,
                    "text": "23-1.46]",
                    "ref_id": null
                },
                {
                    "start": 940,
                    "end": 944,
                    "text": "(24)",
                    "ref_id": "BIBREF80"
                },
                {
                    "start": 1158,
                    "end": 1162,
                    "text": "(27)",
                    "ref_id": "BIBREF82"
                },
                {
                    "start": 1484,
                    "end": 1487,
                    "text": "(9)",
                    "ref_id": null
                },
                {
                    "start": 1668,
                    "end": 1671,
                    "text": "(5)",
                    "ref_id": null
                },
                {
                    "start": 1729,
                    "end": 1733,
                    "text": "(11,",
                    "ref_id": null
                },
                {
                    "start": 1734,
                    "end": 1737,
                    "text": "14,",
                    "ref_id": null
                },
                {
                    "start": 1738,
                    "end": 1741,
                    "text": "28,",
                    "ref_id": "BIBREF83"
                },
                {
                    "start": 1742,
                    "end": 1745,
                    "text": "29)",
                    "ref_id": "BIBREF84"
                },
                {
                    "start": 1994,
                    "end": 1998,
                    "text": "(30)",
                    "ref_id": "BIBREF86"
                }
            ],
            "ref_spans": [],
            "section": "Mental Health Comorbidities"
        },
        {
            "text": "It has been hypothesized that infections may act as triggers for AA; with particular interest in Helicobacter pylori, cytomegalovirus, Epstein-Barr virus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus but others have also been suggested. (9, (31) (32) (33) (34) (35) (36) (37) (38) Some case reports have suggested improvement or resolution of AA with treatment of the associated infection. (33, 39) . However, early small-scale studies have failed to find convincing evidence to support associations. (35, 36, 40) Multiple genetic loci have been identified to be both protective from infection but increase the risk for autoimmune disease. (41) Examples include the HLA variants HLA-DQ2 and HLA-DQ8 which confer protection against viral infections including influenza but are associated with inflammatory bowel disease, (42, 43) and SH2B3 rs3184504*A gene variant protective against Escherichia coli infection but also detrimental for inflammatory bowel disease. (44) These loci which, in the past have conferred a genetic advantage, may still confer a reduced infection risk. (41) It is currently unclear if the genetic predisposition for AA is caused by genetic factors which also confer protection against any common infections. In other autoimmune conditions infection risk is often increased as a result of the pathological changes resulting from the condition itself, the effects of immune-modulatory treatment, or through increased exposure to pathogens through healthcare contact. (45) (46) (47) (48) (49) (50) (51) An understanding of the relative infection rates in people with AA compared to those ",
            "cite_spans": [
                {
                    "start": 263,
                    "end": 266,
                    "text": "(9,",
                    "ref_id": null
                },
                {
                    "start": 267,
                    "end": 271,
                    "text": "(31)",
                    "ref_id": "BIBREF87"
                },
                {
                    "start": 272,
                    "end": 276,
                    "text": "(32)",
                    "ref_id": "BIBREF88"
                },
                {
                    "start": 277,
                    "end": 281,
                    "text": "(33)",
                    "ref_id": "BIBREF89"
                },
                {
                    "start": 282,
                    "end": 286,
                    "text": "(34)",
                    "ref_id": "BIBREF90"
                },
                {
                    "start": 287,
                    "end": 291,
                    "text": "(35)",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 292,
                    "end": 296,
                    "text": "(36)",
                    "ref_id": null
                },
                {
                    "start": 297,
                    "end": 301,
                    "text": "(37)",
                    "ref_id": null
                },
                {
                    "start": 302,
                    "end": 306,
                    "text": "(38)",
                    "ref_id": null
                },
                {
                    "start": 416,
                    "end": 420,
                    "text": "(33,",
                    "ref_id": "BIBREF89"
                },
                {
                    "start": 421,
                    "end": 424,
                    "text": "39)",
                    "ref_id": "BIBREF95"
                },
                {
                    "start": 527,
                    "end": 531,
                    "text": "(35,",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 532,
                    "end": 535,
                    "text": "36,",
                    "ref_id": null
                },
                {
                    "start": 536,
                    "end": 539,
                    "text": "40)",
                    "ref_id": "BIBREF96"
                },
                {
                    "start": 666,
                    "end": 670,
                    "text": "(41)",
                    "ref_id": "BIBREF97"
                },
                {
                    "start": 846,
                    "end": 850,
                    "text": "(42,",
                    "ref_id": "BIBREF98"
                },
                {
                    "start": 851,
                    "end": 854,
                    "text": "43)",
                    "ref_id": "BIBREF99"
                },
                {
                    "start": 989,
                    "end": 993,
                    "text": "(44)",
                    "ref_id": "BIBREF100"
                },
                {
                    "start": 1103,
                    "end": 1107,
                    "text": "(41)",
                    "ref_id": "BIBREF97"
                },
                {
                    "start": 1515,
                    "end": 1519,
                    "text": "(45)",
                    "ref_id": "BIBREF101"
                },
                {
                    "start": 1520,
                    "end": 1524,
                    "text": "(46)",
                    "ref_id": "BIBREF103"
                },
                {
                    "start": 1525,
                    "end": 1529,
                    "text": "(47)",
                    "ref_id": "BIBREF104"
                },
                {
                    "start": 1530,
                    "end": 1534,
                    "text": "(48)",
                    "ref_id": "BIBREF105"
                },
                {
                    "start": 1535,
                    "end": 1539,
                    "text": "(49)",
                    "ref_id": "BIBREF106"
                },
                {
                    "start": 1540,
                    "end": 1544,
                    "text": "(50)",
                    "ref_id": "BIBREF107"
                },
                {
                    "start": 1545,
                    "end": 1549,
                    "text": "(51)",
                    "ref_id": "BIBREF108"
                }
            ],
            "ref_spans": [],
            "section": "Common infections"
        },
        {
            "text": "We aim to perform a series of retrospective studies using a large population-based cohort in England, over a decade (1 st Within the epidemiology theme, our initial objective is to provide a complete description of the incidence and prevalence of AA in England. We will explore the influence of socio-demographic and geographic factors on disease incidence and describe the current service utilisation and management patterns in AA during the year after diagnosis.",
            "cite_spans": [
                {
                    "start": 116,
                    "end": 121,
                    "text": "(1 st",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Aims and Objectives"
        },
        {
            "text": "Within the mental health theme, we will explore the disease burden of common mental health conditions in people with AA compared with matched controls. We will calculate the prevalence of disease at AA diagnosis, the incidence of disease in the first two years after diagnosis and the influence of socio-demographic factors on the prevalence of common mental health conditions in AA. We will describe the mental health treatment burden in people (medication and psychological service use) with AA and depression and anxiety. We will also explore potential associations between AA and both time off work and unemployment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Aims and Objectives"
        },
        {
            "text": "Within the autoimmune and atopic comorbidities theme, we will examine the prevalence of atopic and autoimmune conditions at AA diagnosis, and the incidence Within the common infections theme, we will examine the incidence of multiple common infections in the first five years after diagnosis in people with AA compared with matched controls.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Aims and Objectives"
        },
        {
            "text": "The primary and secondary objects of each study theme are formally described in the Statistical Analysis Plan (Additional file 1). The RCGP RSC database includes patient demographics, diagnoses, laboratory test results, primary care issued prescriptions and processes of care such as clinic visits and specialist referrals. These data are coded using the Read code system. UK general practice records provide several advantages for this study type; UK primary care is a registration-based system (a patient can only register with a single GP), records have been computerised since the 1990s, and pay-forperformance targets (introduced in 2004 through The Quality and Outcomes Framework; QOF) have resulted in consistent high-quality clinical data entry about chronic disease. (54, 55) Studies in many chronic diseases such as atopic dermatitis, rheumatoid arthritis, diabetes, inflammatory bowel disease, and chronic obstructive pulmonary disease have been published using RCGP RSC data. (51, (56) (57) (58) (59) RCGP RSC practices get feedback on their data quality, with a particular ",
            "cite_spans": [
                {
                    "start": 776,
                    "end": 780,
                    "text": "(54,",
                    "ref_id": "BIBREF111"
                },
                {
                    "start": 781,
                    "end": 784,
                    "text": "55)",
                    "ref_id": "BIBREF112"
                },
                {
                    "start": 988,
                    "end": 992,
                    "text": "(51,",
                    "ref_id": "BIBREF108"
                },
                {
                    "start": 993,
                    "end": 997,
                    "text": "(56)",
                    "ref_id": "BIBREF113"
                },
                {
                    "start": 998,
                    "end": 1002,
                    "text": "(57)",
                    "ref_id": "BIBREF114"
                },
                {
                    "start": 1003,
                    "end": 1007,
                    "text": "(58)",
                    "ref_id": null
                },
                {
                    "start": 1008,
                    "end": 1012,
                    "text": "(59)",
                    "ref_id": "BIBREF115"
                }
            ],
            "ref_spans": [],
            "section": "Aims and Objectives"
        },
        {
            "text": "Within RCGP RSC, people with and without AA will be identified using Read diagnostic codes. A range of study designs will be used across the studies and include; repeated cross-sectional design (epidemiology of AA), case-control design (the prevalence of common mental health conditions, atopic and autoimmune conditions, and common infections at AA diagnosis), and matched-cohort design (the incidence of common mental health conditions, atopic and autoimmune conditions, and common infections after AA diagnosis).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study design"
        },
        {
            "text": "We will identify cases of AA using specific diagnostic codes (Supplementary Table   S1 .1, Additional file 2). Confirmed AA will be defined as one or more AA code and no alternative diagnostic code in the subsequent 365 days (alternative diagnoses are defined in Supplementary Table S1.1, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 61,
                    "end": 86,
                    "text": "(Supplementary Table   S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Alopecia areata case detection"
        },
        {
            "text": "For sensitivity analyses we will also extract alopecia recorded where the type has not been specified (Supplementary Table S1 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 102,
                    "end": 125,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Alopecia areata case detection"
        },
        {
            "text": "The incidence and lifetime prevalence of alopecia areata",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1: Epidemiology of alopecia areata"
        },
        {
            "text": "We will describe the incidence and point prevalence of AA over [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] [2017] [2018] inclusive, by age group, sex, ethnicity, and socioeconomic status, and geographical region. Ethnicity will be categorised as follows based on UK census categories:",
            "cite_spans": [
                {
                    "start": 63,
                    "end": 69,
                    "text": "[2009]",
                    "ref_id": null
                },
                {
                    "start": 70,
                    "end": 76,
                    "text": "[2010]",
                    "ref_id": null
                },
                {
                    "start": 77,
                    "end": 83,
                    "text": "[2011]",
                    "ref_id": null
                },
                {
                    "start": 84,
                    "end": 90,
                    "text": "[2012]",
                    "ref_id": null
                },
                {
                    "start": 91,
                    "end": 97,
                    "text": "[2013]",
                    "ref_id": null
                },
                {
                    "start": 98,
                    "end": 104,
                    "text": "[2014]",
                    "ref_id": null
                },
                {
                    "start": 105,
                    "end": 111,
                    "text": "[2015]",
                    "ref_id": null
                },
                {
                    "start": 112,
                    "end": 118,
                    "text": "[2016]",
                    "ref_id": null
                },
                {
                    "start": 119,
                    "end": 125,
                    "text": "[2017]",
                    "ref_id": null
                },
                {
                    "start": 126,
                    "end": 132,
                    "text": "[2018]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Study 1: Epidemiology of alopecia areata"
        },
        {
            "text": "White, Asian, Black African/Caribbean, Mixed, and Other.(61) Index of multiple deprivation (IMD) will be used as a measure of socioeconomic status. (62) Service utilisation in people with alopecia areata",
            "cite_spans": [
                {
                    "start": 148,
                    "end": 152,
                    "text": "(62)",
                    "ref_id": "BIBREF117"
                }
            ],
            "ref_spans": [],
            "section": "Study 1: Epidemiology of alopecia areata"
        },
        {
            "text": "We will assess primary care visit frequency, up to one year, in people newly diagnosed with AA compared to matched controls without AA. Measures of healthcare management will also be assessed in people newly diagnosed with AA up to one year, comprising; secondary care dermatology referrals (Supplementary   Table S1 .3, Additional file 2) and primary care prescriptions for AA treatments (Supplementary Table S1 .4, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 291,
                    "end": 316,
                    "text": "(Supplementary   Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 389,
                    "end": 412,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Study 1: Epidemiology of alopecia areata"
        },
        {
            "text": "We will assess the prevalence and incidence of three common mental conditions as To assess prevalence, we will perform a case-control analysis to compare the prevalence of mental health conditions between people newly diagnosed with AA and controls. To assess incidence, we will perform a matched cohort analysis in the subset of cases and controls free of the mental health conditions of interest at baseline. In addition, we will examine the prevalence and incidence of other mental health conditions; adjustment disorder, agoraphobia, self-harm, and overdose/parasuicide attempts (Supplementary Tables S2.5-S2.9, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2: Mental Health conditions in people with alopecia areata"
        },
        {
            "text": "We will determine the treatment burden of mental health medications in AA (selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, tetracyclic antidepressants, and monoamine oxidase inhibitors, anxiolytic medications) and psychological intervention (referral rates for counselling, secondary care psychiatrist referrals, including the referrals to the clinical psychology services/specialists and UK Improving Access to Table S2 .10, Additional file 2)).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 482,
                    "end": 490,
                    "text": "Table S2",
                    "ref_id": null
                }
            ],
            "section": "Study 2: Mental Health conditions in people with alopecia areata"
        },
        {
            "text": "We will also assess unemployment and time off work in people of working age . Unemployment will be identified using codes relating to unemployment recorded in the clinical record or the issuing of IB113 or ESA113 form (Supplementary Table S3 .1, Additional file 2). These forms are completed by GPs when their patients are accessing incapacity benefits (historically) or employment and support allowance (current) because of a disability or health condition affecting their ability to work. Time off work will be assessed by reporting the rates of issue of Med 3 (Statement of Fitness for Work) certification from primary care (Supplementary Table S3 .2, Additional file 2). These \"fit notes\" are required by employers when employees have periods of absence from work for sickness lasting longer than seven days.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 218,
                    "end": 241,
                    "text": "(Supplementary Table S3",
                    "ref_id": null
                },
                {
                    "start": 627,
                    "end": 650,
                    "text": "(Supplementary Table S3",
                    "ref_id": null
                }
            ],
            "section": "Study 2: Mental Health conditions in people with alopecia areata"
        },
        {
            "text": "We will assess the prevalence and incidence of autoimmune and atopic conditions as listed in Table 1 and defined in Supplementary Tables S4, Additional file 2, in people with AA. To assess prevalence, we will perform a case-control study to compare the prevalence of these conditions between cases and controls. To assess incidence, we will perform a matched cohort study to compare the incidence of new autoimmune and atopic conditions in the same cases and controls after the point of matching. Autoimmune and atopic conditions were included if prevalence has been reported to be 0.3% or greater. (9, (64) (65) (66) (67) This cut-off was based on power calculations suggesting this is minimum background prevalence required to detect ",
            "cite_spans": [
                {
                    "start": 599,
                    "end": 602,
                    "text": "(9,",
                    "ref_id": null
                },
                {
                    "start": 603,
                    "end": 607,
                    "text": "(64)",
                    "ref_id": null
                },
                {
                    "start": 608,
                    "end": 612,
                    "text": "(65)",
                    "ref_id": null
                },
                {
                    "start": 613,
                    "end": 617,
                    "text": "(66)",
                    "ref_id": "BIBREF121"
                },
                {
                    "start": 618,
                    "end": 622,
                    "text": "(67)",
                    "ref_id": "BIBREF122"
                }
            ],
            "ref_spans": [
                {
                    "start": 93,
                    "end": 162,
                    "text": "Table 1 and defined in Supplementary Tables S4, Additional file 2, in",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Study 3: Autoimmune and atopic comorbidities in alopecia areata"
        },
        {
            "text": "We will assess the incidence of common infections in people with AA using a matched cohort study to compare the incidence of common infections in cases and controls. The common infections to be examined are listed in Table 2 and defined in Supplementary Tables S5, Additional file 2.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 217,
                    "end": 224,
                    "text": "Table 2",
                    "ref_id": null
                }
            ],
            "section": "Study 4: common infections in alopecia areata"
        },
        {
            "text": "The full statistical analysis plan is provided in Additional file 1. Briefly, for Study 1, AA prevalence will be calculated by dividing the number of AA cases by the total number of eligible people in the study population. Point prevalence will be reported for the cohort overall and stratified by sex and age. AA incidence will be calculated by dividing the total number of new AA cases by the total person-years of follow-up. Incidence rates will be stratified by calendar year, socio-demographic factors (age group, sex, ethnicity, rural/urban classification and socioeconomic status) and geographical region. Adjusted incidence rates will be estimated using Poisson regression.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical methods"
        },
        {
            "text": "Service utilisation (Study 1 and 2) will be evaluated by calculation of annual primary care attendance rates, treatment rates (prescriptions per person per year), and the total proportion of people with one or more referral for additional services For studies 1 (for comparison of primary care visit frequency only), 2 and 3, matching will be performed as follows: control cohorts will be defined by matching cases with people without a diagnosis of AA or other alopecia. The follow-up period for each matched control will begin at the start of follow-up of their matched case.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical methods"
        },
        {
            "text": "Each case will be nearest neighbour matched with four controls by age and sex within GP practices. After matching, if there are substantial differences in socioeconomic status between cases and controls, re-matching with IMD as an additional matching criterion will be considered. Study 4 will use the same nearest neighbour matching process but cases will be defined as people diagnosed with AA on or before 1 st January 2014, people who develop AA during follow up will be excluded from the pool of available controls prior to matching.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical methods"
        },
        {
            "text": "For Study 2, we will report the prevalence of mental health conditions by sociodemographic subgroups in cases and controls. The burden of treatment for mental health conditions will be estimated as the total proportion of people prescribed each treatment within one year after the study start. The burden of sick days will be estimated as the total proportion of people issued a Med 3 certificate. To assess differences in incident mental health conditions in the two years after the study start, we will use adjusted Cox regression stratified by case/control status. Study 3 (atopic and autoimmune conditions) will similarly compare baseline disease prevalence in cases and controls, and compare incidence of new onset conditions in the five years after the study start using adjusted Cox regression. Infection incidence rates will be estimated by dividing the number of incident common infections by total person-years of follow-up. Adjusted Poisson regression will be used to estimate the association between AA and rates of common infection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical methods"
        },
        {
            "text": "We will compare prevalence (Studies 2-3) and incidence (Studies 2-4) of the study outcomes in people with non-specific alopecia codes only (i.e. no prior or subsequent codes specifying alopecia type).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sensitivity analyses"
        },
        {
            "text": "In Study 4, we will use a Cox regression to estimate time to first infection. We will also compare the results of the study outcomes when 1) people who develop AA during the follow up are included as cases and 2) when we perform matching using the time of AA diagnosis and follow for up to five years after diagnosis (or matched date for controls).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sensitivity analyses"
        },
        {
            "text": "Individual patient data will be anonymised at the point of data extraction. All data will remain in anonymised form and will be held on a secure server at the University of Surrey. All statistical analyses will be performed using R software. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data management"
        },
        {
            "text": "Results derived from this study will be useful in monitoring trends in the incidence of AA in England and may identify factors that influence the disease distribution and treatment patterns. Furthermore, obtaining an accurate picture of the state of AA in the UK will help inform Health Needs Assessments and policy development.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Clinical Implications"
        },
        {
            "text": "A greater understanding of the prevalence of mental health conditions associated with AA and the directionality of these relationships may help with the development of psychological interventions in AA, as the approach required would likely differ if the symptoms patients are experiencing are pervasive or reactive to an episode of hair loss. (12, 68) Awareness of AA as a potential risk factor or associated comorbidity for certain autoimmune and atopic conditions may help reduce delays in diagnosis for these conditions and increase vigilance of GPs and dermatologists when reviewing their patients with AA in detecting co-existent conditions. Future work may focus upon whether improved control of an underlying autoimmune or atopic condition may improve chances of achieving remission in AA. ",
            "cite_spans": [
                {
                    "start": 344,
                    "end": 348,
                    "text": "(12,",
                    "ref_id": null
                },
                {
                    "start": 349,
                    "end": 352,
                    "text": "68)",
                    "ref_id": "BIBREF123"
                }
            ],
            "ref_spans": [],
            "section": "Clinical Implications"
        },
        {
            "text": "Several strengths of our study design are noteworthy. Only two previous studies on the incidence and prevalence of AA have been population-based, with the vast majority being conducted on clinic patients and thus leading to skewed prevalence estimates. This study will also provide a contemporary picture of the burden of AA, as the previous population-based studies were over 20 years ago, and this will be the first AA epidemiology study conducted in the UK. To our knowledge, our study examining common infections will be the first study to attempt to answer the question of whether AA confers protection or increased risk for common infections.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Strengths and limitations of the research methods"
        },
        {
            "text": "A final key strength of this study is the use of the national infections surveillance network to analyse infection risk; with regular feedback to practices with a focus (53) and hence our results are broadly generalisable to the UK as a whole but should not be extended to populations which are dissimilar.",
            "cite_spans": [
                {
                    "start": 169,
                    "end": 173,
                    "text": "(53)",
                    "ref_id": "BIBREF110"
                }
            ],
            "ref_spans": [],
            "section": "Strengths and limitations of the research methods"
        },
        {
            "text": "There are also several limitations of the study design that are worthy of consideration. This study does not attempt to detect cases of AA (or the comorbidities of interest) that do not present to medical attention and hence may underestimate the true burden of disease. Furthermore, only coded data in the database can be used and hence we rely upon accurate coding. Some individuals may need to be excluded due to incomplete data, although in similar studies the exclusion rate due to incomplete data has been low. (70, 71) Prevalence of Med 3 certification is well captured in primary care but the reason for issue is not available meaning that we cannot identify the condition relating to the Med 3 certification. We cannot therefore determine whether the sick leave was as a result of AA. However, our case-control approach will provide a method for comparing Med 3 certificate issue rates in those affected and unaffected by AA. The use of Read codes to identify unemployment is likely to systemically underestimate unemployment prevalence but is likely to be suitable for providing a comparison with controls.",
            "cite_spans": [
                {
                    "start": 517,
                    "end": 521,
                    "text": "(70,",
                    "ref_id": null
                },
                {
                    "start": 522,
                    "end": 525,
                    "text": "71)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Strengths and limitations of the research methods"
        },
        {
            "text": "Another limitation is the possibility of missing treatment information from secondary care. Secondary care records in the UK are frequently not computerised and prescriptions are still commonly hand-written. At present there is no mechanism for universally capturing secondary care prescriptions and linking them to primary care records. We are therefore likely to underestimate prescription rates for those with the most severe disease who are seen frequently in secondary care. Where prescriptions are issued from primary care the indication for the prescription is not available and we can therefore not confirm that the prescription is for the treatment of AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Strengths and limitations of the research methods"
        },
        {
            "text": "We plan to publish the final study results in peer-reviewed journals and present early findings at scientific meetings.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Plans for dissemination"
        },
        {
            "text": "This study series aims to provide the first large scale population-based analysis of the epidemiology of AA in the UK and the current patterns of healthcare utilisation and treatments in this group. We also aim to provide an extensive assessment of the association between common mental health conditions and work-related difficulties in people with AA; reporting the prevalence and incidence of these conditions in people with new onset AA and matched controls. We aim to provide an extensive evaluation of the prevalence and incidence of autoimmune and atopic conditions in people with new onset AA and matched controls. Finally, we aim to provide evidence for baseline common infection risk in people with AA which can be used to support treatment decisions regarding the use of immune-modulating medications for AA. This study series will extend our knowledge of the current disease burden from AA and associated conditions. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "The design of this protocol did not involve patients or this public.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Declarations Patient and Public Involvement statement"
        },
        {
            "text": "The study does not require formal research ethics committee (REC) approval as it will use anonymised routinely collected healthcare data; as defined by the NHS Health Research Authority research decision tool (http://www.hradecisiontools.org.uk/research/) and the University of Surrey own Self-Assessment for Governance and Ethics (SAGE) tool. No patient identifiable information will be available to researchers. All participating practices display information to patients regarding data use through the RCGP RSC network. All patients who choose to opt out of data sharing do not have their data processed as part of RCGP RSC research studies. Approval for data access and use was granted by the RCGP and RSC Research Committee.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics approval and dissemination"
        },
        {
            "text": "Not applicable ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Consent for publication"
        },
        {
            "text": "The RCGP RSC dataset can be accessed by bone fide researchers, approval is on a project-by-project basis (www.rcgp.org.uk/rsc). Researchers wishing to directly analyse the patient-level pseudonymised data will be required to complete information governance training and work on the data from the secure servers at the University of Surrey or University of Oxford. Patient-level data cannot be taken out of the secure networks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Availability of data and materials"
        },
        {
            "text": "SdeL is Director of RCGP RSC, he has received funding for projects from Eli Lilly, ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Competing interests"
        },
        {
            "text": "This research was sponsored and funded by Pfizer (grant number N/A).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Funding statement"
        },
        {
            "text": "The study was designed and developed by CT, MH, SH, ART, AEM, WSC, WRG, and AGM with input from SdeL. The protocol writing was directed and critically reviewed by CT, MH, SH, ART, AEM, WSC, WRG, SdeL, and AGM. Tables   Table 1. The autoimmune and atopic conditions to be explored. For full  definitions see Supplementary Tables S4.1 -S4. 16 Table 2 . The common infections to be explored. *Inclusion of COVID-19 will depend on data availability.",
            "cite_spans": [
                {
                    "start": 338,
                    "end": 340,
                    "text": "16",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 210,
                    "end": 337,
                    "text": "Tables   Table 1. The autoimmune and atopic conditions to be explored. For full  definitions see Supplementary Tables S4.1 -S4.",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 341,
                    "end": 348,
                    "text": "Table 2",
                    "ref_id": null
                }
            ],
            "section": "Authors' contributions"
        },
        {
            "text": "All infections of the upper respiratory tract including rhinitis, pharyngitis, sinusitis, and the common cold Lower respiratory tract infection All infection of the lower respiratory tract including pneumonia and acute bronchitis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Infection Description Upper respiratory tract infection"
        },
        {
            "text": "A subgroup of LRTI consisting of bacterial and viral pneumonias Acute bronchitis A subgroup of LRTI consisting of inflammation of the large and medium airways usually of viral origin Influenza",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pneumonia"
        },
        {
            "text": "Confirmed cases of influenza and cases of influenza-like illness",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Pneumonia"
        },
        {
            "text": "Infections of the urinary tract including cystitis and pyelonephritis",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Skin infection Cellulitis and other infective skin conditions Urinary tract infection"
        },
        {
            "text": "All infections of the genital tract including sexually transmitted infections and nonsexually transmitted infections",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Genital infections"
        },
        {
            "text": "All infections of the gastrointestinal tract including gastroenteritis Herpes simplex",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Gastrointestinal infection"
        },
        {
            "text": "Infections caused by the varicella-zoster virus Meningitis",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Mucocutaneous infections caused but herpes simplex viruses Herpes zoster"
        },
        {
            "text": "All infections, bacterial or viral, causing meningitis COVID- 19 Confirmed or clinically diagnosed COVID-19* ",
            "cite_spans": [
                {
                    "start": 62,
                    "end": 64,
                    "text": "19",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Mucocutaneous infections caused but herpes simplex viruses Herpes zoster"
        },
        {
            "text": "Alopecia areata (AA) is a common cause of immune-mediated, non-scarring hair loss. (1) Clinical presentations of AA are heterogeneous, ranging from well-demarcated patches of hair loss on the scalp to total loss of hair on the scalp (alopecia areata totalis) or entire scalp and body (alopecia areata universalis). (2) Active AA is estimated to affect approximately 0.1-0.2% (2, 3) of the population worldwide, with a lifetime risk of 1.0 -2.1%. (4) (5) (6) Following the initial episode, the majority of those with limited patchy AA will experience spontaneous remission, but over 80% will have subsequent relapses. (7) Spontaneous remission has been reported to occur in less than 10% of those with extensive AA. (7) A number of treatment options can induce hair growth in people with AA, but none have been shown to have a durable impact on remission. (8) AA has been associated with several autoimmune conditions supporting the theory of an underlying autoimmune aetiology. (9, 10) Atopic conditions and mental health disorders have also been demonstrated to be more common in people with AA, (9) (10) (11) although the temporal relationship between psychiatric conditions and AA remains poorly researched. (12) The association between AA and common infections is not well studied.",
            "cite_spans": [
                {
                    "start": 83,
                    "end": 86,
                    "text": "(1)",
                    "ref_id": "BIBREF125"
                },
                {
                    "start": 315,
                    "end": 318,
                    "text": "(2)",
                    "ref_id": null
                },
                {
                    "start": 375,
                    "end": 378,
                    "text": "(2,",
                    "ref_id": null
                },
                {
                    "start": 379,
                    "end": 381,
                    "text": "3)",
                    "ref_id": null
                },
                {
                    "start": 446,
                    "end": 449,
                    "text": "(4)",
                    "ref_id": null
                },
                {
                    "start": 450,
                    "end": 453,
                    "text": "(5)",
                    "ref_id": null
                },
                {
                    "start": 454,
                    "end": 457,
                    "text": "(6)",
                    "ref_id": null
                },
                {
                    "start": 855,
                    "end": 858,
                    "text": "(8)",
                    "ref_id": null
                },
                {
                    "start": 978,
                    "end": 981,
                    "text": "(9,",
                    "ref_id": null
                },
                {
                    "start": 982,
                    "end": 985,
                    "text": "10)",
                    "ref_id": null
                },
                {
                    "start": 1097,
                    "end": 1100,
                    "text": "(9)",
                    "ref_id": null
                },
                {
                    "start": 1101,
                    "end": 1105,
                    "text": "(10)",
                    "ref_id": null
                },
                {
                    "start": 1106,
                    "end": 1110,
                    "text": "(11)",
                    "ref_id": null
                },
                {
                    "start": 1211,
                    "end": 1215,
                    "text": "(12)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Background"
        },
        {
            "text": "This statistical analysis plan covers four related AA studies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Purposes of analyses"
        },
        {
            "text": "Population studies in the USA using the Rochester Epidemiology Project database estimate the lifetime risk of AA to be 2.1%. (4) The database contained information from all patients registered with a healthcare provider in Olmstead County, Minnesota from 1990-2009. Previous studies using this database from 1971-1974 estimated the overall prevalence of AA to be 0.1-0.2%, (13) with no published studies reporting prevalence estimates since this. Other epidemiological studies have assessed the incidence of AA in patients referred to dermatology services. Clinic-based studies from around the world have estimated the incidence of AA to be in the region of 0.57-3.8%. (14) (15) (16) (17) (18) Worldwide, the majority of studies on AA have not found a significant difference in incidence between males and females. (5) AA onset occurs before the age of 40 in 82-86% of cases. (5) To date, there have been no large population-based studies of AA epidemiology in UK populations.",
            "cite_spans": [
                {
                    "start": 125,
                    "end": 128,
                    "text": "(4)",
                    "ref_id": null
                },
                {
                    "start": 373,
                    "end": 377,
                    "text": "(13)",
                    "ref_id": null
                },
                {
                    "start": 669,
                    "end": 673,
                    "text": "(14)",
                    "ref_id": null
                },
                {
                    "start": 674,
                    "end": 678,
                    "text": "(15)",
                    "ref_id": null
                },
                {
                    "start": 679,
                    "end": 683,
                    "text": "(16)",
                    "ref_id": null
                },
                {
                    "start": 684,
                    "end": 688,
                    "text": "(17)",
                    "ref_id": null
                },
                {
                    "start": 689,
                    "end": 693,
                    "text": "(18)",
                    "ref_id": null
                },
                {
                    "start": 876,
                    "end": 879,
                    "text": "(5)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Study 1: Epidemiology of AA"
        },
        {
            "text": "It is well recognised by clinical experts in AA that the condition can have a profound psychological impact and a possible comorbid burden of mental health conditions. A recent USA cross-sectional database study comparing 5,605 patients with AA with matched controls found a higher prevalence of mental health diagnoses in the AA group (32.8% vs 20.0%). (19) In particular, higher rates of depression ( 59-15.35) were observed when compared with controls. (19) These findings concur with previous work and a similar pattern is seen in other countries. (20) (21) (22) (23) Recently a British study identified a bi-directional positive association between major depressive disorder and AA. (24) In a sample of over 400,000 participants, major depressive disorder was seen to increase the risk of incident AA by 90% [HR 1.90, 95%CI 1. 67-2.15] and AA was found to increase the risk of incident major depressive disorder by 34% [HR 1.34, 95%CI 1. 23-1.46] . (24) The association of other common mental health conditions with AA however was not assessed.",
            "cite_spans": [
                {
                    "start": 354,
                    "end": 358,
                    "text": "(19)",
                    "ref_id": null
                },
                {
                    "start": 401,
                    "end": 402,
                    "text": "(",
                    "ref_id": null
                },
                {
                    "start": 403,
                    "end": 412,
                    "text": "59-15.35)",
                    "ref_id": null
                },
                {
                    "start": 456,
                    "end": 460,
                    "text": "(19)",
                    "ref_id": null
                },
                {
                    "start": 552,
                    "end": 556,
                    "text": "(20)",
                    "ref_id": null
                },
                {
                    "start": 557,
                    "end": 561,
                    "text": "(21)",
                    "ref_id": null
                },
                {
                    "start": 562,
                    "end": 566,
                    "text": "(22)",
                    "ref_id": null
                },
                {
                    "start": 567,
                    "end": 571,
                    "text": "(23)",
                    "ref_id": "BIBREF79"
                },
                {
                    "start": 688,
                    "end": 692,
                    "text": "(24)",
                    "ref_id": "BIBREF80"
                },
                {
                    "start": 832,
                    "end": 840,
                    "text": "67-2.15]",
                    "ref_id": null
                },
                {
                    "start": 943,
                    "end": 951,
                    "text": "23-1.46]",
                    "ref_id": null
                },
                {
                    "start": 954,
                    "end": 958,
                    "text": "(24)",
                    "ref_id": "BIBREF80"
                }
            ],
            "ref_spans": [],
            "section": "Study 2: Mental health comorbidities in patients with AA"
        },
        {
            "text": "A central theory in AA pathogenesis is that it is an autoimmune phenomenon resulting from a disruption of hair follicle 'immune privilege', where numerous immunological mechanisms fail to prevent cytotoxic immune attack on cells and antigens present at that site. (25) A number of studies have reported autoimmune conditions to occur more frequently in those with AA than in the general population, however results are conflicting, and studies have been limited by potential recruiting, recall and reporting biases. ( (27) There was no relationship between AA and Hashimoto's thyroiditis or type 1 diabetes (T1DM). A large USA crosssectional study of 3,658 individuals with AA, found that 14.6% had a diagnosis of thyroid disease, 11.1% had T1DM, 4.3% had inflammatory bowel disease, 2.8% had vitligo and 6.3% had psoriasis. (10) These figures were all higher than would be expected in the general population. A recent systematic review and meta-analysis found AA to be significantly associated with Graves' Disease (OR 2.07, 95%CI 1.80-2.38) and Hashimoto's Thyroiditis (OR 2.15; 95%CI 1.71-2.72) but not with SLE, RA, Psoriasis or T1DM. (9) There has also been interest in the prevalence of co-morbid atopy in patients with AA. The prevalence of atopy in patients with AA has been reported to be in the range of 11-38.2% (5) representing cohorts from the USA, India and Singapore. (10, 14, 28, 29) A large metaanalysis found patients with AA had higher odds of having atopic dermatitis (OR 2.36; 95%CI 1.80-3.09) and allergic rhinitis (OR 1.33;95%CI 1.19-1.47) when compared with controls. (9) It is not however surprising from a pathogenesis perspective in terms of shared pathways of autoimmune susceptibility; IL-13 loci have been associated with autoimmune and atopic conditions, and a genome-wide association study established that IL-13 is also susceptible loci for AA. (30)",
            "cite_spans": [
                {
                    "start": 516,
                    "end": 517,
                    "text": "(",
                    "ref_id": null
                },
                {
                    "start": 518,
                    "end": 522,
                    "text": "(27)",
                    "ref_id": "BIBREF82"
                },
                {
                    "start": 1139,
                    "end": 1142,
                    "text": "(9)",
                    "ref_id": null
                },
                {
                    "start": 1323,
                    "end": 1326,
                    "text": "(5)",
                    "ref_id": null
                },
                {
                    "start": 1383,
                    "end": 1387,
                    "text": "(10,",
                    "ref_id": null
                },
                {
                    "start": 1388,
                    "end": 1391,
                    "text": "14,",
                    "ref_id": null
                },
                {
                    "start": 1392,
                    "end": 1395,
                    "text": "28,",
                    "ref_id": "BIBREF83"
                },
                {
                    "start": 1396,
                    "end": 1399,
                    "text": "29)",
                    "ref_id": "BIBREF84"
                }
            ],
            "ref_spans": [],
            "section": "Study 3: Autoimmune and atopic conditions in people with AA"
        },
        {
            "text": "It has been hypothesized that infections may act as triggers for AA; with particular interest in Helicobacter pylori, cytomegalovirus, Epstein-Barr virus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus but others have also been suggested. (9, (31) (32) (33) (34) (35) (36) (37) (38) Some case reports has suggested improvement or resolution of AA with treatment of the associated infection. (33, 39) . However, early small-scale studies have failed to find convincing evidence to support associations. (35, 36, 40) Multiple genetic loci have been identified to be both protective from infection but increase the risk for autoimmune disease. (41) Examples include the HLA variants HLA-DQ2 and HLA-DQ8 which confer protection against viral infections including influenza but are associated with inflammatory bowel disease, (42, 43) and SH2B3 rs3184504*A gene variant protective against Escherichia coli infection but also detrimental for inflammatory bowel disease. (44) These loci which, in the past have conferred a genetic advantage, may still confer a reduced infection risk. (41) It is currently unclear if the genetic predisposition for AA is caused by genetic factors which also confer protection against any common infections. In other autoimmune conditions, infection risk is often increased as a result of the pathological changes resulting from the condition itself, the effects of immune-modulatory treatment, or through increased exposure to pathogens through healthcare contact. (45) (46) (47) (48) (49) (50) (51) An understanding of the relative infection rates in people with AA compared to those without is of particular importance with the emergence of Janus kinase inhibitors as a potential treatment option. (52) Whilst this medication class can produce impressive hair regrowth results even in long-standing, AA their use is associated with some increased infection risk; in particular, urinary tract infections, viral gastroenteritis fungal infections, and varicella zoster infection. (52) ",
            "cite_spans": [
                {
                    "start": 263,
                    "end": 266,
                    "text": "(9,",
                    "ref_id": null
                },
                {
                    "start": 267,
                    "end": 271,
                    "text": "(31)",
                    "ref_id": "BIBREF87"
                },
                {
                    "start": 272,
                    "end": 276,
                    "text": "(32)",
                    "ref_id": "BIBREF88"
                },
                {
                    "start": 277,
                    "end": 281,
                    "text": "(33)",
                    "ref_id": "BIBREF89"
                },
                {
                    "start": 282,
                    "end": 286,
                    "text": "(34)",
                    "ref_id": "BIBREF90"
                },
                {
                    "start": 287,
                    "end": 291,
                    "text": "(35)",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 292,
                    "end": 296,
                    "text": "(36)",
                    "ref_id": null
                },
                {
                    "start": 297,
                    "end": 301,
                    "text": "(37)",
                    "ref_id": null
                },
                {
                    "start": 302,
                    "end": 306,
                    "text": "(38)",
                    "ref_id": null
                },
                {
                    "start": 415,
                    "end": 419,
                    "text": "(33,",
                    "ref_id": "BIBREF89"
                },
                {
                    "start": 420,
                    "end": 423,
                    "text": "39)",
                    "ref_id": "BIBREF95"
                },
                {
                    "start": 526,
                    "end": 530,
                    "text": "(35,",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 531,
                    "end": 534,
                    "text": "36,",
                    "ref_id": null
                },
                {
                    "start": 535,
                    "end": 538,
                    "text": "40)",
                    "ref_id": "BIBREF96"
                },
                {
                    "start": 665,
                    "end": 669,
                    "text": "(41)",
                    "ref_id": "BIBREF97"
                },
                {
                    "start": 845,
                    "end": 849,
                    "text": "(42,",
                    "ref_id": "BIBREF98"
                },
                {
                    "start": 850,
                    "end": 853,
                    "text": "43)",
                    "ref_id": "BIBREF99"
                },
                {
                    "start": 988,
                    "end": 992,
                    "text": "(44)",
                    "ref_id": "BIBREF100"
                },
                {
                    "start": 1102,
                    "end": 1106,
                    "text": "(41)",
                    "ref_id": "BIBREF97"
                },
                {
                    "start": 1515,
                    "end": 1519,
                    "text": "(45)",
                    "ref_id": "BIBREF101"
                },
                {
                    "start": 1520,
                    "end": 1524,
                    "text": "(46)",
                    "ref_id": "BIBREF103"
                },
                {
                    "start": 1525,
                    "end": 1529,
                    "text": "(47)",
                    "ref_id": "BIBREF104"
                },
                {
                    "start": 1530,
                    "end": 1534,
                    "text": "(48)",
                    "ref_id": "BIBREF105"
                },
                {
                    "start": 1535,
                    "end": 1539,
                    "text": "(49)",
                    "ref_id": "BIBREF106"
                },
                {
                    "start": 1540,
                    "end": 1544,
                    "text": "(50)",
                    "ref_id": "BIBREF107"
                },
                {
                    "start": 1545,
                    "end": 1549,
                    "text": "(51)",
                    "ref_id": "BIBREF108"
                },
                {
                    "start": 1750,
                    "end": 1754,
                    "text": "(52)",
                    "ref_id": null
                },
                {
                    "start": 2029,
                    "end": 2033,
                    "text": "(52)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Study 4: Common infections in people with AA"
        },
        {
            "text": "The overall purpose of study 1 is to describe the epidemiology (incidence and prevalence) of AA and to assess the current level of primary care service utilisation and management patterns associated with people diagnosed with AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study objectiv es and endpoints 2.1 Study objectiv es 2.1.1 Study 1"
        },
        {
            "text": "The overall purpose of study 2 is to assess the prevalence and incidence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult people diagnosed with AA relative to a control population of people without a diagnosis of AA. In addition, the study will determine the treatment burden (medications and psychological interventions used to treat mental health conditions), 'sick day' burden, and unemployment burden of AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "The overall purpose of study 3 is to assess the prevalence and incidence of atopic and autoimmune conditions in adult people diagnosed with AA relative to a control population of people without AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "The overall purpose of study 4 is to assess the incidence of common infections in people diagnosed with AA relative to a control population of people without AA. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "Describe the epidemiology of AA: Incidence of AA over time and by age, sex, ethnicity, and sociodemographic factors, and point prevalence by age and sex.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.1.1"
        },
        {
            "text": "Describe current primary care service utilisation and management patterns in AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.1.2"
        },
        {
            "text": "Describe the prevalence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult people diagnosed with AA in a contemporary real-world population compared with matched controls without AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.2.1"
        },
        {
            "text": "Describe the incidence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult people diagnosed with AA in a contemporary real-world population compared with matched controls in the first two years after AA diagnosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.2.2"
        },
        {
            "text": "Describe the mental health treatment burden of adult people diagnosed with AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.2.3"
        },
        {
            "text": "Describe the prevalence of atopic and autoimmune conditions in adult people diagnosed with AA in a contemporary real-world population at diagnosis compared with matched controls without AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.3.1"
        },
        {
            "text": "Describe the incidence of atopic and autoimmune conditions in adult people with AA in a contemporary real-world population compared with matched controls in the first five years after AA diagnosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.3.2"
        },
        {
            "text": "Describe the overall rate of common infections in people with AA in a contemporary realworld population at diagnosis compared with matched controls in the first five years after AA diagnosis. Describe the rates of individual common infections in people with AA in a contemporary real-world population at diagnosis compared with matched controls in the first five years after AA diagnosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.4.1"
        },
        {
            "text": "Describe the geographic distribution of AA incidence within England. English regions comprise; Greater London, South East, South West, West Midlands, North West, North East, Yorkshire and the Humber, East Midlands, and East of England.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.3.1.1"
        },
        {
            "text": "Describe the prevalence of additional mental health conditions (adjustment disorder, agoraphobia, self-harm, and overdose/parasuicide attempts) in adult people diagnosed with AA and controls.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.3.2.1"
        },
        {
            "text": "Describe the burden of 'sick days' in adult people diagnosed with AA and controls.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.3.2.2"
        },
        {
            "text": "Describe the prevalence of unemployment in adult people diagnosed with AA and controls.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.3.2.3"
        },
        {
            "text": "None",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "None ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "The primary endpoints for the four studies are listed in Table 1 .",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 57,
                    "end": 64,
                    "text": "Table 1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Primary endpoint"
        },
        {
            "text": "Diagnosis of AA is the date of the first diagnosis code in the record and no alternative diagnosis that merits exclusion* diagnosed in the subsequent 365 days from date of AA diagnosis (see Supplementary Table S1 .1, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 190,
                    "end": 212,
                    "text": "Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Study Endpoints 1"
        },
        {
            "text": "Diagnosis of AA is the date of the first diagnosis code in the record and no alternative diagnosis that merits exclusion* diagnosed in the subsequent 365 days from date of AA diagnosis (see Supplementary Table S1 .1, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 190,
                    "end": 212,
                    "text": "Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "2"
        },
        {
            "text": "Diagnosis of a common mental health condition categorized as depressive episodes, recurrent depressive disorder or non-phobia related anxiety disorders at the time of AA diagnosis (See Supplementary Tables S2.1 -S2 . 4 , Additional file 2).",
            "cite_spans": [
                {
                    "start": 217,
                    "end": 218,
                    "text": "4",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 185,
                    "end": 214,
                    "text": "Supplementary Tables S2.1 -S2",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "2"
        },
        {
            "text": "Time to diagnosis of a common mental health condition categorized as depressive episodes, recurrent depressive disorder or non-phobia related anxiety disorders in the first two years post AA diagnosis (See Supplementary Tables S2.1 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 206,
                    "end": 231,
                    "text": "Supplementary Tables S2.1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "2"
        },
        {
            "text": "3 Diagnosis of AA is the date of the first diagnosis code in the record and no alternative diagnosis that merits exclusion* diagnosed in the subsequent 365 days from date of AA diagnosis (see Supplementary Table S1 .1, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 192,
                    "end": 214,
                    "text": "Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "-S2.4, Additional file 2)"
        },
        {
            "text": "Diagnosis of an atopic (atopic dermatitis, allergic rhinitis, asthma) or autoimmune condition (Supplementary Tables S4.1 -S4 . 16 , Additional file 2) at the time of AA diagnosis.",
            "cite_spans": [
                {
                    "start": 127,
                    "end": 129,
                    "text": "16",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 94,
                    "end": 124,
                    "text": "(Supplementary Tables S4.1 -S4",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "-S2.4, Additional file 2)"
        },
        {
            "text": "Time to diagnosis of an atopic (atopic dermatitis, allergic rhinitis, asthma) or autoimmune condition (Supplementary Tables S4.1 -S4 . 16 , Additional file 2) in the first five years after AA diagnosis.",
            "cite_spans": [
                {
                    "start": 135,
                    "end": 137,
                    "text": "16",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 102,
                    "end": 132,
                    "text": "(Supplementary Tables S4.1 -S4",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "-S2.4, Additional file 2)"
        },
        {
            "text": "Diagnosis of AA is the date of the first diagnosis code in the record and no alternative diagnosis that merits exclusion* diagnosed in the subsequent 365 days from date of AA diagnosis (see Supplementary Table S1 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 190,
                    "end": 212,
                    "text": "Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "4"
        },
        {
            "text": "Study 1: Explore the incidence of AA by age (children) and age group (adults (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) , (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) , (60,70], (70-80], \u226580). These age groups are provisional. If, during exploratory analysis, we find that these age groups obscure the true incidence of AA (for example if AA incidence rates change substantially across one of these age groups) then we may modify these groupings. Any changes will be clearly stated as such in a final manuscript.",
            "cite_spans": [
                {
                    "start": 77,
                    "end": 81,
                    "text": "(18)",
                    "ref_id": null
                },
                {
                    "start": 82,
                    "end": 86,
                    "text": "(19)",
                    "ref_id": null
                },
                {
                    "start": 87,
                    "end": 91,
                    "text": "(20)",
                    "ref_id": null
                },
                {
                    "start": 92,
                    "end": 96,
                    "text": "(21)",
                    "ref_id": null
                },
                {
                    "start": 97,
                    "end": 101,
                    "text": "(22)",
                    "ref_id": null
                },
                {
                    "start": 102,
                    "end": 106,
                    "text": "(23)",
                    "ref_id": "BIBREF79"
                },
                {
                    "start": 107,
                    "end": 111,
                    "text": "(24)",
                    "ref_id": "BIBREF80"
                },
                {
                    "start": 112,
                    "end": 116,
                    "text": "(25)",
                    "ref_id": null
                },
                {
                    "start": 117,
                    "end": 121,
                    "text": "(26)",
                    "ref_id": "BIBREF81"
                },
                {
                    "start": 122,
                    "end": 126,
                    "text": "(27)",
                    "ref_id": "BIBREF82"
                },
                {
                    "start": 127,
                    "end": 131,
                    "text": "(28)",
                    "ref_id": "BIBREF83"
                },
                {
                    "start": 132,
                    "end": 136,
                    "text": "(29)",
                    "ref_id": "BIBREF84"
                },
                {
                    "start": 137,
                    "end": 141,
                    "text": "(30)",
                    "ref_id": "BIBREF86"
                },
                {
                    "start": 144,
                    "end": 148,
                    "text": "(30)",
                    "ref_id": "BIBREF86"
                },
                {
                    "start": 149,
                    "end": 153,
                    "text": "(31)",
                    "ref_id": "BIBREF87"
                },
                {
                    "start": 154,
                    "end": 158,
                    "text": "(32)",
                    "ref_id": "BIBREF88"
                },
                {
                    "start": 159,
                    "end": 163,
                    "text": "(33)",
                    "ref_id": "BIBREF89"
                },
                {
                    "start": 164,
                    "end": 168,
                    "text": "(34)",
                    "ref_id": "BIBREF90"
                },
                {
                    "start": 169,
                    "end": 173,
                    "text": "(35)",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 174,
                    "end": 178,
                    "text": "(36)",
                    "ref_id": null
                },
                {
                    "start": 179,
                    "end": 183,
                    "text": "(37)",
                    "ref_id": null
                },
                {
                    "start": 184,
                    "end": 188,
                    "text": "(38)",
                    "ref_id": null
                },
                {
                    "start": 189,
                    "end": 193,
                    "text": "(39)",
                    "ref_id": "BIBREF95"
                },
                {
                    "start": 194,
                    "end": 198,
                    "text": "(40)",
                    "ref_id": "BIBREF96"
                },
                {
                    "start": 201,
                    "end": 205,
                    "text": "(50)",
                    "ref_id": "BIBREF107"
                },
                {
                    "start": 206,
                    "end": 210,
                    "text": "(51)",
                    "ref_id": "BIBREF108"
                },
                {
                    "start": 211,
                    "end": 215,
                    "text": "(52)",
                    "ref_id": null
                },
                {
                    "start": 216,
                    "end": 220,
                    "text": "(53)",
                    "ref_id": "BIBREF110"
                },
                {
                    "start": 221,
                    "end": 225,
                    "text": "(54)",
                    "ref_id": "BIBREF111"
                },
                {
                    "start": 226,
                    "end": 230,
                    "text": "(55)",
                    "ref_id": "BIBREF112"
                },
                {
                    "start": 231,
                    "end": 235,
                    "text": "(56)",
                    "ref_id": "BIBREF113"
                },
                {
                    "start": 236,
                    "end": 240,
                    "text": "(57)",
                    "ref_id": "BIBREF114"
                },
                {
                    "start": 241,
                    "end": 245,
                    "text": "(58)",
                    "ref_id": null
                },
                {
                    "start": 246,
                    "end": 250,
                    "text": "(59)",
                    "ref_id": "BIBREF115"
                },
                {
                    "start": 251,
                    "end": 255,
                    "text": "(60)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Other exploratory analyses"
        },
        {
            "text": "The proposed studies will use the retrospectively collected data of all eligible patients within Oxford-Royal College of General Practitioners Research and Surveillance Centre database (RCGP RSC) at the date of data extraction. The RCGP RSC database incorporates pseudonymised primary care records from up to 200 GP practices distributed across England. Details of the cohort included in the database have been published previously. (54) The RCGP RSC cohort size (as of January 2019) is over 2.6 million actively registered patients, and historic records available for up to 5.2 million patients over the last 20 years.",
            "cite_spans": [
                {
                    "start": 433,
                    "end": 437,
                    "text": "(54)",
                    "ref_id": "BIBREF111"
                }
            ],
            "ref_spans": [],
            "section": "General Study Design and P lan"
        },
        {
            "text": "The cohort provides a broadly representative sample of the UK population.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "General Study Design and P lan"
        },
        {
            "text": "The study period for study 2 and study 3 incidence analyses will be ten-years starting January 1, 2009 and ending December 31, 2018 inclusive.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "General Study Design and P lan"
        },
        {
            "text": "For study 4, we will start data collection from the beginning of 2004 when the quality and outcomes framework was first introduced in primary care. The study period will end December 31, 2018.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "General Study Design and P lan"
        },
        {
            "text": "These are non-interventional studies. A range of study designs will be used across the studies as follows:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Design"
        },
        {
            "text": "Cross-sectional design (incidence and prevalence of AA). Cohort design to assess healthcare utilisation in people with AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1:"
        },
        {
            "text": "Case-control design for prevalence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) at AA diagnosis. Matched-cohort design for incidence of such conditions in the first two years after AA diagnosis in the subset of adult people diagnosed with AA without a mental health condition at baseline (and excluding controls if they have a baseline mental health condition).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2:"
        },
        {
            "text": "Case-control design for prevalence of atopic and autoimmune conditions at AA diagnosis. Matched-cohort design for incidence of atopic and autoimmune conditions in the first five years after AA diagnosis in the subset of adult people diagnosed with AA without an atopic/autoimmune condition at baseline (and excluding controls if they have a baseline atopic/autoimmune condition). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3:"
        },
        {
            "text": "Matched-cohort design for incidence of common infections in the first five years after AA diagnosis in the subset of people diagnosed with AA without a common infection at baseline (and excluding controls if they have a baseline common infection).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4:"
        },
        {
            "text": "The case and control cohorts will be identified from the RCGP RSC database. The RCGP RSC database contains complete data on all events and clinical entities coded in UK primary care. These include demographic information, clinical diagnoses, laboratory test results, primary care issued prescriptions, process of care codes (e.g. specialist dermatology reviews), and anthropometric measurements (e.g., body mass index (BMI)), and are coded using the Read Coding system. (55) Read code lists used to define variables have been developed in accordance with published guidelines. (55)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data source and Read codes"
        },
        {
            "text": "Individual patient data will be anonymised at the point of data extraction. All data will remain in anonymised form and will be held on a secure server at the University of Surrey. The data will not be used for any purposes other than for the research which is described in the respective protocols and which has been approved by the RCGP RSC Research Committee. The sponsor, Pfizer Ltd, will not have access to the individual anonymised patient data. Queries will be executed to extract relevant data from the Structured Query Language (SQL) database using the Read code listed in Additional file 2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data extraction"
        },
        {
            "text": "We will identify people diagnosed with AA using diagnosis Read codes which are specific to the condition (see Supplementary Table S1 .1 (AA section), Additional file 2). A person will be considered to have a confirmed AA diagnosis if they have one or more of these diagnoses Read codes and no code for an alternative diagnosis in the subsequent 365 days. Alternative diagnoses which merit exclusion comprise any form of scarring alopecia, (53) traction alopecia, congenital alopecia, androgenetic alopecia, telogen effluvium, tinea capitis, trichotillomania, or secondary syphilis of the scalp (see Supplementary Table S1 .1, Additional file 2). We will identify all incident cases of AA meeting this case definition over the study period which will form the case cohorts for the four studies. We will also extract data on the extent of the alopecia where this has been recorded (See Supplementary Table  S1 Autoimmune conditions were selected based on a combination of expert knowledge and a minimum background population prevalence of 0.3% in the general population (refer to section 4.1.3). Case definition using Read codes for atopic dermatitis has been previously validated. An ontologically driven case definition is used for both allergic rhinitis and asthma. (55) Study 4 will identify common infections using diagnostic Read codes (Supplementary  Tables S5.1 -S5. 12, Additional file 2).",
            "cite_spans": [
                {
                    "start": 1267,
                    "end": 1271,
                    "text": "(55)",
                    "ref_id": "BIBREF112"
                }
            ],
            "ref_spans": [
                {
                    "start": 110,
                    "end": 132,
                    "text": "Supplementary Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 599,
                    "end": 621,
                    "text": "Supplementary Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 884,
                    "end": 907,
                    "text": "Supplementary Table  S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1340,
                    "end": 1372,
                    "text": "(Supplementary  Tables S5.1 -S5.",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "AA definition"
        },
        {
            "text": "Age, sex, socio-economic status (SES), and ethnicity will comprise the socio-economic factors used for stratification of the outcome measures. Ethnicity will be categorized as follows in accordance with the major UK census categories: (58, 59) White, Asian, Black African/Caribbean, Mixed, Other and not recorded. Deprivation will be defined using the official national deprivation measure; index of multiple deprivation (IMD). (60) This will be calculated at the point of data extraction, using patient postcode, with the resultant scores stratified by deprivation quintile according to the national distribution.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Baseline socio-economic characteristics"
        },
        {
            "text": "This will comprise of the incidence of AA over the study period (stratified by age group, sex ethnicity, and SES) and point prevalence (stratified by age and sex). The study will also describe the geographic distribution of AA by region across England.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Epidemiology of AA"
        },
        {
            "text": "Current service utilisation will comprise of annual primary care visit rates, in Study 1 we will compare primary care visit frequency in people with AA and matched controls without AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Current serv ice utilisation and management patterns"
        },
        {
            "text": "The management patterns will comprise of an assessment of the percentage of the people with AA having a secondary care review (by dermatology (study 1) or mental health services (study 2)), and an assessment of primary care medication prescriptions issued to treat AA (Supplementary Table S1 .4, Additional file 2). Primary care visits, secondary care reviews and medication to treat AA will all be limited to those within 365 days of AA diagnosis.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 268,
                    "end": 291,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Current serv ice utilisation and management patterns"
        },
        {
            "text": "This will comprise of the rates for medications and psychological interventions used to treat mental health conditions in people diagnosed with AA. Antidepressant medication classes to be examined comprise; selective serotonin reuptake inhibitors (SSRIs) and related medications (serotonin and norepinephrine reuptake inhibitors; SNRIs), tricyclic antidepressants (TCAs) and related medications (tetracyclic antidepressant TeCAs), and monoamine oxidase inhibitors (MOAIs). Anxiolytic medications to be examined comprise all benzodiazepines and other related medications indicated for use in anxiety states. Psychological interventions comprise of will comprise; referral rates for counselling, secondary care psychiatrist referrals, including the referrals to the clinical psychology services/specialists and UK Improving Access to Psychological Therapies (IAPT) program. Additional mental health conditions consist of adjustment disorder, agoraphobia, self-harm, and overdose/parasuicide attempts and will be identified using the presence of one or more diagnosis codes appearing in the clinical record (Supplementary Tables S2.5 -S2.9 , Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 1104,
                    "end": 1136,
                    "text": "(Supplementary Tables S2.5 -S2.9",
                    "ref_id": null
                }
            ],
            "section": "Mental health treatment, sick day, and unemployment burden"
        },
        {
            "text": "Unemployment will be identified using Read codes relating to unemployment recorded in the primary care record or the issuing of IB113 or ESA113 forms (Supplementary Table S3 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 150,
                    "end": 173,
                    "text": "(Supplementary Table S3",
                    "ref_id": null
                }
            ],
            "section": "Mental health treatment, sick day, and unemployment burden"
        },
        {
            "text": "In the controls, the prevalence of common conditions (e.g. depressive episodes) is assumed to be 10%, less common conditions are assumed to be 1% and rare conditions (e.g. multiple sclerosis) assumed to be 0.1%. Sample size calculations were performed in OpenEpi, (62) results are presented using methods of Kelsey.(63)",
            "cite_spans": [
                {
                    "start": 264,
                    "end": 268,
                    "text": "(62)",
                    "ref_id": "BIBREF117"
                }
            ],
            "ref_spans": [],
            "section": "Sample size calculations"
        },
        {
            "text": "The analysis of the primary endpoint is a descriptive analysis of the incidence and prevalence of AA, and no sample size calculation is therefore applicable.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Our inclusion criteria specify all people with a confirmed diagnosis of AA will be included for analysis. The RCGP RSC database contains information on around 2 million actively registered patients. Based on an AA prevalence of 0.2% (13), we would anticipate a sample size of around 4,000 people diagnosed with AA for this study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Assuming 80% power, a 5% level of statistical significance, and a background population prevalence of 15% for anxiety and 10% for depression, (64) our anticipated sample size for AA (n = 4,000) would be sufficient to detect a prevalence difference of 1.8% in anxiety between those with and without AA, and 1.5% difference in depression between those with and without AA.",
            "cite_spans": [
                {
                    "start": 142,
                    "end": 146,
                    "text": "(64)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "A sample size calculation is applicable to estimate the incidence of atopic and autoimmune conditions in people diagnosed with AA. There is, however, a paucity of large-scale epidemiological data exploring the association between AA and either atopic or autoimmune conditions on which to base the sample size calculations for this study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "A large population-based study based in Taiwan (65) 15 1,706 controls) would be required to detect statistically significant differences between people diagnosed with AA and the control populations.",
            "cite_spans": [
                {
                    "start": 47,
                    "end": 51,
                    "text": "(65)",
                    "ref_id": null
                },
                {
                    "start": 52,
                    "end": 54,
                    "text": "15",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "For the assessment of prevalence of co-existing autoimmune conditions, assuming 80% power, a 5% level of statistical significance, our anticipated sample size for AA (n = 4,000) and an OR 2.0 effect, we would have sufficient power to detect a difference between those with and without AA in autoimmune conditions having >= 0.3% background population prevalence.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "A sample size calculation is applicable to estimate the incidence of common infections in people diagnosed with AA. There is, however, no previous data exploring the association between AA and common infections on which to base the sample size calculations for this study. We therefore estimate the number of people diagnosed with AA we will have for this study (n = 4,000) and use this number to estimate the minimum effect size we are powered to detect. Based on a Cox PH model, 80% power, a 5% level of statistical significance and a 4:1 ratio of controls to cases, we would have sufficient power to detect a difference between those with and without AA in common infections having >= 0.46% background population prevalence.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "The cohorts for studies 1, 2 and 3 (cases and controls) will consist of patients contributing to RCGP RCS database during the study period (between January 1, 2009 and December 31, 2018 inclusive). The cohorts for study 4 (cases and controls) will consist of patients contributing to RCGP RCS database between January 1, 2004 and December 31, 2018 inclusive.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "The AA prevalence population consists of patients actively registered and alive at the end date of the study period (December 31, 2018).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "The AA incidence population consists of patients registered at any point during the study period but without a prior recorded AA diagnosis. The follow-up period for incident cases will begin on the latest of the date of diagnosis indicated by the first diagnostic AA Read code. Follow-up will end at the earliest of the study end-date (December 31, 2018), the date of patient transfer from an included practice or date of death.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "Studies 1 and 4 will include both children and adults. Studies 2 and 3 will include only people aged \u226518 (as at date of AA diagnosis for cases or start of follow-up for controls). Only people aged \u2265 18 and \u2264 65 will be included in the unemployment and sick day analysis (Study 2).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "The following exclusion criteria will be applied:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exclusion Criteria"
        },
        {
            "text": "\u2022 People with the alternative non-AA diagnoses (section 3.4.1) (AA incidence cohort).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exclusion Criteria"
        },
        {
            "text": "\u2022 People with AA diagnosis within 6 months of registration (AA incidence cohort).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exclusion Criteria"
        },
        {
            "text": "\u2022 People with less than 1 year of follow up within the dataset (unless under 1 year old) (AA incidence and AA prevalence cohorts). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exclusion Criteria"
        },
        {
            "text": "The control cohorts will be defined by matching cases with people who have never been diagnosed with AA either prior to or during the study period, by age, sex, and time since practice registration, at GP practice level. After matching an assessment of sociodemographic differences using IMD quintiles will be performed. If there are substantial differences in socioeconomic status between cases and controls, re-matching with IMD as an additional matching criterion will be considered Controls will require at least one year of follow-up when matched to minimize the risk of a non-recorded existing diagnosis of AA. The follow-up period for each matched control will begin at the start of follow-up of their matched case and have the same follow-up time criteria applied (where applicable).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "Each case is matched with four controls using a nearest neighbour matching algorithm (66) to create a baseline matched dataset.",
            "cite_spans": [
                {
                    "start": 85,
                    "end": 89,
                    "text": "(66)",
                    "ref_id": "BIBREF121"
                }
            ],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "Study 1 will include all matched patients to compare rates of primary care visits. Study 2 (incidence of mental health after AA diagnosis) and study 3 (incidence of atopic and autoimmune conditions) will both use a subset of the baseline matched dataset; cases will be people diagnosed with AA without the relevant condition at their start of follow up, controls will be people not diagnosed with AA and without the relevant condition at their start of follow up.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "The matching for the incidence of common infections (study 4) will use a different approach to studies 2 and 3: cases will be people diagnosed with AA on or before 1 st January 2014 (exact date will be dependent on data availability) without the relevant infection, controls will be people not diagnosed with AA prior to this date and without the relevant infection. People who develop AA during the follow up will be excluded from the pool of available cohorts prior to matching. This approach will mitigate systematic recording bias that is likely due to an increased propensity of people with incident AA to consult within the months following diagnosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "The case-control design studies (prevalence of mental health at AA diagnosis (study 2), and prevalence of atopic and autoimmune conditions at AA diagnosis (study 3)) will both define cases as people newly diagnosed with AA over the study period. For each case, the prevalence of the conditions of interest as at the date of AA diagnosis will be retrospectively established. Controls will be people not diagnosed with AA. For each control, the date of AA diagnosis of their matched case counterpart will then be used as the baseline date and the prevalence of the conditions of interest on that date will be retrospectively established.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "In Study 2 and Study 3, the same baseline cases and control cohorts will be used for both the case-control and matched-cohort analyses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "To check the validity of our AA definition (section 3.4.1), annual incident trends of specified alopecia (AA), (Supplementary Table S1 .1, Additional file 2), non-specific alopecia (Supplementary Table S1 .1, Additional file 2) and other specified alopecia (Supplementary  Table S1 .1, Additional file 2) will be analysed for the purpose of identifying changes in coding practice. The AA case definition may be amended based on the results of this analysis if considered appropriate and necessary. Any changes required will be reported in full in a final study publication. The mean, standard deviation (sd) and any other statistical measures, will be reported to one decimal place. Continuous data will be summarised in the form of means, sd, median, interquartile range (IQR) and range as appropriate. Categorical data will be summarised using frequencies and proportions. Chi-squared and t-tests will be performed to compare the frequency of dichotomous variables and the values of continuous variables where relevant. 95% CIs will be reported for main effect sizes. Statistical significance will be assessed using p<0.05. Actual p-values will be reported except for p-values less than 3 decimal places which will be reported as \"<0.001\". P-values >0.1 will be reported to one decimal place, p-values between 0.01 and 0.1 will be reported to 2 decimal places, and pvalues between 0.001 and 0.01 will be reported to three decimal places.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 111,
                    "end": 134,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 181,
                    "end": 204,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 257,
                    "end": 281,
                    "text": "(Supplementary  Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "AA definition exploratory analyses"
        },
        {
            "text": "The assessment of any associations with baseline characteristics and the outcomes of interest (mental health conditions (study 2), autoimmune and atopic conditions (study 3) and common infections (study 4)) will be assessed using logistic regression, Cox proportional hazards models, Poisson regression or zero-inflated Poisson regression as appropriate depending on the characteristics of the outcome variable. A standard set of features will be used in all multivariable models: age, sex, ethnicity, socioeconomic status, BMI, smoking status, alcohol status, and historical propensity to consult (defined as the number of primary care visits an individual has in the year prior to their study start date). Specific co-morbidity adjustment will be specific to each analysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "AA definition exploratory analyses"
        },
        {
            "text": "Assumptions of statistical approaches will be assessed, and transformations used if necessary (although it is not anticipated that the data will violate model assumptions).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "AA definition exploratory analyses"
        },
        {
            "text": "AA incidence: Incident cases will be defined as people with a first ever diagnostic Read code for AA during the study period. To ensure cases are truly incident, people with an AA diagnosis within six months of registering with a practice will be excluded from the analysis (unless under one year old). Incidence of new onset AA will be calculated by dividing the total number of new cases by the total person-years of follow-up for the total eligible population over the study period. Incidence rates will be reported for the complete cohort and stratified by calendar year, sex and age (categorised), and SES factors. Adjusted incidence rates by socio-demographic factors (including geographic area classification) will be estimated using Poisson regression.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "AA point prevalence: Prevalence cases will be defined as all people with a historical diagnostic Read code for AA and no exclusion code within one year of AA diagnosis. For this prevalence analysis all people will be included regardless of the date of AA diagnosis in relation to the date of registration with a practice. Cases with < 365 days of follow up from date of registration will be excluded from the analysis (unless under one year old). Point prevalence will be calculated by dividing the number of prevalent cases by the total number of eligible people in the study population at the study end date (December 31, 2018). Point prevalence will be reported for the complete cohort and stratified by sex and age (categorised). We anticipate some attrition of recording of AA in the historic records. This is particularly likely to be the case in records preceding the computerisation of primary care which occurred in the 1990s. If we observe evidence of this being a major source of error in our point calculations (as evidenced by a falling point incidence in the older adult population despite there being a substantial number of incident diagnoses in this age group) then we will consider using the actuarial life table method to estimate lifetime AA risk (67) .",
            "cite_spans": [
                {
                    "start": 1267,
                    "end": 1271,
                    "text": "(67)",
                    "ref_id": "BIBREF122"
                }
            ],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Service utilisation and management patterns: Service utilisation will be evaluated by calculation of the annual rates of primary care visits for people diagnosed with AA in the year following diagnosis. Primary care visits will be identified from the patient's electronic health record.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Management patterns will be evaluated by calculation of annual proportion of people referred for dermatology review in people diagnosed with AA in the year following diagnosis. Secondary care dermatology reviews will be identified from Read codes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "In addition, management patterns will also comprise of the percentage of people diagnosed with AA and prescribed AA medication, in primary care, grouped by medication class during the year following diagnosis. Prescription information will be identified using Read and EMIS codes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Prevalence of mental health conditions: Prevalence will be calculated by dividing the number of prevalent people at the study start date by the total number of eligible people in the study population at the same time point.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "The prevalence of each common mental health condition (depressive episodes, recurrent depressive disorder and anxiety disorder) category for people diagnosed with AA will be reported in Study 2 and compared to the prevalence in the control population without AA. The prevalence of mental health conditions by socio-demographic subgroups will also be reported.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "Incidence of mental health conditions: Incident cases will be defined as in Study 1. Incidence rates of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) within two years of diagnosis date (matched follow-up start date for controls) will be calculated in both cases and controls and compared.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "Risk of developing a mental health condition (grouped by mental health condition category) will be examined using time to failure analysis. Initially, unadjusted Cox proportional hazards models, stratified by matched set (AA versus non-AA), will be used to provide overall hazard ratios (HRs) as summary estimates for the association of the presence of AA with the time to each mental health condition category in separate models. Models will be subsequently adjusted for standard set factors (section 6.1) and comorbidities (type 2 diabetes (T2DM), hypertension, atrial fibrillation, angina, acute myocardial infarction, stroke, heart failure, chronic liver disease, dementia, RA, asthma, Chronic obstructive pulmonary disease, Chronic Kidney Disease stage 3-5 (CKD), malignancy and inflammatory bowel disease) in multivariable analysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "Mental health treatment and management patterns: The burden of treatment for mental health conditions will be evaluated as the total percentage of people diagnosed with AA and prescribed, within one year of AA diagnosis, a medication used to treat mental health conditions (section 3.8) (e.g. SSRIs), grouped by mental health condition category.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "Management patterns will be evaluated by calculation of annual proportion of people referred for psychiatrist referral and counselling in people diagnosed with AA in the year following diagnosis (Supplementary Table S2 .10, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 195,
                    "end": 218,
                    "text": "(Supplementary Table S2",
                    "ref_id": null
                }
            ],
            "section": "Study 2"
        },
        {
            "text": "Prevalence of atopic and autoimmune conditions: The prevalence of atopic and autoimmune conditions in both cases and controls will be reported and compared.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "Incidence of atopic and autoimmune conditions: Incidence rates of atopic and autoimmune conditions within five years of diagnosis date (matched follow-up start date for controls) will be calculated in both cases and controls and compared.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "Risk of developing an atopic or autoimmune condition will be examined using time to failure analysis. Initially, unadjusted Cox proportional hazards models, stratified by matched set (AA versus non-AA), will be used to provide overall HRs as summary estimates for the association of the presence of AA with the time to each of atopic and autoimmune conditions in separate models. Models will be subsequently adjusted for standard set factors (section 6.1) and comorbidities (hypertension, hyperlipidaemia, T2DM, peripheral arterial disease, atrial fibrillation, angina, myocardial infarction, stroke, heart failure, CKD, chronic obstructive pulmonary disorder (COPD), chronic liver disease, malignancy, dementia, fracture history, depression) in multivariable analysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "Incidence of common infections: Incidence rates of common infections within five years of diagnosis date (matched follow-up start date for controls) will be calculated at both overall and individual infection levels in both cases and controls and compared. : Initially, infection incidence rates in people with and without AA will be estimated by dividing the number of incident common infections by the sum of person-years of follow-up for each cohort over the period of interest. Unadjusted Poisson regression models, stratified by matched set (AA versus controls), will be used to provide overall incident rate ratios as summary estimates for the association between rates of common infections and the presence of AA. Models will subsequently be adjusted for standard set factors (section 6.1) and comorbidities (hypertension, hyperlipidaemia, T2DM, peripheral arterial disease, atrial fibrillation, angina, myocardial infarction, stroke, heart failure, CKD, COPD, chronic liver disease, malignancy, dementia, RA, depression).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "Geographical distribution of AA: The geographic distribution of people with AA will be calculated from the disease incidence. The adjusted incident rate ratios will be reported. Models will be adjusted for age category, sex, ethnicity, IMD and geographic area classification derived using patient postcode at the point of data extraction.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Stratified prevalence of mental health conditions: The prevalence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) by sociodemographic subgroups will also be reported in both cases and controls. Additional mental health conditions: The prevalence of additional mental health conditions (adjustment disorder, agoraphobia, self-harm, and overdose/parasuicide attempts) will be estimated as the total percentage of people diagnosed with AA and with the presence of one or more diagnosis codes appearing in the clinical record Sick day and unemployment burden: The burden of sick days will be estimated as the total percentage of people diagnosed with AA and issued one or more Med 3certificate. The burden of unemployment will be estimated as the total percentage of people diagnosed with AA and with a Read code relating to unemployment recorded in the primary care record or an IB113 or ESA113 form issued.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "Not applicable.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "Not applicable.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "Study 2: Sensitivity analyses will be performed to compare the baseline prevalence and incidence over two years post alopecia diagnosis of the three primary mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in people with non-specific alopecia codes only (i.e. no prior or subsequent codes specifying alopecia type) using the same matching process used for the primary analyses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sensitiv ity analysis"
        },
        {
            "text": "Study 3: We will replicate this sensitivity analysis to compare the baseline prevalence and incidence of atopic and autoimmune conditions in people with non-specific alopecia codes only.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sensitiv ity analysis"
        },
        {
            "text": "Study 4: In the common infections theme, we will use a survival model to investigate time to first infection. We will also compare the results of the study outcomes when 1) we increase the number of cases to include people who develop AA during the follow up and 2) use a similar matching approach to the other studies: perform matching using the time of AA diagnosis and follow for up to five years after diagnosis (or matched date for controls). Both of these approaches will be used to investigate the effect of bias.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sensitiv ity analysis"
        },
        {
            "text": "These studies will use the missing indicator variable method as missing data are considered likely not to be missing at random, meaning multiple imputation approaches will lack validity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Missing data"
        },
        {
            "text": "Patient will need to be excluded from analyses based on a matched design if they have incomplete data in the fields (age, sex) required to run the matching process. In similar studies, the exclusion rate due to incomplete data has been low (68, 69) . ",
            "cite_spans": [
                {
                    "start": 240,
                    "end": 244,
                    "text": "(68,",
                    "ref_id": "BIBREF123"
                },
                {
                    "start": 245,
                    "end": 248,
                    "text": "69)",
                    "ref_id": "BIBREF124"
                }
            ],
            "ref_spans": [],
            "section": "Missing data"
        },
        {
            "text": "These are discussed in the associated protocol manuscript.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Limitations"
        },
        {
            "text": "All statistical analyses will be performed using R software.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical softw are"
        },
        {
            "text": "Study approval will be requested from the Research Committee of the RCGP RSC. These studies do not meet the requirements for formal ethics board review in their current form as defined using the NHS Health Research Authority research decision tool (http://www.hra-decisiontools.org.uk/research/).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics"
        },
        {
            "text": "The study will be conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor and follow generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE), and Good Epidemiological Practice (GEP) guidelines issued by the International Epidemiological Association (IEA). Study reporting will be conducted in accordance with the relevant EQUATOR (Enhancing the QUAlity and Transparency Of health Research) guidelines. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 Supplementary table S1.4. Medications which may be issued in primary care for the treatment of alopecia areata.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 583,
                    "end": 808,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 809,
                    "end": 1034,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1035,
                    "end": 1260,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1261,
                    "end": 1486,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1487,
                    "end": 1712,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1713,
                    "end": 1938,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1939,
                    "end": 2164,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 2165,
                    "end": 2390,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 2391,
                    "end": 2616,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 2617,
                    "end": 2902,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Ethics"
        },
        {
            "text": "* topical steroids will be grouped by potency; mild, moderate, potent, and very potent. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y 10",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 88,
                    "end": 369,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Acknow ledgements"
        },
        {
            "text": "Supplementary 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All Gouging own body parts Xa2nz",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 14,
                    "end": 239,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 240,
                    "end": 465,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 466,
                    "end": 691,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Gouging own flesh Xa2o0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Gouging own eyes Xa2o1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Gouging own rectum Xa30D",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Gouging own vagina E2731 All Head-banging Xa2o2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Banging own head against object Xa2o3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Banging own head against own body parts Xa2pI",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Hitting self Xa2pJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Punching self Xa2pK",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Slapping self X766S All Head-hitting Xa2p3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Inserting foreign bodies into own orifices Ua14Q",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Self-electrocution Xa2pQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Nipping self Xa2pM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Picking own skin Xa2pR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Pinching self Xa2pN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Rubbing own skin X766T All Scratches self Xa303",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Self-scalding Ua14N",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Self-incineration X766L All Self-mutilation X766M",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Self-mutilation of hands Xa2nl",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Self-mutilation of genitalia X766N",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Self-mutilation of penis X766O",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Self-mutilation of eyes Xa2nm",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Enucleation of own eyes X766P",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Self-mutilation of ears Xa2no",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Self-inducing a prolapse Xa2nq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Breaking own bones Xa2nr",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Pulling own teeth out Xa2nt",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Eating own flesh Xa2nv",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All All Suicide and selfinflicted injury by jumping from residential premises",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "Suicide and selfinflicted injury by jumping from other manmade structure TK72.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from natural sites TK72.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from natural sites TK7z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from high place NOS TKx.. All Suicide and selfinflicted injury by other means",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "Suicide and selfinflicted injury by jumping or lying before moving object TKx01",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by lying before moving object TKx0z All Suicide and selfinflicted injury by jumping or lying before moving object NOS TKx1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by burns or fire TKx2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by scald TKx3.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by extremes of cold TKx4.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by electrocution TKx5.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by crashing of motor vehicle TKx6.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by crashing of aircraft All Suicide or selfinflicted injury by handgun TK51.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by shotgun TK52.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by hunting rifle TK53.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by military firearm TK54.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by other firearm TK55.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by explosives TK5z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by firearms and explosives NOS Xa3jF",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Attempted suicide -firearms Xa3jO",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide -firearms TK6.. All Suicide or selfinflicted injury by cutting and stabbing TK60.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by cutting TK61.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by stabbing",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "Suicide and selfinflicted injury by cutting and stabbing instruments NOS Xa3jG",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK6z. All"
        },
        {
            "text": "All Attempted suicide -cut/stab Xa3jP All Suicide -cut/stab TK7.. All Suicide or self injury by jumping from a height TK70.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK6z. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from residential premises",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK6z. All"
        },
        {
            "text": "Suicide and selfinflicted injury by jumping from other man-made structure TK72.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from natural sites TK72.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from natural sites TK7z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from high place NOS X71B6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide or self injury by jumping from high man-made structure X71B7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide or self injury by jumping from high building X71B8 All Suicide or self injury by jumping from bridge X71B9 All Suicide or self injury by jumping from high natural feature X71BA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide or self injury by jumping off cliff Xa3jH",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Attempted suicide -jumping from a high place Xa3jQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide -jumping from a high place TKx.. All Suicide and selfinflicted injury by other means",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "Suicide and selfinflicted injury by jumping or lying before moving object TKx00",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping before moving object TKx01",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by lying before moving object TKx0z All Suicide and selfinflicted injury by jumping or lying before moving object NOS TKxy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by other specified means TKxz.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by other means NOS TKx1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by burning or fire TKx2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by scalding X71BF",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by igniting petrol soaked clothing All Attempted suicide NOS Xa3jR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide NOS X71B3 All Self poisoning by gas TK1.. All Suicide and selfinflicted poisoning by gases in domestic use TK21.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by other carbon monoxide TK2y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by other gases and vapours TK2z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by gases and vapours NOS X71B4",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Self poisoning by carbon monoxide TK20.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Self poisoning by motor vehicle exhaust gas X71B5 All Self poisoning by coal gas X71BB",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury associated with moving vehicles TKx5.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by crashing motor vehicle TKx6.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by crashing of aircraft X71BC",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by placing self in path of moving vehicle X71BD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by placing self in path of moving motor vehicle X71BE All Suicide or self injury by placing self in path of moving railway vehicle XE22J",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or attempted suicide by drowning Xa3jE",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Attempted suicide -drowning Xa3jN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide -drowning XM1Fs",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Self hanging, strangulation or suffocation TK3.. All Suicide and selfinflicted injury by hanging, strangulation and suffocation TK30.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or attempted suicide by hanging Xa3jL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide -hanging",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "Suicide and selfinflicted injury by other means of hanging, strangulation and suffocation",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3y. All"
        },
        {
            "text": "Suicide and selfinflicted injury by hanging, strangulation and suffocation NOS XE22I",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by suffocation by plastic bag Xa3jD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Attempted suicide -suffocation Xa3jM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Suicide -suffocation TK50.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by handgun Ua1AA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Hanging self Ua1AB",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Drowning self Ua1A9",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Jumping from height Ua1A8",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Jumping from building Ua1A7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Jumping from bridge Ua14U",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Jumping from cliff Ua1AE",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self-asphyxiation All Self-strangulation Ua1AC",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self-suffocation Ua14S",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Throwing self in front of vehicle Ua14T",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Throwing self in front of train X71B0 All Self poisoning by non-drug solid or liquid agents TK07.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self poisoning by corrosive or caustic substance TK08.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self poisoning by arsenic or its compounds X71B2 All Self poisoning by plants or parts of plants XM1FX",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self poisoning by agricultural chemical",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "Suicide and selfinflicted poisoning by agricultural and horticultural chemical and pharmaceutical preparations other than plant foods and fertilizers X71B1 All Self poisoning by paraquat Ua14R",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All All Deliberate self poisoning TK0.. All Suicide and selfinflicted poisoning by solid and liquid substances X71Am",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Deliberate overdose of drug or pharmaceutical preparation TK00. All Suicide and selfinflicted poisoning by analgesics, antipyretics and anti-rheumatics TK01.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by barbiturates TK010",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by amobarbital TK011",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by Barbitone TK012",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by Butabarbitone TK013",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by Pentabarbitone TK014",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by phenobarbital TK015",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by secobarbital TK01z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by barbiturates TK02.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by other sedatives and hypnotics",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "Suicide and selfinflicted poisoning by tranquillisers and other psychotropic agents TK04.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by other drugs and medicines TK05.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by drug or medicine NOS X71Ap",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of aspirin X71Ax",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of diazepam X71Av",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of methadone X71Az",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of temazepam X71Ar",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of co-proxamol X71At",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of diamorphine X71Aw",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of benzodiazepine X71Au",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of dihydrocodeine X71As",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of opiate analgesic X71Ay",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of chlordiazepoxide X71Aq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of combined analgesic X71An",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of non-opiate analgesics Xa0Jl",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of non-steroidal anti-inflammatory agent XaR4S",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of prescription only medication Xa62F",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional over-the-counter product overdose Xa65i",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional bismuth compound overdose Xa65m",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional sucralfate overdose Xa65q",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional liquorice overdose Xa65u",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional misoprostol overdose Xa65z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cimetidine overdose Xa663",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional famotidine overdose Xa667",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nizatidine overdose All Intentional imipramine overdose Xa6E9",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional iprindole overdose Xa6ED",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional lofepramine overdose Xa6EH",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nortriptyline overdose Xa6EL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional protriptyline overdose Xa6EP",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional trimipramine overdose Xa6Zp",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of tricyclic antidepressant Xa6EU",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional phenelzine overdose Xa6EY",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional iproniazid overdose Xa6Ec",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional isocarboxazid overdose Xa6Eg",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tranylcypromine overdose Xa6Ek",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional moclobemide overdose Xa6Eo",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tryptophan overdose Xa6Es",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional venlafaxine overdose Xa6Ex",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional sertraline overdose Xa6F1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional paroxetine overdose Xa6F5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nefazodone overdose Xa6F9",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional citalopram overdose Xa6FD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional fluoxetine overdose Xa6FH",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional fluvoxamine overdose Xa6FM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional maprotiline overdose Xa6FQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional mianserin overdose Xa6FU",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional trazodone overdose Xa6FY",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional viloxazine overdose Xa6Fd",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional beclamide overdose Xa6Fh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional lamotrigine overdose Xa6Fl",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional piracetam overdose Xa6Fp",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional gabapentin overdose Xa6Ft",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by sodium valproate Xa6Fy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional methylphenobarbital overdose Xa6G2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional phenobarbital overdose Xa6G6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional primidone overdose Xa6GA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by carbamazepine Xa6GE",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional vigabatrin overdose X711g",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Accidental overdose of phenytoin Xa6GL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ethosuximide overdose Xa6GP",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional clonazepam overdose Xa6GV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional zopiclone overdose Xa6GZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional zolpidem overdose Xa6Gd",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chlormezanone overdose Xa6Gh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional methyprylone overdose All Intentional thiethylperazine overdose Xa6Jq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chlorpromazine overdose Xa6Ju",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional pipotiazine overdose Xa6Jy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional promazine overdose Xa6K2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional thioridazine overdose Xa6K6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional perphenazine overdose Xa6KA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional prochlorperazine overdose Xa6KE",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional trifluoperazine overdose Xa6KJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chlorprothixene overdose Xa6KN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flupentixol decanoate overdose Xa6KR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional zuclopenthixol decanoate overdose Xa6KV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional zuclopenthixol overdose Xa6KZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flupentixol overdose Xa6Kd",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oxypertine overdose Xa6Kh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional remoxipride overdose Xa6Kj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of non-barbiturate hypnotic Xa6Ko",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional selegiline overdose Xa6Kt",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional amfetamine overdose Xa6Ky",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antabuse overdose Xa6L3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cannabis overdose Xa6L7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by lysergic acid Xa6LB",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional psilocybin overdose Xa6LF",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional mescaline overdose Xa6LJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of ecstasy Xa6LN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by cocaine Xa6LR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by crack cocaine Xa6LV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional caffeine overdose Xa6Lb",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional atenolol overdose Xa6Lf",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional propranolol overdose Xa6Lh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of beta-adrenergic blocking drug Xa6Lm",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional phenoxybenzamine overdose Xa6Lq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nicotine overdose Xa6Lu",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by calcium-channel blockers Xa6Lz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional pilocarpine overdose Xa6M3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional acetylcholine overdose Xa6M7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional anticholinesterase overdose Xa6MD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional metaraminol overdose Xa6MI",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional salbutamol overdose Xa6ML",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of isoprenaline Xa6MQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional clonidine overdose Xa6MV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional hyoscine overdose Xa6MZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional atropine overdose Xa6Me",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional acetylcysteine overdose Xa6Mj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nikethamide overdose All Intentional diphenhydramine overdose Xa6N0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional thonzylamine overdose Xa6N4",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tripelennamine overdose Xa6N8",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional hydroxyzine overdose Xa6ND",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional aminophylline overdose Xa6NH",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional theophylline overdose Xa6NL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional bronchodilator preparations overdose Xa6NR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional dithranol overdose Xa6NW",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional gamolenic acid overdose Xa6Nb",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional etretinate overdose Xa6Nf",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional acitretin overdose Xa6Nj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tretinoin overdose Xa6Nn",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional isotretinoin overdose Xa6Nt",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional allopurinol overdose Xa6Nx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional colchicine overdose Xa6O3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional baclofen overdose Xa6O7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional methocarbamol overdose Xa6OB",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional gold salt overdose Xa6OG",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional papaverine overdose Xa6OL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional prostaglandin overdose Xa6OS",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional naloxone overdose Xa6OW",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional protamine sulphate overdose Xa6Oa",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional alternative medicine overdose Xa6Oj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flucytosine overdose Xa6On",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional griseofulvin overdose Xa6Or",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional amphotericin B overdose Xa6Ov",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nystatin overdose Xa6P0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional idoxuridine overdose Xa6P5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional pyrimethamine overdose Xa6P9",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chloroquine overdose Xa6PD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional primaquine overdose Xa6PH",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional quinine overdose Xa6PL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional mefloquine overdose Xa6PP",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional proguanil overdose Xa6PU",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional piperazine overdose Xa6PY",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tiabendazole overdose Xa6Pe",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional kanamycin overdose Xa6Pi",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional streptomycin overdose Xa6Pm",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional gentamicin overdose Xa6Pq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tobramycin overdose Xa6Pu",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional netilmicin overdose Xa6Pz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional erythromycin overdose Xa6Q3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional azithromycin overdose Xa6Q7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional clarithromycin overdose All Intentional nitrofuran derivative overdose Xa6QV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional fusidic acid overdose Xa6QZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional 4-quinolones overdose Xa6Qe",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ampicillin overdose Xa6Qj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cloxacillin overdose Xa6Qn",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional carbenicillin overdose Xa6Qr",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flucloxacillin overdose Xa6Qx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefadroxil overdose Xa6R1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefalexin overdose Xa6R5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cephalothin overdose Xa6R9",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefazolin overdose Xa6RD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefradine overdose Xa6RH",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional latamoxef overdose Xa6RM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefaclor overdose Xa6RQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefuroxime overdose Xa6RU",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cephamandole overdose Xa6RZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefotaxime overdose Xa6Rd",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftazidime overdose Xa6Rh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftizoxime overdose Xa6Rl",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefixime overdose Xa6Rp",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefodizime overdose Xa6Rt",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefpodoxime overdose Xa6Rx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftriaxone overdose Xa6SA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefpirome overdose Xa6S1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftibuten overdose Xa6S5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefsulodin overdose Xa6SG",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional doxycycline overdose Xa6SK",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional minocycline overdose Xa6SO",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oxytetracycline overdose Xa6SS",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tetracycline overdose Xa6SW",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chloramphenicol overdose Xa6Sa",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional co-trimoxazole overdose Xa6Sf",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antimony compound overdose Xa6Sj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional hydroxyquinoline overdose Xa6Sp",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional rifampin overdose Xa6St",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional isoniazid overdose Xa6Sx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ethambutol overdose Xa6T1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antileprotic drug overdose Xa6T5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional pesticide product overdose Xa6TB",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional gamma globulin overdose Xa6TF",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional vaccine overdose All Intentional prednisone overdose Xa6Th",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional dexamethasone overdose Xa6Tl",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional insulin overdose Xa6Tr",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional acetohexamide overdose Xa6Tv",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chlorpropamide overdose Xa6Tz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by glibenclamide Xa6U3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tolbutamide overdose Xa6U8",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by metformin Xa6UD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional progestogen overdose Xa6UI",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nandrolone overdose Xa6UM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oxymetholone overdose Xa6UQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional methandriol overdose Xa6UU",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oral contraceptive overdose Xa6UZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional testosterone overdose Xa6Ud",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oestrogen overdose Xa6Ui",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional liothyronine overdose Xa6Xh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional streptokinase overdose Xa6Xl",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional urokinase overdose Xa6Um",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional thyroxin overdose Xa6Uz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional heparin overdose Xa6V3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional coumarin overdose Xa6V7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional warfarin sodium overdose Xa6VD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ferrous sulphate overdose Xa6VI",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional iodide overdose Xa6VN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional vitamin A overdose Xa6VR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional vitamin D overdose Xa6VV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional vitamin K overdose Xa6Va",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nicotinic acid derivative overdose Xa6Ve",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional folic acid overdose Xa6Vi",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional potassium overdose Xa6Vo",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional clofibrate overdose Xa6Vu",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional disopyramide overdose Xa6Vy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional quinidine overdose Xa6W2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional procainamide overdose Xa6W7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional bretylium overdose Xa6WC",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional amiodarone overdose Xa6WJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional bendroflumethiazide overdose Xa6WN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chlorothiazide overdose Xa6WS",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional furosemide overdose Xa6WW",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional bumetanide overdose Xa6Wa",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional etacrynic acid overdose All Intentional ketoprofen poisoning Xa4mY",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ketorolac poisoning Xa4mc",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional mefenamic acid poisoning Xa4mg",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nabumetone poisoning Xa4mj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional naproxen poisoning Xa4mn",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nefopam poisoning Xa4mr",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oxyphenbutazone poisoning Xa4mu",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional phenylbutazone poisoning Xa4my",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional piroxicam poisoning Xa4n2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional sulindac poisoning Xa4n6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tenoxicam poisoning Xa4nA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tiaprofenic acid poisoning Xa4nE",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tolmetin poisoning Xa4nJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional radiopharmaceutical poisoning Xa4nR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional X-ray contrast media poisoning Xa4nV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional magnetic resonance imaging contrast media poisoning Xa4nN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional X-ray diagnostic contrast media poisoning Xa4nZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional allergen extract vaccine poisoning Xa4nd",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional diagnostic dye poisoning Xa53n",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional dextromethorphan poisoning Xa53q",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional guaifenesin poisoning Xa53t",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional terpin hydrate poisoning Xa53w",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional poisoning by bronchodilator drug Xa53z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional aminophylline poisoning Xa542",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional theophylline poisoning Xa545",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional poisoning by herbal asthma mixture Xa548",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional anti-common cold drug poisoning Xa54B",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional local antipruritic poisoning Xa54E",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional local astringent and detergent poisoning Xa54H",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional hair treatment poisoning Xa54L",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional allopurinol poisoning Xa54O",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional colchicine poisoning Xa54R",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional probenecid poisoning Xa54X",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional gold salt poisoning Xa54a",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antirheumatic poisoning Xa54v",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chelating agent poisoning Xa54z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional alternative medicine poisoning Xa556",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flucytosine poisoning Xa559",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional griseofulvin poisoning Xa55C",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional amphotericin B poisoning All Intentional clarithromycin poisoning Xa56Q",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oleandomycin poisoning Xa56T",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional spiramycin poisoning Xa56X",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional sodium fusidate poisoning Xa56b",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional spectinomycin poisoning Xa56f",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional vancomycin poisoning Xa56j",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional trimethoprim poisoning Xa56m",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nitrofuran derivative poisoning Xa56q",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional fusidic acid poisoning Xa56u",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional 4-quinolones poisoning Xa6QZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional 4-quinolones overdose Xa56x",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ampicillin poisoning Xa570",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cloxacillin poisoning Xa573",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional carbenicillin poisoning Xa576",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional penicillin G poisoning Xa57A",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flucloxacillin poisoning Xa57E",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional piperacillin poisoning Xa57J",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefadroxil poisoning Xa57M",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefalexin poisoning Xa57P",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cephalothin poisoning Xa57T",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefazolin poisoning Xa57X",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefradine poisoning Xa57b",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional latamoxef poisoning Xa57k",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefuroxime poisoning Xa57g",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefaclor poisoning Xa57o",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cephamandole poisoning Xa57t",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefotaxime poisoning Xa57x",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftazidime poisoning Xa581",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftizoxime poisoning Xa585",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefixime poisoning Xa589",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefodizime poisoning Xa58D",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefpodoxime poisoning Xa58H",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftriaxone poisoning Xa58L",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftibuten poisoning Xa58P",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefsulodin poisoning All Intentional minocycline poisoning Xa58p",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oxytetracycline poisoning Xa58s",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tetracycline poisoning Xa58v",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chloramphenicol poisoning Xa58z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional co-trimoxazole poisoning Xa59F",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional hydroxyquinoline poisoning Xa59I",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional diiodohydroxyquinoline poisoning Xa59L",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional rifampin poisoning Xa59O",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional isoniazid poisoning Xa59R",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ethambutol poisoning Xa59U",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cycloserine poisoning Xa59Y",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antileprotic drug poisoning Xa59b",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ethionamide poisoning Xa59e",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional para-aminosalicylic acid poisoning Xa59h",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional sulphone poisoning Xa59l",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional pesticide product poisoning All Psychoanalytic and psychodynamic therapy Xa8IJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Long-term exploratory psychotherapy 3841.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Psychoanalysis XaA8V",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Generic psychoanalysis XaA8W",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Independent psychoanalysis XaA8T",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Kleinian psychoanalysis XaA8U",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Bion-based group psychoanalysis XaA8X",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Classical psychoanalysis All Bion-based group psychoanalysis 384Z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Psychological analysis NOS Xa8IM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Jungian-based therapy Xa8IN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Generic Jungian-based therapy Xa8IP",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Analytical psychology Xa8IR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Long-term psychodynamic psychotherapy XaA8Z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Developmental psychodynamic psychotherapy XaA8c",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Supportive expressive psychodynamic psychotherapy XaA8d",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Psychodynamic-interpersonal psychotherapy XaEVq All Psychodynamic psychotherapy Xad7C",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Focal psychodynamic therapy Xa8IR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Long-term psychodynamic psychotherapy XaA8Z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Developmental psychodynamic psychotherapy XaA8c",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Supportive expressive psychodynamic psychotherapy XaA8d",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Psychodynamic-interpersonal psychotherapy Xa8II",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Short-term psychodynamic therapy XaXuc All Dynamic interpersonal therapy XaA9g",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Specific task orientated psychotherapy XE0iL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Psychotherapy/sociotherapy 8G9Z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Other psychotherapy NOS 8G9.. All Other psychotherapy ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "Supplementary ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "Supplementary ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of atopic and autoimmune conditions w ith R ead code lists."
        },
        {
            "text": "Term ID Description J40.. All Regional enteritis-Crohn's disease J400.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Regional enteritis of the small bowel J4000",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Regional enteritis of the duodenum J4001",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Regional enteritis of the jejunum J4002 All Crohn's disease of the termnal ileum J4003",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Crohn's disease of the ileum unspecified J4004",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Crohn's disease of the ileum NOS J4005",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Exacerbation of Crohn's disease of small intestine J400z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Crohn's disease of the small bowel NOS J40.. All Crohn's disease J4010",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Regional enteritis of the colon J4011",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Regional enteritis of the rectum J4012",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Exacerbation of Crohn's disease of large intestine J401z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Crohn's disease of the largel bowel NOS J40z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Crohn's disease Xa0lh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Regional enteritis X302r",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Crohn's jejunitis X302t",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Crohn's ileitis J4003 All Crohn's disease of the ileum unspecified J4004 All Crohn's disease of the ileum NOS J4002 All Crohn's disease of terminal ileum J400.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Regional enteritis of small bowel XaK6C",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Exacerbation of Crohn's disease of small intestine J400z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Crohn's disease of the small bowel NOS J401.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Regional enteritis of the large bowel XE0af",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Crohn's disease of the large bowel NOS XaK6D",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Exacerbation of Crohn's disease of large intestine J40z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Regional enteritis NOS J4010 All Crohn's colitis J4011 All Crohn's proctitis X3050",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Perianal Crohn's disease Jyu40",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All [X]Other Crohn's disease J4001",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "Y30Fy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "Regional enteritis of the jejunum All Hypothyroidism due to iodide trapping defect X40Hw",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Hypothyroidism due to iodide organification defect X40Hx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Hypothyroidism due to coupling defect X40Hy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Hypothyroidism due to deiodase defect X40Hz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Hypothyroidism due to thyroglobulin synthesis defect Cyu11",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All All Hypothyroidism due to iodide trapping defect X40Hw",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Hypothyroidism due to iodide organification defect X40Hx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Hypothyroidism due to coupling defect X40Hy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Hypothyroidism due to deiodase defect X40Hz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Hypothyroidism due to thyroglobulin synthesis defect Cyu11",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All [X]Other specified hypothyroidism Xa3ec",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Hypothyroidism -congenital and acquired Xa08g",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Transient neonatal hypothyroidism Q4337",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Neonatal jaundice with congenital hypothyroidism All Multiple sclerosis monitoring administration XaX9F",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Multiple sclerosis monitoring first letter XaX9H",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Multiple sclerosis monitoring second letter XaX9J",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Multiple sclerosis monitoring telephone invitation XaX9L",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Multiple sclerosis monitoring third letter F20.. All Multiple sclerosis XaP1V",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Secondary progressive multiple sclerosis XaP1B",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Relapsing and remitting multiple sclerosis XaP0r",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Primary progressive multiple sclerosis XaP0X",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Malignant multiple sclerosis XaOzZ All Benign multiple sclerosis X005c",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute relapsing multiple sclerosis X005d",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Chronic progressive multiple sclerosis X005e",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Remittent-progressive multiple sclerosis F200.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Multiple sclerosis of the brainstem F201.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Multiple sclerosis of the spinal cord F202.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Generalised multiple sclerosis ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "Supplementary All Acute non suppurative otitis media F5100",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute otitis media with effusion F5101",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute serous otitis media F5102",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute mucoid otitis media F5103",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute sanguinous otitis media F5104",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute allergic serous otitis media F5105",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute allergic mucoid otitis media F5106",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute allergic sanguinous otitis media F510z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute nonsuppurative otitis media NOS F52..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Suppurative and unspecified otitis media F520.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute suppurative otitis media F5200",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute suppurative otitis media tympanic membrane intact F5201",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute suppurative otitis media tympanic membrane ruptured F5203",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute suppurative otitis media due to disease EC F520z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute suppurative otitis media NOS F526.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute left otitis media F527.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute right otitis media F528.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute bilateral otitis media F52z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Otitis media NOS H00..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute nasopharyngitis H01.. All Acute sinusitis H010.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute maxillary sinusitis H011.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute frontal sinusitis H012.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute ethmoidal sinusitis H013.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute sphenoidal sinusitis H014.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute rhinosinusitis H01y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Other acute sinusitis H01y0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute pansinusitis H01yz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Other acute sinusitis NOS H01z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute sinusitis NOS H02..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute pharyngitis H020.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute gangrenous pharyngitis H021.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute phlegmonous pharyngitis H022.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute ulcerative pharyngitis All Acute pneumococcal pharyngitis H0231",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute staphylococcal pharyngitis H023z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute bacterial pharyngitis NOS H024.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute viral pharyngitis H025.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Allergic pharyngitis H02z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute pharyngitis NOS H03..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute tonsillitis H030.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute erythematous tonsillitis H031.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute follicular tonsillitis H032.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute ulcerative tonsillitis H033.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute catarrhal tonsillitis H034.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute gangrenous tonsillitis H035.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute bacterial tonsillitis H0350",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute pneumococcal tonsillitis H0351",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute staphylococcal tonsillitis H035z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute bacterial tonsillitis NOS H036.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute viral tonsillitis H037.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Recurrent acute tonsillitis H03z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute tonsillitis NOS H04..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute laryngitis and tracheitis H040.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute laryngitis H0400",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute oedematous laryngitis H0401",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute ulcerative laryngitis H0402",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute catarrhal laryngitis H0403",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute phlegmonous laryngitis H0404",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute haemophilus influenzae laryngitis H0405",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute pneumococcal laryngitis H0406",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute suppurative laryngitis H040w",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute viral laryngitis unspecified H040x",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute bacterial laryngitis unspecified H040z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute laryngitis NOS H041.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute tracheitis H0410",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute tracheitis without obstruction H0411",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute tracheitis with obstruction H041z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute tracheitis NOS H042.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute laryngotracheitis H0420",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute laryngotracheitis without obstruction H0421",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute laryngotracheitis with obstruction H042z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute laryngotracheitis NOS H043.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute epiglottitis (non strep) H0430",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute epiglottitis without obstruction All Acute obstructive laryngitis H043z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute epiglottitis NOS H044.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Croup H04z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute laryngitis and tracheitis NOS H05..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "Other acute upper respiratory infections H050.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute laryngopharyngitis H051.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute upper respiratory tract infection H052.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Pharyngotracheitis H053.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Tracheopharyngitis H054.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Recurrent upper respiratory tract infection H055.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Pharyngolaryngitis H05y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "Other upper respiratory infections of multiple sites H05z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Upper respiratory infection NOS H0y..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "Other specified acute respiratory infections H0z..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute respiratory infection NOS Read CTV3 Code Term ID Description",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Streptococcal laryngitis A3403",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Streptococcal tonsillitis A740.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Herpangina AA12.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Vincent's angina -pharyngitis F51..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Non-suppurative otitis media with eustachian tube disorders F510.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute non-suppurative otitis media F5100",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute otitis media: [with effusion] or [secretory] F5101",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute non-suppurative otitis media -serous F5102",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute non-suppurative otitis media -mucoid F5103",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute non-suppurative otitis media -sanguinous F5104",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute allergic serous otitis media F5105",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute allergic mucoid otitis media F5106",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute allergic sanguinous otitis media F510z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute non-suppurative otitis media NOS F52..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Suppurative and unspecified otitis media F520.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute suppurative otitis media F5200",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute suppurative otitis media -tympanic membrane intact F5201",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute suppurative otitis media -tympanic membrane ruptured F5203",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute suppurative otitis media due to disease EC F520z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute suppurative otitis media NOS F526.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute left otitis media F527.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute right otitis media F528.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute bilateral otitis media F52z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Ear infection &/or otitis media NOS FyuP0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All [X]Other acute non-suppurative otitis media H00.. All (Acute nasopharyngitis or rhinitis) or (common cold) All Acute maxillary sinusitis H011.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute frontal sinusitis H012.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute ethmoidal sinusitis H013.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute sphenoidal sinusitis H014.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All NULL H01y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Other acute sinusitis H01y0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute pansinusitis H01yz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Other acute sinusitis NOS H01z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute sinusitis NOS H02.. All Acute gangrenous pharyngitis H021.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute phlegmonous pharyngitis H022.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute ulcerative pharyngitis H023.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute bacterial pharyngitis H0230",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute pneumococcal pharyngitis H0231",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute staphylococcal pharyngitis H023z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute bacterial pharyngitis NOS H024.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute viral pharyngitis H025.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Allergic pharyngitis H02z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute pharyngitis NOS H03..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Tonsillitis (& acute) H030.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute erythematous tonsillitis H031.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute follicular tonsillitis H032.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute ulcerative tonsillitis H033.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute catarrhal tonsillitis H034.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute gangrenous tonsillitis H035.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute bacterial tonsillitis H0350",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute pneumococcal tonsillitis H0351",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute staphylococcal tonsillitis H035z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute bacterial tonsillitis NOS H036.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute viral tonsillitis H037.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Recurrent acute tonsillitis H03z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute tonsillitis NOS H04..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All NULL H040.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute laryngitis H0400",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute oedematous laryngitis H0401",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute ulcerative laryngitis H0402",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute catarrhal laryngitis H0403",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute phlegmonous laryngitis H0404",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute haemophilus influenzae laryngitis H0405",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute pneumococcal laryngitis All Acute viral laryngitis unspecified H040x",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute bacterial laryngitis unspecified H040z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute laryngitis NOS H041.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute tracheitis H0410",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute tracheitis without obstruction H0411",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute tracheitis with obstruction H041z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute tracheitis NOS H042.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Laryngotracheitis (& acute) H0420",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute laryngotracheitis without obstruction H0421",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute laryngotracheitis with obstruction H042z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute laryngotracheitis NOS H043.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Epiglottitis: [viral] or [acute non streptococcal] H0430",
            "cite_spans": [
                {
                    "start": 18,
                    "end": 25,
                    "text": "[viral]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute epiglottitis without obstruction H0431",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute epiglottitis with obstruction H0432",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All NULL H043z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute epiglottitis NOS H044.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All NULL H04z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "All Acute laryngitis and tracheitis NOS H05..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "Other acute upper respiratory infections H050.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute laryngopharyngitis H051.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All NULL H052.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All NULL H053.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Tracheopharyngitis H054.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Recurrent upper respiratory tract infection H055.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Pharyngolaryngitis H05y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Other upper respiratory infections of multiple sites H05z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Upper respiratory tract infection (& viral) NOS H0y..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "Other specified acute respiratory infections H0z..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute respiratory infection NOS X00iq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Recurrent acute suppurative otitis media X00m1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Pott's puffy tumour X00mH",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute herpes simplex pharyngitis X00mI",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute herpes zoster pharyngitis X00mJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Enteroviral lymphonodular pharyngitis X00mL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Glandular fever pharyngitis X00mq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Vincent's tonsillitis X00n1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute simple laryngitis X00n2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Vincent's laryngitis X00n4",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute membranous laryngitis X00n5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Acute subglottic laryngitis X00n6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Recurrent allergic croup ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "Term ID Description H20.. All Viral pneumonia H200.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to adenovirus H201.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to respiratory syncytial virus H202.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to parainfluenza virus H203.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to human metapneumovirus H20y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Viral pneumonia NEC H20y0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Severe acute respiratory syndrome H20z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Viral pneumonia NOS H21.. All Lobar (pneumococcal) pneumonia H22.. All Other bacterial pneumonia H220.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to klebsiella pneumoniae H221.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to pseudomonas H222.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to haemophilus influenzae H223.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to streptococcus H2230",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to streptococcus, group B H224.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to staphylococcus H22y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to other specified bacteria H22y0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to escherichia coli H22y1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to proteus H22y2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia -Legionella H22y3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to Gram negative bacteria H22yX",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to other aerobic gram-negative bacteria H22yz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to bacteria NOS H22z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Bacterial pneumonia NOS H23.. All Pneumonia due to other specified organisms H230.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to Eaton's agent H231.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to mycoplasma pneumoniae H232.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to pleuropneumonia like organisms H233.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Chlamydial pneumonia H23z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to specified organism NOS H24.. All Pneumonia with infectious diseases EC H240.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with measles H241.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with cytomegalic inclusion disease H242.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with ornithosis H243.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with whooping cough H244.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with tularaemia H245.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with anthrax H246.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with aspergillosis All Acute viral bronchitis unspecified H060x",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute bacterial bronchitis unspecified H060z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute bronchitis NOS H061.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute bronchiolitis H0610 All Acute capillary bronchiolitis H0611 All Acute obliterating bronchiolitis H0612",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute bronchiolitis with bronchospasm H0613 All Acute exudative bronchiolitis H0614 All Obliterating fibrous bronchiolitis H0615 All Acute bronchiolitis due to respiratory syncytial virus H0616 All Acute bronchiolitis due to other specified organisms H0617",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All NULL H061z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute bronchiolitis NOS H062.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All NULL ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "Term ID Description H20.. All Viral pneumonia H200.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to adenovirus H201.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to respiratory syncytial virus H202.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to parainfluenza virus H203.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to human metapneumovirus H20y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Viral pneumonia NEC H20y0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Severe acute respiratory syndrome H20z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Viral pneumonia NOS H21.. All Lobar (pneumococcal) pneumonia H22.. All Other bacterial pneumonia H220.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to klebsiella pneumoniae H221.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to pseudomonas H222.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to haemophilus influenzae H223.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to streptococcus H2230",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to streptococcus, group B H224.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to staphylococcus H22y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to other specified bacteria H22y0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to escherichia coli H22y1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to proteus H22y2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia -Legionella H22y3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to Gram negative bacteria H22yX",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to other aerobic gram-negative bacteria H22yz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to bacteria NOS H22z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Bacterial pneumonia NOS H23.. All Pneumonia due to other specified organisms H230.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to Eaton's agent H231.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to mycoplasma pneumoniae H232.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to pleuropneumonia like organisms H233.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Chlamydial pneumonia H23z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia due to specified organism NOS H24.. All Pneumonia with infectious diseases EC H240.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with measles H241.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with cytomegalic inclusion disease H242.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with ornithosis H243.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with whooping cough H244.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with tularaemia H245.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with anthrax H246.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with aspergillosis H247.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Pneumonia with other systemic mycoses All Acute viral bronchitis unspecified H060x",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute bacterial bronchitis unspecified H060z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute bronchitis NOS H061.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute bronchiolitis H0610 All Acute capillary bronchiolitis H0611 All Acute obliterating bronchiolitis H0612 All Acute bronchiolitis with bronchospasm H0613 All Acute exudative bronchiolitis H0614 All Obliterating fibrous bronchiolitis H0615 All Acute bronchiolitis due to respiratory syncytial virus H0616 All Acute bronchiolitis due to other specified organisms H0617",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All NULL H061z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Acute bronchiolitis NOS H062.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All NULL All Larva migrans of skin Xa0kT",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic granuloma of skin Xa0Qy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Complicated donovanosis Xa0Ws",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Staphylococcus aureus superficial folliculitis Xa139",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Site-specific infective disorders of skin Xa13A",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Intertrigo Xa13C",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Submammary monilia Xa1y2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Abscess of toe All Acute amoebic dysentery A051.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Chronic intestinal amoebiasis A052.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic nondysenteric colitis A053.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic liver abscess A054.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic lung abscess A055.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic brain abscess A056.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic skin ulceration A05y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic infection of other sites A05y0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic appendicitis A05y1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic balanitis A05y2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoeboma A05yz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All Amoebic infection of other sites NOS A05z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "All ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "Alopecia Areata (AA) is a common cause of immune-mediated non-scarring hair loss. Links between AA and common mental health, autoimmune and atopic conditions, and common infections have previously been described but remain incompletely elucidated and contemporary descriptions of the epidemiology of AA in the UK are lacking.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introduction:"
        },
        {
            "text": "Retrospective study series using a large population-based cohort (5. In the epidemiology theme, we will describe the incidence and point prevalence of AA overall and by age, sex, and sociodemographic factors. Healthcare utilisation (primary care visits and secondary care referrals) and treatments for AA will also be assessed. In the mental health theme, we will explore the prevalence and incidence of mental-health conditions (anxiety, depressive episodes, recurrent depressive disorder, adjustment disorder, agoraphobia, self-harm, and parasuicide) in people with AA compared with matched controls. We will also explore mental health treatment patterns (medication and psychological interventions), time off work and unemployment rates. Within the ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods and analysis:"
        },
        {
            "text": "\uf0b7 We will use a nationally representative primary care database of over 5.2 million people to explore the epidemiology of alopecia areata (AA), as well as associations of AA with mental health conditions, autoimmune and atopic conditions, and common infections. \uf0b7 As national guidelines recommend initial assessment and management of AA is undertaken in primary care, this study will provide an accurate contemporary analysis of AA epidemiology in England in both children and adults. \uf0b7 The Oxford-RCGP-RSC primary care dataset has a high level of completeness on sociodemographic and geographic data and therefore enables an assessment of variation in the incidence and prevalence of AA across England. \uf0b7 Oxford-RCGP-RSC is the primary infectious disease sentinel network for the UK; the common in infections to be explored are all regularly monitored conditions within the network. \uf0b7 A limitation of the study is that a validated case definition of AA is not available for primary care databases; this will be mitigated by additional analysis to explore the sensitivity of findings when non-specific alopecia diagnostic codes (e.g. unspecified alopecia) are included.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Strengths and limitations of this study"
        },
        {
            "text": "Alopecia areata, epidemiology, incidence, prevalence, common mental health conditions, depression, anxiety, autoimmune disease, atopic conditions, study protocol, common infections. Following the initial episode, the majority of those with limited patchy AA will experience spontaneous remission, but over 80% will have subsequent relapses.(7) Spontaneous remission has been reported to occur in less than 10% of those with extensive AA. This study series, using a large contemporary population-based sample aims to explore and describe many important elements of AA over four key areas: i) the ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Key words:"
        },
        {
            "text": "A central theory in AA pathogenesis is that it is an autoimmune phenomenon resulting from a disruption of hair follicle 'immune privilege', where numerous There has also been interest in the prevalence of co-morbid atopy in patients with AA. The prevalence of atopy in patients with AA has been reported to be in the range of 11-38.2%(5) representing cohorts from the USA, India and Singapore . ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 conditions, and a genome-wide association study established that IL-13 is also susceptible loci for AA. (30) ",
            "cite_spans": [
                {
                    "start": 395,
                    "end": 396,
                    "text": "(",
                    "ref_id": null
                },
                {
                    "start": 787,
                    "end": 791,
                    "text": "(30)",
                    "ref_id": "BIBREF86"
                }
            ],
            "ref_spans": [
                {
                    "start": 397,
                    "end": 682,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Autoimmune and atopic comorbidities"
        },
        {
            "text": "It has been hypothesized that infections may act as triggers for AA; with particular interest in Helicobacter pylori, cytomegalovirus, Epstein-Barr virus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus but others have also been suggested. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 263,
                    "end": 488,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Common infections"
        },
        {
            "text": "We aim to perform a series of retrospective studies using a large population-based cohort in England, over a decade (1 st January 2009 to 1 st January 2019) exploring AA in four theme areas: epidemiology, mental health, autoimmune and atopic comorbidities and common infections.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Aims and Objectives"
        },
        {
            "text": "Within the epidemiology theme, our initial objective is to provide a complete description of the incidence and prevalence of AA in England. We will explore the influence of socio-demographic and geographic factors on disease incidence and describe the current service utilisation and management patterns in AA during the year after diagnosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Aims and Objectives"
        },
        {
            "text": "Within the mental health theme, we will explore the disease burden of common mental health conditions in people with AA compared with matched controls. We will calculate the prevalence of disease at AA diagnosis, the incidence of disease in the first two years after diagnosis and the influence of socio-demographic factors on the prevalence of common mental health conditions in AA. We will describe the mental health treatment burden in people (medication and psychological service use) with AA and depression and anxiety. We will also explore potential associations between AA and both time off work and unemployment.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Aims and Objectives"
        },
        {
            "text": "Within the autoimmune and atopic comorbidities theme, we will examine the prevalence of atopic and autoimmune conditions at AA diagnosis, and the incidence Within the common infections theme, we will examine the incidence of multiple common infections in the first five years after diagnosis in people with AA compared with matched controls.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Aims and Objectives"
        },
        {
            "text": "The primary and secondary objects of each study theme are formally described in the Statistical Analysis Plan (Additional file 1). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Aims and Objectives"
        },
        {
            "text": "These studies will use routinely collected and collated data from the Oxford-Royal ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods and analysis Data source"
        },
        {
            "text": "Within RCGP RSC, people with and without AA will be identified using Read diagnostic codes. A range of study designs will be used across the studies and include; repeated cross-sectional design (epidemiology of AA), case-control design (the prevalence of common mental health conditions, atopic and autoimmune conditions, and common infections at AA diagnosis), and matched-cohort design (the incidence of common mental health conditions, atopic and autoimmune conditions, and common infections after AA diagnosis).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study design"
        },
        {
            "text": "We will identify cases of AA using specific diagnostic codes (Supplementary Table   S1 .1, Additional file 2). Confirmed AA will be defined as one or more AA code and no alternative diagnostic code in the subsequent 365 days (alternative diagnoses are defined in Supplementary Table S1.1, Additional file 2). Specificity of findings to this case definition will be evaluated (see Sensitivity analysis and Supplementary ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 61,
                    "end": 86,
                    "text": "(Supplementary Table   S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Alopecia areata case detection"
        },
        {
            "text": "We will describe the incidence and point prevalence of AA over [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] [2017] [2018] inclusive, by age group, sex, ethnicity, and socioeconomic status, and geographical region. Ethnicity will be categorised as follows based on UK census categories:",
            "cite_spans": [
                {
                    "start": 63,
                    "end": 69,
                    "text": "[2009]",
                    "ref_id": null
                },
                {
                    "start": 70,
                    "end": 76,
                    "text": "[2010]",
                    "ref_id": null
                },
                {
                    "start": 77,
                    "end": 83,
                    "text": "[2011]",
                    "ref_id": null
                },
                {
                    "start": 84,
                    "end": 90,
                    "text": "[2012]",
                    "ref_id": null
                },
                {
                    "start": 91,
                    "end": 97,
                    "text": "[2013]",
                    "ref_id": null
                },
                {
                    "start": 98,
                    "end": 104,
                    "text": "[2014]",
                    "ref_id": null
                },
                {
                    "start": 105,
                    "end": 111,
                    "text": "[2015]",
                    "ref_id": null
                },
                {
                    "start": 112,
                    "end": 118,
                    "text": "[2016]",
                    "ref_id": null
                },
                {
                    "start": 119,
                    "end": 125,
                    "text": "[2017]",
                    "ref_id": null
                },
                {
                    "start": 126,
                    "end": 132,
                    "text": "[2018]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "The incidence and lifetime prevalence of alopecia areata"
        },
        {
            "text": "White, Asian, Black African/Caribbean, Mixed, and Other.(61) Index of multiple deprivation (IMD) will be used as a measure of socioeconomic status.(62)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "The incidence and lifetime prevalence of alopecia areata"
        },
        {
            "text": "We will assess primary care visit frequency, up to one year, in people newly diagnosed with AA compared to matched controls without AA. Measures of healthcare management will also be assessed in people newly diagnosed with AA up to one year, comprising; secondary care dermatology referrals (Supplementary   Table S1 .3, Additional file 2) and primary care prescriptions for AA treatments (Supplementary Table S1 .4, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 291,
                    "end": 316,
                    "text": "(Supplementary   Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 389,
                    "end": 412,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Service utilisation in people with alopecia areata"
        },
        {
            "text": "We will assess the prevalence and incidence of three common mental conditions as 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 To assess prevalence, we will perform a case-control analysis to compare the prevalence of mental health conditions between people newly diagnosed with AA and controls. To assess incidence, we will perform a matched cohort analysis in the subset of cases and controls free of the mental health conditions of interest at baseline. In addition, we will examine the prevalence and incidence of other mental health conditions; adjustment disorder, agoraphobia, self-harm, and overdose/parasuicide attempts (Supplementary Tables S2.5-S2.9, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 81,
                    "end": 306,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Study 2: Mental Health conditions in people with alopecia areata"
        },
        {
            "text": "We will determine the treatment burden of mental health medications in AA (selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, tetracyclic antidepressants, and monoamine oxidase inhibitors, anxiolytic medications) and psychological intervention (referral rates for counselling, secondary care psychiatrist referrals, including the referrals to the clinical psychology services/specialists and UK Improving Access to Table S2 .10, Additional file 2)).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 482,
                    "end": 490,
                    "text": "Table S2",
                    "ref_id": null
                }
            ],
            "section": "Study 2: Mental Health conditions in people with alopecia areata"
        },
        {
            "text": "We will also assess unemployment and time off work in people of working age . Unemployment will be identified using codes relating to unemployment recorded in the clinical record or the issuing of IB113 or ESA113 form (Supplementary Table S3 Table S3 .2, Additional file 2). These \"fit notes\" are required by employers when employees have periods of absence from work for sickness lasting longer than seven days.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 218,
                    "end": 241,
                    "text": "(Supplementary Table S3",
                    "ref_id": null
                },
                {
                    "start": 242,
                    "end": 250,
                    "text": "Table S3",
                    "ref_id": null
                }
            ],
            "section": "Study 2: Mental Health conditions in people with alopecia areata"
        },
        {
            "text": "We will assess the prevalence and incidence of autoimmune and atopic conditions as listed in Table 1 and defined in Supplementary Tables S4, Additional file 2, in people with AA. To assess prevalence, we will perform a case-control study to compare the prevalence of these conditions between cases and controls. To assess incidence, we will perform a matched cohort study to compare the incidence of new autoimmune and atopic conditions in the same cases and controls after the point of matching. Autoimmune and atopic conditions were included if prevalence has been reported to be 0.3% or greater. (9, (64) (65) (66) (67) This cut-off was based on power calculations suggesting this is minimum background prevalence required to detect ",
            "cite_spans": [
                {
                    "start": 599,
                    "end": 602,
                    "text": "(9,",
                    "ref_id": null
                },
                {
                    "start": 603,
                    "end": 607,
                    "text": "(64)",
                    "ref_id": null
                },
                {
                    "start": 608,
                    "end": 612,
                    "text": "(65)",
                    "ref_id": null
                },
                {
                    "start": 613,
                    "end": 617,
                    "text": "(66)",
                    "ref_id": "BIBREF121"
                },
                {
                    "start": 618,
                    "end": 622,
                    "text": "(67)",
                    "ref_id": "BIBREF122"
                }
            ],
            "ref_spans": [
                {
                    "start": 93,
                    "end": 162,
                    "text": "Table 1 and defined in Supplementary Tables S4, Additional file 2, in",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Study 3: Autoimmune and atopic comorbidities in alopecia areata"
        },
        {
            "text": "We will assess the incidence of common infections in people with AA using a matched cohort study to compare the incidence of common infections in cases and controls. The common infections to be examined are listed in Table 2 and defined in Supplementary Tables S5, Additional file 2.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 217,
                    "end": 224,
                    "text": "Table 2",
                    "ref_id": null
                }
            ],
            "section": "Study 4: common infections in alopecia areata"
        },
        {
            "text": "The full statistical analysis plan is provided in Additional file 1. Briefly, for Study 1, AA prevalence will be calculated by dividing the number of AA cases by the total number of eligible people in the study population. Point prevalence will be reported for the cohort overall and stratified by sex and age. AA incidence will be calculated by dividing the total number of new AA cases by the total person-years of follow-up. Incidence rates will be stratified by calendar year, socio-demographic factors (age group, sex, ethnicity, rural/urban classification and socioeconomic status) and geographical region. Adjusted incidence rates will be estimated using For studies 1 (for comparison of primary care visit frequency only), 2 and 3, matching will be performed as follows: control cohorts will be defined by matching cases with people without a diagnosis of AA or other alopecia. The follow-up period for each matched control will begin at the start of follow-up of their matched case.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical methods"
        },
        {
            "text": "Each case will be nearest neighbour matched with four controls by age and sex within GP practices. After matching, if there are substantial differences in socioeconomic status between cases and controls, re-matching with IMD as an additional matching criterion will be considered. Study 4 will use the same nearest neighbour matching process but cases will be defined as people diagnosed with AA on or before 1 st January 2014, people who develop AA during follow up will be excluded from the pool of available controls prior to matching.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical methods"
        },
        {
            "text": "For Study 2, we will report the prevalence of mental health conditions by sociodemographic subgroups in cases and controls. The burden of treatment for mental health conditions will be estimated as the total proportion of people prescribed each treatment within one year after the study start. The burden of sick days will be estimated as the total proportion of people issued a Med 3 certificate. To assess differences in incident mental health conditions in the two years after the study start, we will use adjusted Cox regression stratified by case/control status. Study 3 (atopic and autoimmune conditions) will similarly compare baseline disease prevalence in cases and controls, and compare incidence of new onset conditions in the five years after the study start using adjusted Cox regression. Infection incidence rates will be estimated by dividing the number of incident common infections by total person-years of follow-up. Adjusted Poisson regression will be used to estimate the association between AA and rates of common infection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical methods"
        },
        {
            "text": "To evaluate the specificity of any identified associations to our AA case definition, in sensitivity analysis we will extract alopecia recorded where the type has not been specified (Supplementary Table S1 .1, Additional file 2). We will then assess the characteristics of people with non-specific alopecia codes only (i.e. no prior or subsequent codes specifying alopecia type) compared to the primary AA cohort. If the characteristics are not markedly different, which would indicate the groups are clinically different and not comparable, we will evaluate major study outcomes in this non-specific AA cohort and compare results to those obtained for the primary AA cohort. We will also evaluate whether stratifying analyses by alopecia extent is possible, dependent on how well this is recorded in primary care data (Supplementary Table S1 .2, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 182,
                    "end": 205,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 819,
                    "end": 842,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Sensitivity analyses"
        },
        {
            "text": "In Study 4, we will use a Cox regression to estimate time to first infection. We will also compare the results of the study outcomes when 1) people who develop AA during the follow up are included as cases and 2) when we perform matching using the time of AA diagnosis and follow for up to five years after diagnosis (or matched date for controls). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sensitivity analyses"
        },
        {
            "text": "Results derived from this study will be useful in monitoring trends in the incidence of AA in England and may identify factors that influence the disease distribution and treatment patterns. Furthermore, obtaining an accurate picture of the state of AA in the UK will help inform Health Needs Assessments and policy development. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Clinical Implications"
        },
        {
            "text": "Several strengths of our study design are noteworthy. Only two previous studies on the incidence and prevalence of AA have been population-based, with the vast majority being conducted on clinic patients and thus leading to skewed prevalence estimates. This study will also provide a contemporary picture of the burden of AA, as the previous population-based studies were over 20 years ago, and this will be the first AA epidemiology study conducted in the UK. To our knowledge, our study examining common infections will be the first study to attempt to answer the question of whether AA confers protection or increased risk for common infections.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Strengths and limitations of the research methods"
        },
        {
            "text": "A final key strength of this study is the use of the national infections surveillance network to analyse infection risk; with regular feedback to practices with a focus on the quality of infections recording the quality of recording of these infection events higher in this network than other data sources.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Strengths and limitations of the research methods"
        },
        {
            "text": "A limitation of the study is the lack of a validated AA case definition using primary care data. We are unable to develop one as we have access only to coded anonymised healthcare record data for this study. However, our ontological approach to detecting cases of AA and associated comorbidities will improve accuracy compared to the use of diagnostic codes alone.(69, 70) Exclusion of individuals with potentially confounding conditions (i.e. other causes of hair loss) will also improve the accuracy of our estimates. The algorithms used to detect common mental health conditions have been previously validated in UK primary care. The completeness of GP data coding for prescriptions, referrals and issue of Med 3 certificates will ensure that our findings on AA and comorbidity Furthermore, only coded data in the database can be used and hence we rely upon accurate coding. Some individuals may need to be excluded due to incomplete data, although in similar studies the exclusion rate due to incomplete data has been low.(72, 73) Prevalence of Med 3 certification is well captured in primary care but the reason for issue is not available meaning that we cannot identify the condition relating to the Med 3 certification. We cannot therefore determine whether the sick leave was as a result of AA. However, our case-control approach will provide a method for comparing Med 3 certificate issue rates in those affected and unaffected by AA. The use of Read codes to identify unemployment is likely to systemically under- Another limitation is the possibility of missing treatment information from secondary care. Secondary care records in the UK are frequently not computerised and prescriptions are still commonly hand-written. At present there is no mechanism for universally capturing secondary care prescriptions and linking them to primary care records. We are therefore likely to underestimate prescription rates for those with the most severe disease who are seen frequently in secondary care. Where prescriptions are issued from primary care the indication for the prescription is not available and we can therefore not confirm that the prescription is for the treatment of AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Strengths and limitations of the research methods"
        },
        {
            "text": "Individual patient data will be anonymised at the point of data extraction. All data will remain in anonymised form and will be held on a secure server at the University of Surrey. All statistical analyses will be performed using R software.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data management"
        },
        {
            "text": "The design of this protocol did not involve patients or this public. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Patient and Public Involvement"
        },
        {
            "text": "This study series aims to provide the first large scale population-based analysis of the epidemiology of AA in the UK and the current patterns of healthcare utilisation and treatments in this group. We also aim to provide an extensive assessment of the association between common mental health conditions and work-related difficulties in people with AA; reporting the prevalence and incidence of these conditions in people with new onset AA and matched controls. We aim to provide an extensive evaluation of the prevalence and incidence of autoimmune and atopic conditions in people with new onset AA and matched controls. Finally, we aim to provide evidence for baseline common infection risk in people with AA which can be used to support treatment decisions regarding the use of immune-modulating medications for AA. This study series will extend our knowledge of the current disease burden from AA and associated conditions. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusions"
        },
        {
            "text": "The RCGP RSC dataset can be accessed by bone fide researchers, approval is on a project-by-project basis (www.rcgp.org.uk/rsc). Researchers wishing to directly analyse the patient-level pseudonymised data will be required to complete information governance training and work on the data from the secure servers at the University of Surrey or University of Oxford. Patient-level data cannot be taken out of the secure networks.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Availability of data and materials"
        },
        {
            "text": "SdeL ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Competing interests"
        },
        {
            "text": "This research was sponsored and funded by Pfizer.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Funding statement"
        },
        {
            "text": "The study was designed and developed by CT, MH, SH, ART, AEM, WSC, WRG, and AGM with input from SdeL. The protocol writing was directed and critically reviewed by CT, MH, SH, ART, AEM, WSC, WRG, SdeL, and AGM. ................................................................................................................................... ..................................................................... ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 210,
                    "end": 341,
                    "text": "...................................................................................................................................",
                    "ref_id": null
                },
                {
                    "start": 342,
                    "end": 411,
                    "text": ".....................................................................",
                    "ref_id": null
                }
            ],
            "section": "Authors' contributions"
        },
        {
            "text": "Alopecia areata (AA) is a common cause of immune-mediated, non-scarring hair loss. (1) Clinical presentations of AA are heterogeneous, ranging from well-demarcated patches of hair loss on the scalp to total loss of hair on the scalp (alopecia areata totalis) or entire scalp and body (alopecia areata universalis). (2) Active AA is estimated to affect approximately 0.1-0.2% (2, 3)of the population worldwide, with a lifetime risk of 1.0 -2.1%. (4) (5) (6) Following the initial episode, the majority of those with limited patchy AA will experience spontaneous remission, but over 80% will have subsequent relapses. (7) Spontaneous remission has been reported to occur in less than 10% of those with extensive AA. (7) A number of treatment options can induce hair growth in people with AA, but none have been shown to have a durable impact on remission. (8) AA has been associated with several autoimmune conditions supporting the theory of an underlying autoimmune aetiology. (9, 10) Atopic conditions and mental health disorders have also been demonstrated to be more common in people with AA, (9) (10) (11) although the temporal relationship between psychiatric conditions and AA remains poorly researched. (12) The association between AA and common infections is not well studied.",
            "cite_spans": [
                {
                    "start": 83,
                    "end": 86,
                    "text": "(1)",
                    "ref_id": "BIBREF125"
                },
                {
                    "start": 315,
                    "end": 318,
                    "text": "(2)",
                    "ref_id": null
                },
                {
                    "start": 445,
                    "end": 448,
                    "text": "(4)",
                    "ref_id": null
                },
                {
                    "start": 449,
                    "end": 452,
                    "text": "(5)",
                    "ref_id": null
                },
                {
                    "start": 453,
                    "end": 456,
                    "text": "(6)",
                    "ref_id": null
                },
                {
                    "start": 1096,
                    "end": 1099,
                    "text": "(9)",
                    "ref_id": null
                },
                {
                    "start": 1100,
                    "end": 1104,
                    "text": "(10)",
                    "ref_id": null
                },
                {
                    "start": 1105,
                    "end": 1109,
                    "text": "(11)",
                    "ref_id": null
                },
                {
                    "start": 1210,
                    "end": 1214,
                    "text": "(12)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Background"
        },
        {
            "text": "This statistical analysis plan covers four related AA studies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Purposes of analyses"
        },
        {
            "text": "Population studies in the USA using the Rochester Epidemiology Project database estimate the lifetime risk of AA to be 2.1%. (4) The database contained information from all patients registered with a healthcare provider in Olmstead County, Minnesota from 1990-2009. Previous studies using this database from 1971-1974 estimated the overall prevalence of AA to be 0.1-0.2%, (13) with no published studies reporting prevalence estimates since this. Other epidemiological studies have assessed the incidence of AA in patients referred to dermatology services. Clinic-based studies from around the world have estimated the incidence of AA to be in the region of 0.57-3.8%. (14) (15) (16) (17) (18) Worldwide, the majority of studies on AA have not found a significant difference in incidence between males and females. (5) There has also been interest in the prevalence of co-morbid atopy in patients with AA. The prevalence of atopy in patients with AA has been reported to be in the range of 11-38.2% (5) representing cohorts from the USA, India and Singapore. (10, 14, 28, 29) A large metaanalysis found patients with AA had higher odds of having atopic dermatitis (OR 2.36; 95%CI 1.80-3.09) and allergic rhinitis (OR 1.33;95%CI 1.19-1.47) when compared with controls. (9) It is not however surprising from a pathogenesis perspective in terms of shared pathways of autoimmune susceptibility; IL-13 loci have been associated with autoimmune and atopic conditions, and a genome-wide association study established that IL-13 is also susceptible loci for AA. (30)",
            "cite_spans": [
                {
                    "start": 373,
                    "end": 377,
                    "text": "(13)",
                    "ref_id": null
                },
                {
                    "start": 669,
                    "end": 673,
                    "text": "(14)",
                    "ref_id": null
                },
                {
                    "start": 674,
                    "end": 678,
                    "text": "(15)",
                    "ref_id": null
                },
                {
                    "start": 679,
                    "end": 683,
                    "text": "(16)",
                    "ref_id": null
                },
                {
                    "start": 684,
                    "end": 688,
                    "text": "(17)",
                    "ref_id": null
                },
                {
                    "start": 689,
                    "end": 693,
                    "text": "(18)",
                    "ref_id": null
                },
                {
                    "start": 1059,
                    "end": 1063,
                    "text": "(10,",
                    "ref_id": null
                },
                {
                    "start": 1064,
                    "end": 1067,
                    "text": "14,",
                    "ref_id": null
                },
                {
                    "start": 1068,
                    "end": 1071,
                    "text": "28,",
                    "ref_id": "BIBREF83"
                },
                {
                    "start": 1072,
                    "end": 1075,
                    "text": "29)",
                    "ref_id": "BIBREF84"
                }
            ],
            "ref_spans": [],
            "section": "Study 1: Epidemiology of AA"
        },
        {
            "text": "It has been hypothesized that infections may act as triggers for AA; with particular interest in Helicobacter pylori, cytomegalovirus, Epstein-Barr virus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus but others have also been suggested. (9, (31) (32) (33) (34) (35) (36) (37) (38) Some case reports has suggested improvement or resolution of AA with treatment of the associated infection. (33, 39) . However, early small-scale studies have failed to find convincing evidence to support associations. (35, 36, 40) Multiple genetic loci have been identified to be both protective from infection but increase the risk for autoimmune disease. (41) Examples include the HLA variants HLA-DQ2 and HLA-DQ8 which confer protection against viral infections including influenza but are associated with inflammatory bowel disease, (42, 43) and SH2B3 rs3184504*A gene variant protective against Escherichia coli infection but also detrimental for inflammatory bowel disease. (44) These loci which, in the past have conferred a genetic advantage, may still confer a reduced infection risk. (41) It is currently unclear if the genetic predisposition for AA is caused by genetic factors which also confer protection against any common infections. In other autoimmune conditions, infection risk is often increased as a result of the pathological changes resulting from the condition itself, the effects of immune-modulatory treatment, or through increased exposure to pathogens through healthcare contact. (45) (46) (47) (48) (49) (50) (51) An understanding of the relative infection rates in people with AA compared to those without is of particular importance with the emergence of Janus kinase inhibitors as a potential treatment option. (52) Whilst this medication class can produce impressive hair regrowth results even in long-standing, AA their use is associated with some increased infection risk; in particular, urinary tract infections, viral gastroenteritis fungal infections, and varicella zoster infection. (52) ",
            "cite_spans": [
                {
                    "start": 263,
                    "end": 266,
                    "text": "(9,",
                    "ref_id": null
                },
                {
                    "start": 267,
                    "end": 271,
                    "text": "(31)",
                    "ref_id": "BIBREF87"
                },
                {
                    "start": 272,
                    "end": 276,
                    "text": "(32)",
                    "ref_id": "BIBREF88"
                },
                {
                    "start": 277,
                    "end": 281,
                    "text": "(33)",
                    "ref_id": "BIBREF89"
                },
                {
                    "start": 282,
                    "end": 286,
                    "text": "(34)",
                    "ref_id": "BIBREF90"
                },
                {
                    "start": 287,
                    "end": 291,
                    "text": "(35)",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 292,
                    "end": 296,
                    "text": "(36)",
                    "ref_id": null
                },
                {
                    "start": 297,
                    "end": 301,
                    "text": "(37)",
                    "ref_id": null
                },
                {
                    "start": 302,
                    "end": 306,
                    "text": "(38)",
                    "ref_id": null
                },
                {
                    "start": 415,
                    "end": 419,
                    "text": "(33,",
                    "ref_id": "BIBREF89"
                },
                {
                    "start": 420,
                    "end": 423,
                    "text": "39)",
                    "ref_id": "BIBREF95"
                },
                {
                    "start": 526,
                    "end": 530,
                    "text": "(35,",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 531,
                    "end": 534,
                    "text": "36,",
                    "ref_id": null
                },
                {
                    "start": 535,
                    "end": 538,
                    "text": "40)",
                    "ref_id": "BIBREF96"
                },
                {
                    "start": 665,
                    "end": 669,
                    "text": "(41)",
                    "ref_id": "BIBREF97"
                },
                {
                    "start": 845,
                    "end": 849,
                    "text": "(42,",
                    "ref_id": "BIBREF98"
                },
                {
                    "start": 850,
                    "end": 853,
                    "text": "43)",
                    "ref_id": "BIBREF99"
                },
                {
                    "start": 988,
                    "end": 992,
                    "text": "(44)",
                    "ref_id": "BIBREF100"
                },
                {
                    "start": 1102,
                    "end": 1106,
                    "text": "(41)",
                    "ref_id": "BIBREF97"
                },
                {
                    "start": 1515,
                    "end": 1519,
                    "text": "(45)",
                    "ref_id": "BIBREF101"
                },
                {
                    "start": 1520,
                    "end": 1524,
                    "text": "(46)",
                    "ref_id": "BIBREF103"
                },
                {
                    "start": 1525,
                    "end": 1529,
                    "text": "(47)",
                    "ref_id": "BIBREF104"
                },
                {
                    "start": 1530,
                    "end": 1534,
                    "text": "(48)",
                    "ref_id": "BIBREF105"
                },
                {
                    "start": 1535,
                    "end": 1539,
                    "text": "(49)",
                    "ref_id": "BIBREF106"
                },
                {
                    "start": 1540,
                    "end": 1544,
                    "text": "(50)",
                    "ref_id": "BIBREF107"
                },
                {
                    "start": 1545,
                    "end": 1549,
                    "text": "(51)",
                    "ref_id": "BIBREF108"
                },
                {
                    "start": 1750,
                    "end": 1754,
                    "text": "(52)",
                    "ref_id": null
                },
                {
                    "start": 2029,
                    "end": 2033,
                    "text": "(52)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Study 4: Common infections in people with AA"
        },
        {
            "text": "The overall purpose of study 1 is to describe the epidemiology (incidence and prevalence) of AA and to assess the current level of primary care service utilisation and management patterns associated with people diagnosed with AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study objectiv es and endpoints 2.1 Study objectiv es 2.1.1 Study 1"
        },
        {
            "text": "The overall purpose of study 2 is to assess the prevalence and incidence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult people diagnosed with AA relative to a control population of people without a diagnosis of AA. In addition, the study will determine the treatment burden (medications and psychological interventions used to treat mental health conditions), 'sick day' burden, and unemployment burden of AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "The overall purpose of study 3 is to assess the prevalence and incidence of atopic and autoimmune conditions in adult people diagnosed with AA relative to a control population of people without AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "The overall purpose of study 4 is to assess the incidence of common infections in people diagnosed with AA relative to a control population of people without AA. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "Describe current primary care service utilisation and management patterns in AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.1.2"
        },
        {
            "text": "Describe the prevalence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult people diagnosed with AA in a contemporary real-world population compared with matched controls without AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.2.1"
        },
        {
            "text": "Describe the incidence of common mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in adult people diagnosed with AA in a contemporary real-world population compared with matched controls in the first two years after AA diagnosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.2.2"
        },
        {
            "text": "Describe the mental health treatment burden of adult people diagnosed with AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.2.3"
        },
        {
            "text": "Describe the prevalence of atopic and autoimmune conditions in adult people diagnosed with AA in a contemporary real-world population at diagnosis compared with matched controls without AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.3.1"
        },
        {
            "text": "Describe the incidence of atopic and autoimmune conditions in adult people with AA in a contemporary real-world population compared with matched controls in the first five years after AA diagnosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.3.2"
        },
        {
            "text": "Describe the overall rate of common infections in people with AA in a contemporary realworld population at diagnosis compared with matched controls in the first five years after AA diagnosis. Describe the rates of individual common infections in people with AA in a contemporary real-world population at diagnosis compared with matched controls in the first five years after AA diagnosis. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.2.4.1"
        },
        {
            "text": "Describe the prevalence of additional mental health conditions (adjustment disorder, agoraphobia, self-harm, and overdose/parasuicide attempts) in adult people diagnosed with AA and controls.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.3.2.1"
        },
        {
            "text": "Describe the burden of 'sick days' in adult people diagnosed with AA and controls.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.3.2.2"
        },
        {
            "text": "Describe the prevalence of unemployment in adult people diagnosed with AA and controls.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2.3.2.3"
        },
        {
            "text": "None",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "None ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "The primary endpoints for the four studies are listed in Table 1 . ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 57,
                    "end": 64,
                    "text": "Table 1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Primary endpoint"
        },
        {
            "text": "Study 1: Explore the incidence of AA by age (children) and age group (adults (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) , (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) , (60,70], (70-80], \u226580). These age groups are provisional. If, during exploratory analysis, we find that these age groups obscure the true incidence of AA (for example if AA incidence rates change substantially across one of these age groups) then we may modify these groupings. Any changes will be clearly stated as such in a final manuscript.",
            "cite_spans": [
                {
                    "start": 77,
                    "end": 81,
                    "text": "(18)",
                    "ref_id": null
                },
                {
                    "start": 82,
                    "end": 86,
                    "text": "(19)",
                    "ref_id": null
                },
                {
                    "start": 87,
                    "end": 91,
                    "text": "(20)",
                    "ref_id": null
                },
                {
                    "start": 92,
                    "end": 96,
                    "text": "(21)",
                    "ref_id": null
                },
                {
                    "start": 97,
                    "end": 101,
                    "text": "(22)",
                    "ref_id": null
                },
                {
                    "start": 102,
                    "end": 106,
                    "text": "(23)",
                    "ref_id": "BIBREF79"
                },
                {
                    "start": 107,
                    "end": 111,
                    "text": "(24)",
                    "ref_id": "BIBREF80"
                },
                {
                    "start": 112,
                    "end": 116,
                    "text": "(25)",
                    "ref_id": null
                },
                {
                    "start": 117,
                    "end": 121,
                    "text": "(26)",
                    "ref_id": "BIBREF81"
                },
                {
                    "start": 122,
                    "end": 126,
                    "text": "(27)",
                    "ref_id": "BIBREF82"
                },
                {
                    "start": 127,
                    "end": 131,
                    "text": "(28)",
                    "ref_id": "BIBREF83"
                },
                {
                    "start": 132,
                    "end": 136,
                    "text": "(29)",
                    "ref_id": "BIBREF84"
                },
                {
                    "start": 137,
                    "end": 141,
                    "text": "(30)",
                    "ref_id": "BIBREF86"
                },
                {
                    "start": 144,
                    "end": 148,
                    "text": "(30)",
                    "ref_id": "BIBREF86"
                },
                {
                    "start": 149,
                    "end": 153,
                    "text": "(31)",
                    "ref_id": "BIBREF87"
                },
                {
                    "start": 154,
                    "end": 158,
                    "text": "(32)",
                    "ref_id": "BIBREF88"
                },
                {
                    "start": 159,
                    "end": 163,
                    "text": "(33)",
                    "ref_id": "BIBREF89"
                },
                {
                    "start": 164,
                    "end": 168,
                    "text": "(34)",
                    "ref_id": "BIBREF90"
                },
                {
                    "start": 169,
                    "end": 173,
                    "text": "(35)",
                    "ref_id": "BIBREF91"
                },
                {
                    "start": 174,
                    "end": 178,
                    "text": "(36)",
                    "ref_id": null
                },
                {
                    "start": 179,
                    "end": 183,
                    "text": "(37)",
                    "ref_id": null
                },
                {
                    "start": 184,
                    "end": 188,
                    "text": "(38)",
                    "ref_id": null
                },
                {
                    "start": 189,
                    "end": 193,
                    "text": "(39)",
                    "ref_id": "BIBREF95"
                },
                {
                    "start": 194,
                    "end": 198,
                    "text": "(40)",
                    "ref_id": "BIBREF96"
                },
                {
                    "start": 201,
                    "end": 205,
                    "text": "(50)",
                    "ref_id": "BIBREF107"
                },
                {
                    "start": 206,
                    "end": 210,
                    "text": "(51)",
                    "ref_id": "BIBREF108"
                },
                {
                    "start": 211,
                    "end": 215,
                    "text": "(52)",
                    "ref_id": null
                },
                {
                    "start": 216,
                    "end": 220,
                    "text": "(53)",
                    "ref_id": "BIBREF110"
                },
                {
                    "start": 221,
                    "end": 225,
                    "text": "(54)",
                    "ref_id": "BIBREF111"
                },
                {
                    "start": 226,
                    "end": 230,
                    "text": "(55)",
                    "ref_id": "BIBREF112"
                },
                {
                    "start": 231,
                    "end": 235,
                    "text": "(56)",
                    "ref_id": "BIBREF113"
                },
                {
                    "start": 236,
                    "end": 240,
                    "text": "(57)",
                    "ref_id": "BIBREF114"
                },
                {
                    "start": 241,
                    "end": 245,
                    "text": "(58)",
                    "ref_id": null
                },
                {
                    "start": 246,
                    "end": 250,
                    "text": "(59)",
                    "ref_id": "BIBREF115"
                },
                {
                    "start": 251,
                    "end": 255,
                    "text": "(60)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Other exploratory analyses"
        },
        {
            "text": "The proposed studies will use the retrospectively collected data of all eligible patients within Oxford-Royal College of General Practitioners Research and Surveillance Centre database (RCGP RSC) at the date of data extraction. The RCGP RSC database incorporates pseudonymised primary care records from up to 200 GP practices distributed across England. Details of the cohort included in the database have been published previously. (54) The RCGP RSC cohort size (as of January 2019) is over 2.6 million actively registered patients, and historic records available for up to 5.2 million patients over the last 20 years.",
            "cite_spans": [
                {
                    "start": 433,
                    "end": 437,
                    "text": "(54)",
                    "ref_id": "BIBREF111"
                }
            ],
            "ref_spans": [],
            "section": "General Study Design and P lan"
        },
        {
            "text": "The cohort provides a broadly representative sample of the UK population.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "General Study Design and P lan"
        },
        {
            "text": "The study period for study 2 and study 3 incidence analyses will be ten-years starting January 1, 2009 and ending December 31, 2018 inclusive.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "General Study Design and P lan"
        },
        {
            "text": "For study 4, we will start data collection from the beginning of 2004 when the quality and outcomes framework was first introduced in primary care. The study period will end December 31, 2018.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "General Study Design and P lan"
        },
        {
            "text": "These are non-interventional studies. A range of study designs will be used across the studies as follows:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Design"
        },
        {
            "text": "Cross-sectional design (incidence and prevalence of AA). Cohort design to assess healthcare utilisation in people with AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1:"
        },
        {
            "text": "Case-control design for prevalence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) at AA diagnosis. Matched-cohort design for incidence of such conditions in the first two years after AA diagnosis in the subset of adult people diagnosed with AA without a mental health condition at baseline (and excluding controls if they have a baseline mental health condition).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2:"
        },
        {
            "text": "Case-control design for prevalence of atopic and autoimmune conditions at AA diagnosis. Matched-cohort design for incidence of atopic and autoimmune conditions in the first five years after AA diagnosis in the subset of adult people diagnosed with AA without an atopic/autoimmune condition at baseline (and excluding controls if they have a baseline atopic/autoimmune condition). ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3:"
        },
        {
            "text": "Matched-cohort design for incidence of common infections in the first five years after AA diagnosis in the subset of people diagnosed with AA without a common infection at baseline (and excluding controls if they have a baseline common infection).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4:"
        },
        {
            "text": "The case and control cohorts will be identified from the RCGP RSC database. The RCGP RSC database contains complete data on all events and clinical entities coded in UK primary care. These include demographic information, clinical diagnoses, laboratory test results, primary care issued prescriptions, process of care codes (e.g. specialist dermatology reviews), and anthropometric measurements (e.g., body mass index (BMI)), and are coded using the Read Coding system. (55) Read code lists used to define variables have been developed in accordance with published guidelines. (55)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data source and Read codes"
        },
        {
            "text": "Individual patient data will be anonymised at the point of data extraction. All data will remain in anonymised form and will be held on a secure server at the University of Surrey. The data will not be used for any purposes other than for the research which is described in the respective protocols and which has been approved by the RCGP RSC Research Committee. The sponsor, Pfizer Ltd, will not have access to the individual anonymised patient data. Queries will be executed to extract relevant data from the Structured Query Language (SQL) database using the Read code listed in Additional file 2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data extraction"
        },
        {
            "text": "We will identify people diagnosed with AA using diagnosis Read codes which are specific to the condition (see Supplementary Table S1 .1 (AA section), Additional file 2). A person will be considered to have a confirmed AA diagnosis if they have one or more of these diagnoses Read codes and no code for an alternative diagnosis in the subsequent 365 days. Alternative diagnoses which merit exclusion comprise any form of scarring alopecia, (53) traction alopecia, congenital alopecia, androgenetic alopecia, telogen effluvium, tinea capitis, trichotillomania, or secondary syphilis of the scalp (see Supplementary Table S1 .1, Additional file 2). We will identify all incident cases of AA meeting this case definition over the study period which will form the case cohorts for the four studies. We will also extract data on the extent of the alopecia where this has been recorded (See Supplementary Table  S1 .2, Additional file 2). Study 2 will identify three groups of common mental health conditions defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD10) classification (56) (depressive episodes (F32), recurrent depressive disorder (F33), and non-phobia related anxiety disorders (F41)) identified using algorithms validated in UK primary care. (57) Study 3 will identify atopic conditions and autoimmune conditions respectively (Supplementary Tables S4.1 -S4 . 16 , Additional file 2) using diagnostic Read codes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   13 Autoimmune conditions were selected based on a combination of expert knowledge and a minimum background population prevalence of 0.3% in the general population (refer to section 4.1.3). Case definition using Read codes for atopic dermatitis has been previously validated. An ontologically driven case definition is used for both allergic rhinitis and asthma. (55) Study 4 will identify common infections using diagnostic Read codes (Supplementary  Tables S5.1 -S5. 12, Additional file 2).",
            "cite_spans": [
                {
                    "start": 1428,
                    "end": 1430,
                    "text": "16",
                    "ref_id": null
                },
                {
                    "start": 2127,
                    "end": 2131,
                    "text": "(55)",
                    "ref_id": "BIBREF112"
                }
            ],
            "ref_spans": [
                {
                    "start": 110,
                    "end": 132,
                    "text": "Supplementary Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 599,
                    "end": 621,
                    "text": "Supplementary Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 884,
                    "end": 907,
                    "text": "Supplementary Table  S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1395,
                    "end": 1425,
                    "text": "(Supplementary Tables S4.1 -S4",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1481,
                    "end": 1767,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   13",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 2200,
                    "end": 2232,
                    "text": "(Supplementary  Tables S5.1 -S5.",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "AA definition"
        },
        {
            "text": "Age, sex, socio-economic status (SES), and ethnicity will comprise the socio-economic factors used for stratification of the outcome measures. Ethnicity will be categorized as follows in accordance with the major UK census categories: (58, 59) White, Asian, Black African/Caribbean, Mixed, Other and not recorded. Deprivation will be defined using the official national deprivation measure; index of multiple deprivation (IMD). (60) This will be calculated at the point of data extraction, using patient postcode, with the resultant scores stratified by deprivation quintile according to the national distribution.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Baseline socio-economic characteristics"
        },
        {
            "text": "This will comprise of the incidence of AA over the study period (stratified by age group, sex ethnicity, and SES) and point prevalence (stratified by age and sex). The study will also describe the geographic distribution of AA by region across England.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Epidemiology of AA"
        },
        {
            "text": "Current service utilisation will comprise of annual primary care visit rates, in Study 1 we will compare primary care visit frequency in people with AA and matched controls without AA.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Current serv ice utilisation and management patterns"
        },
        {
            "text": "The management patterns will comprise of an assessment of the percentage of the people with AA having a secondary care review (by dermatology (study 1) or mental health services (study 2)), and an assessment of primary care medication prescriptions issued to treat AA (Supplementary Table S1 .4, Additional file 2). Primary care visits, secondary care reviews and medication to treat AA will all be limited to those within 365 days of AA diagnosis.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 268,
                    "end": 291,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Current serv ice utilisation and management patterns"
        },
        {
            "text": "This will comprise of the rates for medications and psychological interventions used to treat mental health conditions in people diagnosed with AA. Antidepressant medication classes to be examined comprise; selective serotonin reuptake inhibitors (SSRIs) and related medications (serotonin and norepinephrine reuptake inhibitors; SNRIs), tricyclic antidepressants (TCAs) and related medications (tetracyclic antidepressant TeCAs), and monoamine oxidase inhibitors (MOAIs). Anxiolytic medications to be examined comprise all benzodiazepines and other related medications indicated for use in anxiety states. Psychological interventions comprise of will comprise; referral rates for counselling, secondary care psychiatrist referrals, including the referrals to the clinical psychology services/specialists and UK Improving Access to Psychological Therapies (IAPT) program. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   14 Additional mental health conditions consist of adjustment disorder, agoraphobia, self-harm, and overdose/parasuicide attempts and will be identified using the presence of one or more diagnosis codes appearing in the clinical record (Supplementary Tables S2.5 -S2.9, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 872,
                    "end": 1158,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   14",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Mental health treatment, sick day, and unemployment burden"
        },
        {
            "text": "Unemployment will be identified using Read codes relating to unemployment recorded in the primary care record or the issuing of IB113 or ESA113 forms (Supplementary Table S3 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 150,
                    "end": 173,
                    "text": "(Supplementary Table S3",
                    "ref_id": null
                }
            ],
            "section": "Mental health treatment, sick day, and unemployment burden"
        },
        {
            "text": "In the controls, the prevalence of common conditions (e.g. depressive episodes) is assumed to be 10%, less common conditions are assumed to be 1% and rare conditions (e.g. multiple sclerosis) assumed to be 0.1%. Sample size calculations were performed in OpenEpi, (62) results are presented using methods of Kelsey.(63)",
            "cite_spans": [
                {
                    "start": 264,
                    "end": 268,
                    "text": "(62)",
                    "ref_id": "BIBREF117"
                }
            ],
            "ref_spans": [],
            "section": "Sample size calculations"
        },
        {
            "text": "The analysis of the primary endpoint is a descriptive analysis of the incidence and prevalence of AA, and no sample size calculation is therefore applicable.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Our inclusion criteria specify all people with a confirmed diagnosis of AA will be included for analysis. The RCGP RSC database contains information on around 2 million actively registered patients. Based on an AA prevalence of 0.2% (13), we would anticipate a sample size of around 4,000 people diagnosed with AA for this study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Assuming 80% power, a 5% level of statistical significance, and a background population prevalence of 15% for anxiety and 10% for depression, (64) our anticipated sample size for AA (n = 4,000) would be sufficient to detect a prevalence difference of 1.8% in anxiety between those with and without AA, and 1.5% difference in depression between those with and without AA.",
            "cite_spans": [
                {
                    "start": 142,
                    "end": 146,
                    "text": "(64)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "A sample size calculation is applicable to estimate the incidence of atopic and autoimmune conditions in people diagnosed with AA. There is, however, a paucity of large-scale epidemiological data exploring the association between AA and either atopic or autoimmune conditions on which to base the sample size calculations for this study.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "A large population-based study based in Taiwan (65) found associations between the presence of AA and the presence of atopic dermatitis (OR 2.24, 95% CI 1.95-2.58) and allergic rhinitis (OR 1.29, 95% CI 1.18-1.41), and with the autoimmune condition psoriasis (OR 2.80, 95% CI 2.24-3.50). No associations were found in either asthma (atopic) or RA (autoimmune). Applying an estimate informed by this study of OR 2.0 for atopic conditions and OR 2.8 for autoimmune conditions, assuming 80% power, a 5% level of statistical significance, a 4:1 ratio of controls to cases and a probability of outcome in the control cohort of 1% (less common condition prevalence) for both atopic and autoimmune conditions, a total (both cases and controls) sample size of 6,034 for atopic conditions (1,207 cases and 4,827 controls) and 2,133 for autoimmune conditions (427 cases and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   15 1,706 controls) would be required to detect statistically significant differences between people diagnosed with AA and the control populations.",
            "cite_spans": [
                {
                    "start": 47,
                    "end": 51,
                    "text": "(65)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 864,
                    "end": 1150,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   15",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Study 3"
        },
        {
            "text": "For the assessment of prevalence of co-existing autoimmune conditions, assuming 80% power, a 5% level of statistical significance, our anticipated sample size for AA (n = 4,000) and an OR 2.0 effect, we would have sufficient power to detect a difference between those with and without AA in autoimmune conditions having >= 0.3% background population prevalence.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "A sample size calculation is applicable to estimate the incidence of common infections in people diagnosed with AA. There is, however, no previous data exploring the association between AA and common infections on which to base the sample size calculations for this study. We therefore estimate the number of people diagnosed with AA we will have for this study (n = 4,000) and use this number to estimate the minimum effect size we are powered to detect. Based on a Cox PH model, 80% power, a 5% level of statistical significance and a 4:1 ratio of controls to cases, we would have sufficient power to detect a difference between those with and without AA in common infections having >= 0.46% background population prevalence.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "The cohorts for studies 1, 2 and 3 (cases and controls) will consist of patients contributing to RCGP RCS database during the study period (between January 1, 2009 and December 31, 2018 inclusive). The cohorts for study 4 (cases and controls) will consist of patients contributing to RCGP RCS database between January 1, 2004 and December 31, 2018 inclusive.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "The AA prevalence population consists of patients actively registered and alive at the end date of the study period (December 31, 2018).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "The AA incidence population consists of patients registered at any point during the study period but without a prior recorded AA diagnosis. The follow-up period for incident cases will begin on the latest of the date of diagnosis indicated by the first diagnostic AA Read code. Follow-up will end at the earliest of the study end-date (December 31, 2018), the date of patient transfer from an included practice or date of death.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "Studies 1 and 4 will include both children and adults. Studies 2 and 3 will include only people aged \u226518 (as at date of AA diagnosis for cases or start of follow-up for controls). Only people aged \u2265 18 and \u2264 65 will be included in the unemployment and sick day analysis (Study 2).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Inclusion Criteria"
        },
        {
            "text": "The following exclusion criteria will be applied:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exclusion Criteria"
        },
        {
            "text": "\u2022 People with the alternative non-AA diagnoses (section 3.4.1) (AA incidence cohort).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exclusion Criteria"
        },
        {
            "text": "\u2022 People with AA diagnosis within 6 months of registration (AA incidence cohort).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Exclusion Criteria"
        },
        {
            "text": "\u2022 People with less than 1 year of follow up within the dataset (unless under 1 year old) (AA incidence and AA prevalence cohorts). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 131,
                    "end": 356,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Exclusion Criteria"
        },
        {
            "text": "The control cohorts will be defined by matching cases with people who have never been diagnosed with AA either prior to or during the study period, by age, sex, and time since practice registration, at GP practice level. After matching an assessment of sociodemographic differences using IMD quintiles will be performed. If there are substantial differences in socioeconomic status between cases and controls, re-matching with IMD as an additional matching criterion will be considered Controls will require at least one year of follow-up when matched to minimize the risk of a non-recorded existing diagnosis of AA. The follow-up period for each matched control will begin at the start of follow-up of their matched case and have the same follow-up time criteria applied (where applicable).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "Each case is matched with four controls using a nearest neighbour matching algorithm (66) to create a baseline matched dataset.",
            "cite_spans": [
                {
                    "start": 85,
                    "end": 89,
                    "text": "(66)",
                    "ref_id": "BIBREF121"
                }
            ],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "Study 1 will include all matched patients to compare rates of primary care visits. Study 2 (incidence of mental health after AA diagnosis) and study 3 (incidence of atopic and autoimmune conditions) will both use a subset of the baseline matched dataset; cases will be people diagnosed with AA without the relevant condition at their start of follow up, controls will be people not diagnosed with AA and without the relevant condition at their start of follow up.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "The matching for the incidence of common infections (study 4) will use a different approach to studies 2 and 3: cases will be people diagnosed with AA on or before 1 st January 2014 (exact date will be dependent on data availability) without the relevant infection, controls will be people not diagnosed with AA prior to this date and without the relevant infection. People who develop AA during the follow up will be excluded from the pool of available cohorts prior to matching. This approach will mitigate systematic recording bias that is likely due to an increased propensity of people with incident AA to consult within the months following diagnosis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "The case-control design studies (prevalence of mental health at AA diagnosis (study 2), and prevalence of atopic and autoimmune conditions at AA diagnosis (study 3)) will both define cases as people newly diagnosed with AA over the study period. For each case, the prevalence of the conditions of interest as at the date of AA diagnosis will be retrospectively established. Controls will be people not diagnosed with AA. For each control, the date of AA diagnosis of their matched case counterpart will then be used as the baseline date and the prevalence of the conditions of interest on that date will be retrospectively established.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "In Study 2 and Study 3, the same baseline cases and control cohorts will be used for both the case-control and matched-cohort analyses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Matching process"
        },
        {
            "text": "To check the validity of our AA definition (section 3.4.1), annual incident trends of specified alopecia (AA), (Supplementary Table S1 .1, Additional file 2), non-specific alopecia (Supplementary Table S1 .1, Additional file 2) and other specified alopecia (Supplementary  Table S1 .1, Additional file 2) will be analysed for the purpose of identifying changes in coding practice. The AA case definition may be amended based on the results of this analysis if considered appropriate and necessary. Any changes required will be reported in full in a final study publication. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The mean, standard deviation (sd) and any other statistical measures, will be reported to one decimal place. Continuous data will be summarised in the form of means, sd, median, interquartile range (IQR) and range as appropriate. Categorical data will be summarised using frequencies and proportions. Chi-squared and t-tests will be performed to compare the frequency of dichotomous variables and the values of continuous variables where relevant. 95% CIs will be reported for main effect sizes. Statistical significance will be assessed using p<0.05. Actual p-values will be reported except for p-values less than 3 decimal places which will be reported as \"<0.001\". P-values >0.1 will be reported to one decimal place, p-values between 0.01 and 0.1 will be reported to 2 decimal places, and pvalues between 0.001 and 0.01 will be reported to three decimal places.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 111,
                    "end": 134,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 181,
                    "end": 204,
                    "text": "(Supplementary Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 257,
                    "end": 281,
                    "text": "(Supplementary  Table S1",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 574,
                    "end": 799,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "AA definition exploratory analyses"
        },
        {
            "text": "The assessment of any associations with baseline characteristics and the outcomes of interest (mental health conditions (study 2), autoimmune and atopic conditions (study 3) and common infections (study 4)) will be assessed using logistic regression, Cox proportional hazards models, Poisson regression or zero-inflated Poisson regression as appropriate depending on the characteristics of the outcome variable. A standard set of features will be used in all multivariable models: age, sex, ethnicity, socioeconomic status, BMI, smoking status, alcohol status, and historical propensity to consult (defined as the number of primary care visits an individual has in the year prior to their study start date). Specific co-morbidity adjustment will be specific to each analysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "AA definition exploratory analyses"
        },
        {
            "text": "Assumptions of statistical approaches will be assessed, and transformations used if necessary (although it is not anticipated that the data will violate model assumptions).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "AA definition exploratory analyses"
        },
        {
            "text": "AA incidence: Incident cases will be defined as people with a first ever diagnostic Read code for AA during the study period. To ensure cases are truly incident, people with an AA diagnosis within six months of registering with a practice will be excluded from the analysis (unless under one year old). Incidence of new onset AA will be calculated by dividing the total number of new cases by the total person-years of follow-up for the total eligible population over the study period. Incidence rates will be reported for the complete cohort and stratified by calendar year, sex and age (categorised), and SES factors. Adjusted incidence rates by socio-demographic factors (including geographic area classification) will be estimated using Poisson regression.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "AA point prevalence: Prevalence cases will be defined as all people with a historical diagnostic Read code for AA and no exclusion code within one year of AA diagnosis. For this prevalence analysis all people will be included regardless of the date of AA diagnosis in relation to the date of registration with a practice. Cases with < 365 days of follow up from date of registration will be excluded from the analysis (unless under one year old). Point prevalence will be calculated by dividing the number of prevalent cases by the total number of eligible people in the study population at the study end date (December 31, 2018) . Point prevalence will be reported for the complete cohort and stratified by sex and age (categorised). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   18 We anticipate some attrition of recording of AA in the historic records. This is particularly likely to be the case in records preceding the computerisation of primary care which occurred in the 1990s. If we observe evidence of this being a major source of error in our point calculations (as evidenced by a falling point incidence in the older adult population despite there being a substantial number of incident diagnoses in this age group) then we will consider using the actuarial life table method to estimate lifetime AA risk (67) .",
            "cite_spans": [
                {
                    "start": 1555,
                    "end": 1559,
                    "text": "(67)",
                    "ref_id": "BIBREF122"
                }
            ],
            "ref_spans": [
                {
                    "start": 610,
                    "end": 629,
                    "text": "(December 31, 2018)",
                    "ref_id": "FIGREF59"
                },
                {
                    "start": 735,
                    "end": 1021,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   18",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Study 1"
        },
        {
            "text": "Service utilisation and management patterns: Service utilisation will be evaluated by calculation of the annual rates of primary care visits for people diagnosed with AA in the year following diagnosis. Primary care visits will be identified from the patient's electronic health record.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Management patterns will be evaluated by calculation of annual proportion of people referred for dermatology review in people diagnosed with AA in the year following diagnosis. Secondary care dermatology reviews will be identified from Read codes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "In addition, management patterns will also comprise of the percentage of people diagnosed with AA and prescribed AA medication, in primary care, grouped by medication class during the year following diagnosis. Prescription information will be identified using Read and EMIS codes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Prevalence of mental health conditions: Prevalence will be calculated by dividing the number of prevalent people at the study start date by the total number of eligible people in the study population at the same time point.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "The prevalence of each common mental health condition (depressive episodes, recurrent depressive disorder and anxiety disorder) category for people diagnosed with AA will be reported in Study 2 and compared to the prevalence in the control population without AA. The prevalence of mental health conditions by socio-demographic subgroups will also be reported.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "Incidence of mental health conditions: Incident cases will be defined as in Study 1. Incidence rates of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) within two years of diagnosis date (matched follow-up start date for controls) will be calculated in both cases and controls and compared.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "Risk of developing a mental health condition (grouped by mental health condition category) will be examined using time to failure analysis. Initially, unadjusted Cox proportional hazards models, stratified by matched set (AA versus non-AA), will be used to provide overall hazard ratios (HRs) as summary estimates for the association of the presence of AA with the time to each mental health condition category in separate models. Models will be subsequently adjusted for standard set factors (section 6.1) and comorbidities (type 2 diabetes (T2DM), hypertension, atrial fibrillation, angina, acute myocardial infarction, stroke, heart failure, chronic liver disease, dementia, RA, asthma, Chronic obstructive pulmonary disease, Chronic Kidney Disease stage 3-5 (CKD), malignancy and inflammatory bowel disease) in multivariable analysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 2"
        },
        {
            "text": "The burden of treatment for mental health conditions will be evaluated as the total percentage of people diagnosed with 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   19 AA and prescribed, within one year of AA diagnosis, a medication used to treat mental health conditions (section 3.8) (e.g. SSRIs), grouped by mental health condition category.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 120,
                    "end": 406,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   19",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Mental health treatment and management patterns:"
        },
        {
            "text": "Management patterns will be evaluated by calculation of annual proportion of people referred for psychiatrist referral and counselling in people diagnosed with AA in the year following diagnosis (Supplementary Table S2 .10, Additional file 2).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 195,
                    "end": 218,
                    "text": "(Supplementary Table S2",
                    "ref_id": null
                }
            ],
            "section": "Mental health treatment and management patterns:"
        },
        {
            "text": "Prevalence of atopic and autoimmune conditions: The prevalence of atopic and autoimmune conditions in both cases and controls will be reported and compared.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "Incidence of atopic and autoimmune conditions: Incidence rates of atopic and autoimmune conditions within five years of diagnosis date (matched follow-up start date for controls) will be calculated in both cases and controls and compared.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "Risk of developing an atopic or autoimmune condition will be examined using time to failure analysis. Initially, unadjusted Cox proportional hazards models, stratified by matched set (AA versus non-AA), will be used to provide overall HRs as summary estimates for the association of the presence of AA with the time to each of atopic and autoimmune conditions in separate models. Models will be subsequently adjusted for standard set factors (section 6.1) and comorbidities (hypertension, hyperlipidaemia, T2DM, peripheral arterial disease, atrial fibrillation, angina, myocardial infarction, stroke, heart failure, CKD, chronic obstructive pulmonary disorder (COPD), chronic liver disease, malignancy, dementia, fracture history, depression) in multivariable analysis.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "Incidence of common infections: Incidence rates of common infections within five years of diagnosis date (matched follow-up start date for controls) will be calculated at both overall and individual infection levels in both cases and controls and compared. : Initially, infection incidence rates in people with and without AA will be estimated by dividing the number of incident common infections by the sum of person-years of follow-up for each cohort over the period of interest. Unadjusted Poisson regression models, stratified by matched set (AA versus controls), will be used to provide overall incident rate ratios as summary estimates for the association between rates of common infections and the presence of AA. Models will subsequently be adjusted for standard set factors (section 6.1) and comorbidities (hypertension, hyperlipidaemia, T2DM, peripheral arterial disease, atrial fibrillation, angina, myocardial infarction, stroke, heart failure, CKD, COPD, chronic liver disease, malignancy, dementia, RA, depression).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "Geographical distribution of AA: The geographic distribution of people with AA will be calculated from the disease incidence. The adjusted incident rate ratios will be reported. Models will be adjusted for age category, sex, ethnicity, IMD and geographic area classification derived using patient postcode at the point of data extraction.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 1"
        },
        {
            "text": "Stratified prevalence of mental health conditions: The prevalence of mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) by sociodemographic subgroups will also be reported in both cases and controls. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   20 Additional mental health conditions: The prevalence of additional mental health conditions (adjustment disorder, agoraphobia, self-harm, and overdose/parasuicide attempts) will be estimated as the total percentage of people diagnosed with AA and with the presence of one or more diagnosis codes appearing in the clinical record Sick day and unemployment burden: The burden of sick days will be estimated as the total percentage of people diagnosed with AA and issued one or more Med 3certificate. The burden of unemployment will be estimated as the total percentage of people diagnosed with AA and with a Read code relating to unemployment recorded in the primary care record or an IB113 or ESA113 form issued.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 248,
                    "end": 534,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   20",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Study 2"
        },
        {
            "text": "Not applicable.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 3"
        },
        {
            "text": "Not applicable.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study 4"
        },
        {
            "text": "Study 2: Sensitivity analyses will be performed to compare the baseline prevalence and incidence over two years post alopecia diagnosis of the three primary mental health conditions (depressive episodes, recurrent depressive disorder and anxiety disorder) in people with non-specific alopecia codes only (i.e. no prior or subsequent codes specifying alopecia type) using the same matching process used for the primary analyses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sensitiv ity analysis"
        },
        {
            "text": "Study 3: We will replicate this sensitivity analysis to compare the baseline prevalence and incidence of atopic and autoimmune conditions in people with non-specific alopecia codes only.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sensitiv ity analysis"
        },
        {
            "text": "Study 4: In the common infections theme, we will use a survival model to investigate time to first infection. We will also compare the results of the study outcomes when 1) we increase the number of cases to include people who develop AA during the follow up and 2) use a similar matching approach to the other studies: perform matching using the time of AA diagnosis and follow for up to five years after diagnosis (or matched date for controls). Both of these approaches will be used to investigate the effect of bias.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sensitiv ity analysis"
        },
        {
            "text": "These studies will use the missing indicator variable method as missing data are considered likely not to be missing at random, meaning multiple imputation approaches will lack validity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Missing data"
        },
        {
            "text": "Patient will need to be excluded from analyses based on a matched design if they have incomplete data in the fields (age, sex) required to run the matching process. In similar studies, the exclusion rate due to incomplete data has been low (68, 69) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 ",
            "cite_spans": [
                {
                    "start": 240,
                    "end": 244,
                    "text": "(68,",
                    "ref_id": "BIBREF123"
                },
                {
                    "start": 245,
                    "end": 248,
                    "text": "69)",
                    "ref_id": "BIBREF124"
                }
            ],
            "ref_spans": [
                {
                    "start": 251,
                    "end": 476,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Missing data"
        },
        {
            "text": "These are discussed in the associated protocol manuscript.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Study Limitations"
        },
        {
            "text": "All statistical analyses will be performed using R software.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistical softw are"
        },
        {
            "text": "Study approval will be requested from the Research Committee of the RCGP RSC. These studies do not meet the requirements for formal ethics board review in their current form as defined using the NHS Health Research Authority research decision tool (http://www.hra-decisiontools.org.uk/research/).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics"
        },
        {
            "text": "The study will be conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor and follow generally accepted research practices described in Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE), and Good Epidemiological Practice (GEP) guidelines issued by the International Epidemiological Association (IEA). Study reporting will be conducted in accordance with the relevant EQUATOR (Enhancing the QUAlity and Transparency Of health Research) guidelines.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics"
        },
        {
            "text": "Medical writing support was provided by Louise Jordan at Momentum Data and was funded by Pfizer. Editorial support was provided by Anita Lynam, Andrew McGovern, and John Dennis at Momentum Data and was funded by Pfizer. The authors would like to acknowledge project management support from Filipa Ferreira of the University of Oxford and University of Surrey. Matthew Harries was supported by the NIHR Manchester. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 414,
                    "end": 639,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 640,
                    "end": 865,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Acknow ledgements"
        },
        {
            "text": "Supplementary 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 * topical steroids will be grouped by potency; mild, moderate, potent, and very potent. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y 10",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 14,
                    "end": 239,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 240,
                    "end": 465,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 466,
                    "end": 691,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 692,
                    "end": 917,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 918,
                    "end": 1143,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1232,
                    "end": 1513,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Codes used to define alopecia areata and related clinical conditions, dermatology referrals, and treatments for alopecia areata w hich may be issued in primary care"
        },
        {
            "text": "Supplementary 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All Adjustment reaction with anxious mood E292y",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 14,
                    "end": 239,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 240,
                    "end": 465,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 466,
                    "end": 691,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 692,
                    "end": 917,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 918,
                    "end": 1143,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1144,
                    "end": 1369,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Adjustment reaction with mixed disturbance of emotion E292z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Adjustment reaction with disturbance of other emotion NOS E293.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Adjustment reaction with predominant disturbance of conduct E2930",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Adjustment reaction with aggression E2931",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Adjustment reaction with antisocial behaviour E2932 All Adjustment reaction with destructiveness E293z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "All Adjustment reaction with predominant disturbance of conduct NOS",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify mental health conditions and treatments"
        },
        {
            "text": "Adjustment reaction with mixed disturbance of emotion and conduct E29y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Other adjustment reactions E29y2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Adjustment reaction with physical symptoms E29y3 All Elective mutism due to an adjustment reaction E29y5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Other adjustment reaction with withdrawal E29yz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Other adjustment reactions NOS E29z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Adjustment reaction NOS Read CTV3 Code Term ID Description E29.. All Adjustment disorder E290.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Brief depressive adjustment reaction E290z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Brief depressive reaction NOS E291.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Prolonged depressive adjustment reaction E2924 All Adjustment reaction with anxious mood E292y",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Adjustment reaction with mixed disturbance of emotion E293.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Adjustment reaction with predominant disturbance of conduct E2930 All Adjustment reaction with aggression E2931 All Adjustment reaction with antisocial behaviour E2932 All Adjustment reaction with destructiveness E293z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "All Adjustment reaction with predominant disturbance of conduct NOS",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "Adjustment reaction with mixed disturbance of emotion and conduct",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E294. All"
        },
        {
            "text": "Adjustment reaction with predominant disturbance of other emotions E292z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Adjustment reaction with disturbance of other emotion NOS E29y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Other adjustment reactions 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All Gouging own body parts Xa2nz",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 31,
                    "end": 256,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 257,
                    "end": 482,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 483,
                    "end": 708,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "E292. All"
        },
        {
            "text": "All Gouging own flesh Xa2o0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Gouging own eyes Xa2o1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Gouging own rectum Xa30D",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Gouging own vagina E2731 All Head-banging Xa2o2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Banging own head against object Xa2o3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Banging own head against own body parts Xa2pI",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Hitting self Xa2pJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Punching self Xa2pK",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Slapping self X766S All Head-hitting Xa2p3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Inserting foreign bodies into own orifices Ua14Q",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Self-electrocution Xa2pQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Nipping self Xa2pM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Picking own skin Xa2pR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Pinching self Xa2pN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Rubbing own skin X766T All Scratches self Xa303",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Self-scalding Ua14N",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Self-incineration X766L All Self-mutilation X766M",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Self-mutilation of hands Xa2nl",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Self-mutilation of genitalia X766N",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Self-mutilation of penis X766O",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Self-mutilation of eyes Xa2nm",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Enucleation of own eyes X766P",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Self-mutilation of ears Xa2no",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Self-inducing a prolapse Xa2nq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Breaking own bones Xa2nr",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Pulling own teeth out Xa2nt",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All Eating own flesh Xa2nv",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "All All Suicide and selfinflicted injury by jumping from residential premises",
            "cite_spans": [],
            "ref_spans": [],
            "section": "E292. All"
        },
        {
            "text": "Suicide and selfinflicted injury by jumping from other manmade structure TK72.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from natural sites TK72.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from natural sites TK7z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from high place NOS TKx.. All Suicide and selfinflicted injury by other means",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "Suicide and selfinflicted injury by jumping or lying before moving object TKx01",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by lying before moving object TKx0z All Suicide and selfinflicted injury by jumping or lying before moving object NOS TKx1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by burns or fire TKx2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by scald TKx3.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by extremes of cold TKx4.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by electrocution TKx5.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by crashing of motor vehicle TKx6.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by crashing of aircraft All Suicide or selfinflicted injury by handgun TK51.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by shotgun TK52.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by hunting rifle TK53.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by military firearm TK54.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by other firearm TK55.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by explosives TK5z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by firearms and explosives NOS Xa3jF",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Attempted suicide -firearms Xa3jO",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide -firearms TK6.. All Suicide or selfinflicted injury by cutting and stabbing TK60.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by cutting TK61.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by stabbing",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "Suicide and selfinflicted injury by cutting and stabbing instruments NOS Xa3jG",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK6z. All"
        },
        {
            "text": "All Attempted suicide -cut/stab Xa3jP All Suicide -cut/stab TK7.. All Suicide or self injury by jumping from a height TK70.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK6z. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from residential premises",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK6z. All"
        },
        {
            "text": "Suicide and selfinflicted injury by jumping from other man-made structure TK72.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from natural sites TK72.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from natural sites TK7z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping from high place NOS X71B6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide or self injury by jumping from high man-made structure X71B7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide or self injury by jumping from high building X71B8 All Suicide or self injury by jumping from bridge X71B9 All Suicide or self injury by jumping from high natural feature X71BA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide or self injury by jumping off cliff Xa3jH",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Attempted suicide -jumping from a high place Xa3jQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "All Suicide -jumping from a high place TKx.. All Suicide and selfinflicted injury by other means",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK71. All"
        },
        {
            "text": "Suicide and selfinflicted injury by jumping or lying before moving object TKx00",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by jumping before moving object TKx01",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by lying before moving object TKx0z All Suicide and selfinflicted injury by jumping or lying before moving object NOS TKxy.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by other specified means TKxz.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by other means NOS TKx1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by burning or fire TKx2.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by scalding X71BF",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by igniting petrol soaked clothing All Attempted suicide NOS Xa3jR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide NOS X71B3 All Self poisoning by gas TK1.. All Suicide and selfinflicted poisoning by gases in domestic use TK21.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by other carbon monoxide TK2y.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by other gases and vapours TK2z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by gases and vapours NOS X71B4",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Self poisoning by carbon monoxide TK20.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Self poisoning by motor vehicle exhaust gas X71B5 All Self poisoning by coal gas X71BB",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury associated with moving vehicles TKx5.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by crashing motor vehicle TKx6.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by crashing of aircraft X71BC",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by placing self in path of moving vehicle X71BD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or self injury by placing self in path of moving motor vehicle X71BE All Suicide or self injury by placing self in path of moving railway vehicle XE22J",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or attempted suicide by drowning Xa3jE",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Attempted suicide -drowning Xa3jN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide -drowning XM1Fs",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Self hanging, strangulation or suffocation TK3.. All Suicide and selfinflicted injury by hanging, strangulation and suffocation TK30.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide or attempted suicide by hanging Xa3jL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "All Suicide -hanging",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TKx0. All"
        },
        {
            "text": "Suicide and selfinflicted injury by other means of hanging, strangulation and suffocation",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3y. All"
        },
        {
            "text": "Suicide and selfinflicted injury by hanging, strangulation and suffocation NOS XE22I",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Suicide and selfinflicted injury by suffocation by plastic bag Xa3jD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Attempted suicide -suffocation Xa3jM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Suicide -suffocation TK50.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Suicide or selfinflicted injury by handgun Ua1AA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Hanging self Ua1AB",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Drowning self Ua1A9",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Jumping from height Ua1A8",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Jumping from building Ua1A7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Jumping from bridge Ua14U",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Jumping from cliff Ua1AE",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self-asphyxiation All Self-strangulation Ua1AC",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self-suffocation Ua14S",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Throwing self in front of vehicle Ua14T",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Throwing self in front of train X71B0 All Self poisoning by non-drug solid or liquid agents TK07.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self poisoning by corrosive or caustic substance TK08.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self poisoning by arsenic or its compounds X71B2 All Self poisoning by plants or parts of plants XM1FX",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "All Self poisoning by agricultural chemical",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK3z. All"
        },
        {
            "text": "Suicide and selfinflicted poisoning by agricultural and horticultural chemical and pharmaceutical preparations other than plant foods and fertilizers X71B1 All Self poisoning by paraquat Ua14R",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All All Deliberate overdose of drug or pharmaceutical preparation TK00. All Suicide and selfinflicted poisoning by analgesics, antipyretics and anti-rheumatics TK01.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by barbiturates TK010",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by amobarbital TK011",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by Barbitone TK012",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by Butabarbitone TK013",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by Pentabarbitone TK014",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by phenobarbital TK015",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by secobarbital TK01z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and self inflicted injury by barbiturates TK02.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by other sedatives and hypnotics",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK06. All"
        },
        {
            "text": "Suicide and selfinflicted poisoning by tranquillisers and other psychotropic agents TK04.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by other drugs and medicines TK05.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Suicide and selfinflicted poisoning by drug or medicine NOS X71Ap",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of aspirin X71Ax",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of diazepam X71Av",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of methadone X71Az",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of temazepam X71Ar",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of co-proxamol X71At",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of diamorphine X71Aw",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of benzodiazepine X71Au",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of dihydrocodeine X71As",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of opiate analgesic X71Ay",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of chlordiazepoxide X71Aq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of combined analgesic X71An",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of non-opiate analgesics Xa0Jl",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Deliberate overdose of non-steroidal anti-inflammatory agent XaR4S",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of prescription only medication Xa62F",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional over-the-counter product overdose Xa65i",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional bismuth compound overdose Xa65m",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional sucralfate overdose Xa65q",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional liquorice overdose Xa65u",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional misoprostol overdose Xa65z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cimetidine overdose Xa663",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional famotidine overdose Xa667",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nizatidine overdose 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   48   Xa6Ji  All  Intentional fluphenazine enanthate overdose  Xa6Jm  All  Intentional thiethylperazine overdose  Xa6Jq  All  Intentional chlorpromazine overdose  Xa6Ju  All  Intentional pipotiazine overdose  Xa6Jy  All  Intentional promazine overdose  Xa6K2 All Intentional thioridazine overdose Xa6K6",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 36,
                    "end": 261,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 262,
                    "end": 803,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   48   Xa6Ji  All  Intentional fluphenazine enanthate overdose  Xa6Jm  All  Intentional thiethylperazine overdose  Xa6Jq  All  Intentional chlorpromazine overdose  Xa6Ju  All  Intentional pipotiazine overdose  Xa6Jy  All  Intentional promazine overdose  Xa6K2",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional perphenazine overdose Xa6KA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional prochlorperazine overdose Xa6KE",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional trifluoperazine overdose Xa6KJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chlorprothixene overdose Xa6KN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flupentixol decanoate overdose Xa6KR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional zuclopenthixol decanoate overdose Xa6KV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional zuclopenthixol overdose Xa6KZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flupentixol overdose Xa6Kd",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oxypertine overdose Xa6Kh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional remoxipride overdose Xa6Kj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of non-barbiturate hypnotic Xa6Ko",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional selegiline overdose Xa6Kt",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional amfetamine overdose Xa6Ky",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antabuse overdose Xa6L3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cannabis overdose Xa6L7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by lysergic acid Xa6LB",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional psilocybin overdose Xa6LF",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional mescaline overdose Xa6LJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of ecstasy Xa6LN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by cocaine Xa6LR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by crack cocaine Xa6LV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional caffeine overdose Xa6Lb",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional atenolol overdose Xa6Lf",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional propranolol overdose Xa6Lh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of beta-adrenergic blocking drug Xa6Lm",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional phenoxybenzamine overdose Xa6Lq",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nicotine overdose Xa6Lu",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose by calcium-channel blockers Xa6Lz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional pilocarpine overdose Xa6M3",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional acetylcholine overdose Xa6M7",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional anticholinesterase overdose Xa6MD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional metaraminol overdose Xa6MI",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional salbutamol overdose Xa6ML",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional overdose of isoprenaline Xa6MQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional clonidine overdose Xa6MV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional hyoscine overdose Xa6MZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional atropine overdose Xa6Me",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional acetylcysteine overdose Xa6Mj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nikethamide overdose 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   50   Xa6QB  All  Intentional sodium fusidate overdose  Xa6QF  All  Intentional spectinomycin overdose  Xa6QJ  All  Intentional vancomycin overdose  Xa6QN  All  Intentional trimethoprim overdose  Xa6QR All Intentional nitrofuran derivative overdose Xa6QV",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 37,
                    "end": 262,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 263,
                    "end": 747,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   50   Xa6QB  All  Intentional sodium fusidate overdose  Xa6QF  All  Intentional spectinomycin overdose  Xa6QJ  All  Intentional vancomycin overdose  Xa6QN  All  Intentional trimethoprim overdose  Xa6QR",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional fusidic acid overdose Xa6QZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional 4-quinolones overdose Xa6Qe",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ampicillin overdose Xa6Qj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cloxacillin overdose Xa6Qn",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional carbenicillin overdose Xa6Qr",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flucloxacillin overdose Xa6Qx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefadroxil overdose Xa6R1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefalexin overdose Xa6R5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cephalothin overdose Xa6R9",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefazolin overdose Xa6RD",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefradine overdose Xa6RH",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional latamoxef overdose Xa6RM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefaclor overdose Xa6RQ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefuroxime overdose Xa6RU",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cephamandole overdose Xa6RZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefotaxime overdose Xa6Rd",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftazidime overdose Xa6Rh",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftizoxime overdose Xa6Rl",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefixime overdose Xa6Rp",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefodizime overdose Xa6Rt",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefpodoxime overdose Xa6Rx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftriaxone overdose Xa6SA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefpirome overdose Xa6S1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ceftibuten overdose Xa6S5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cefsulodin overdose Xa6SG",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional doxycycline overdose Xa6SK",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional minocycline overdose Xa6SO",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oxytetracycline overdose Xa6SS",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tetracycline overdose Xa6SW",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chloramphenicol overdose Xa6Sa",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional co-trimoxazole overdose Xa6Sf",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antimony compound overdose Xa6Sj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional hydroxyquinoline overdose Xa6Sp",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional rifampin overdose Xa6St",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional isoniazid overdose Xa6Sx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ethambutol overdose Xa6T1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antileprotic drug overdose Xa6T5",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional pesticide product overdose Xa6TB",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional gamma globulin overdose Xa6TF",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional vaccine overdose 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   54   Xa4mC  All  Intentional fenbufen poisoning  Xa4mG  All  Intentional fenoprofen poisoning  Xa4mK  All  Intentional flurbiprofen poisoning  Xa4mN  All  Intentional ibuprofen poisoning  Xa4mQ  All  Intentional indometacin poisoning  Xa4mU All Intentional ketoprofen poisoning Xa4mY",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 33,
                    "end": 258,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 259,
                    "end": 484,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 485,
                    "end": 710,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 711,
                    "end": 1235,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   54   Xa4mC  All  Intentional fenbufen poisoning  Xa4mG  All  Intentional fenoprofen poisoning  Xa4mK  All  Intentional flurbiprofen poisoning  Xa4mN  All  Intentional ibuprofen poisoning  Xa4mQ  All  Intentional indometacin poisoning  Xa4mU",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ketorolac poisoning Xa4mc",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional mefenamic acid poisoning Xa4mg",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nabumetone poisoning Xa4mj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional naproxen poisoning Xa4mn",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional nefopam poisoning Xa4mr",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oxyphenbutazone poisoning Xa4mu",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional phenylbutazone poisoning Xa4my",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional piroxicam poisoning Xa4n2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional sulindac poisoning Xa4n6",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tenoxicam poisoning Xa4nA",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tiaprofenic acid poisoning Xa4nE",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tolmetin poisoning Xa4nJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional radiopharmaceutical poisoning Xa4nR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional X-ray contrast media poisoning Xa4nV",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional magnetic resonance imaging contrast media poisoning Xa4nN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional X-ray diagnostic contrast media poisoning Xa4nZ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional allergen extract vaccine poisoning Xa4nd",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional diagnostic dye poisoning Xa53n",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional dextromethorphan poisoning Xa53q",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional guaifenesin poisoning Xa53t",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional terpin hydrate poisoning Xa53w",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional poisoning by bronchodilator drug Xa53z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional aminophylline poisoning Xa542",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional theophylline poisoning Xa545",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional poisoning by herbal asthma mixture Xa548",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional anti-common cold drug poisoning Xa54B",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional local antipruritic poisoning Xa54E",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional local astringent and detergent poisoning Xa54H",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional hair treatment poisoning Xa54L",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional allopurinol poisoning Xa54O",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional colchicine poisoning Xa54R",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional probenecid poisoning Xa54X",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional gold salt poisoning Xa54a",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antirheumatic poisoning Xa54v",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chelating agent poisoning Xa54z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional alternative medicine poisoning Xa556",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional flucytosine poisoning Xa559",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional griseofulvin poisoning Xa55C",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional amphotericin B poisoning 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   56   Xa58U  All  Intentional cefpirome poisoning  Xa58X  All  Intentional cephaloridine poisoning  Xa58a  All  Intentional sulfadiazine poisoning  Xa58d  All  Intentional sulphafurazole poisoning  Xa58g  All  Intentional sulfamethoxazole poisoning  Xa58j All Intentional doxycycline poisoning Xa58m",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 41,
                    "end": 266,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 267,
                    "end": 805,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   56   Xa58U  All  Intentional cefpirome poisoning  Xa58X  All  Intentional cephaloridine poisoning  Xa58a  All  Intentional sulfadiazine poisoning  Xa58d  All  Intentional sulphafurazole poisoning  Xa58g  All  Intentional sulfamethoxazole poisoning  Xa58j",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional minocycline poisoning Xa58p",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional oxytetracycline poisoning Xa58s",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional tetracycline poisoning Xa58v",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional chloramphenicol poisoning Xa58z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional co-trimoxazole poisoning Xa59F",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional hydroxyquinoline poisoning Xa59I",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional diiodohydroxyquinoline poisoning Xa59L",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional rifampin poisoning Xa59O",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional isoniazid poisoning Xa59R",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ethambutol poisoning Xa59U",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional cycloserine poisoning Xa59Y",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional antileprotic drug poisoning Xa59b",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional ethionamide poisoning Xa59e",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional para-aminosalicylic acid poisoning Xa59h",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional sulphone poisoning Xa59l",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Intentional pesticide product poisoning 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   60   XaA8Y  All  Lacanian psychoanalysis  XaA8g  All  Group psychoanalysis  XaA8U All Bion-based group psychoanalysis 384Z.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 44,
                    "end": 269,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 270,
                    "end": 495,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 496,
                    "end": 721,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 722,
                    "end": 1087,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   60   XaA8Y  All  Lacanian psychoanalysis  XaA8g  All  Group psychoanalysis  XaA8U",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "TK03. All"
        },
        {
            "text": "All Psychological analysis NOS Xa8IM",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Jungian-based therapy Xa8IN",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Generic Jungian-based therapy Xa8IP",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Analytical psychology Xa8IR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Long-term psychodynamic psychotherapy XaA8Z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Developmental psychodynamic psychotherapy XaA8c",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Supportive expressive psychodynamic psychotherapy XaA8d",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Psychodynamic-interpersonal psychotherapy XaEVq All Psychodynamic psychotherapy Xad7C",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Focal psychodynamic therapy Xa8IR",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Long-term psychodynamic psychotherapy XaA8Z",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Developmental psychodynamic psychotherapy XaA8c",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Supportive expressive psychodynamic psychotherapy XaA8d",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Psychodynamic-interpersonal psychotherapy Xa8II",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Short-term psychodynamic therapy XaXuc All Dynamic interpersonal therapy XaA9g",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Specific task orientated psychotherapy XE0iL",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Psychotherapy/sociotherapy 8G9Z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "TK03. All"
        },
        {
            "text": "All Other psychotherapy NOS 8G9.. All Other psychotherapy 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 58,
                    "end": 283,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "TK03. All"
        },
        {
            "text": "Supplementary 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All Hypothyroidism due to iodide trapping defect X40Hw",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 14,
                    "end": 239,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 240,
                    "end": 465,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 466,
                    "end": 691,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 692,
                    "end": 917,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 918,
                    "end": 1992,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1993,
                    "end": 2218,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 2219,
                    "end": 2727,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 2728,
                    "end": 2953,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 2954,
                    "end": 3179,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 3180,
                    "end": 3405,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "All Hypothyroidism due to iodide organification defect X40Hx",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "All Hypothyroidism due to coupling defect X40Hy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "All Hypothyroidism due to deiodase defect X40Hz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "All Hypothyroidism due to thyroglobulin synthesis defect Cyu11",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "All [X]Other specified hypothyroidism Xa3ec",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "All Hypothyroidism -congenital and acquired Xa08g",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "All Transient neonatal hypothyroidism Q4337",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "All Neonatal jaundice with congenital hypothyroidism 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All Other specified cellulitis and abscess M03y0",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 53,
                    "end": 278,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 279,
                    "end": 504,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 505,
                    "end": 730,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 731,
                    "end": 956,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 957,
                    "end": 1182,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1183,
                    "end": 1691,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1692,
                    "end": 1917,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 1918,
                    "end": 2143,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 2144,
                    "end": 2369,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 2370,
                    "end": 3727,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 3728,
                    "end": 6500,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 6501,
                    "end": 7858,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                },
                {
                    "start": 7859,
                    "end": 8650,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Codes used to identify time off w ork and unemployment"
        },
        {
            "text": "All Cellulitis and abscess of head unspecified M03z.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Cellulitis and abscess NOS M03z0",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Cellulitis NOS M03z1",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Abscess NOS M03zz",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Cellulitis and abscess NOS M04.. All Acute lymphadenitis M040.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute lymphadenitis of trunk M041.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute lymphadenitis of upper limb M042.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute lymphadenitis of lower limb M043.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute lymphadenitis of face, head and neck M05.. All Impetigo M050.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Impetigo contagiosa unspecified M051.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Impetigo contagiosa bullosa M052.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Impetigo contagiosa gyrata M053.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Impetigo circinata M054.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Impetigo neonatorum M055.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Impetigo simplex M056.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Impetigo follicularis M057.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All Larva migrans of skin Xa0kT",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 4,
                    "end": 512,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Amoebic granuloma of skin Xa0Qy",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Complicated donovanosis Xa0Ws",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Staphylococcus aureus superficial folliculitis Xa139",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Site-specific infective disorders of skin Xa13A",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Intertrigo Xa13C",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Submammary monilia Xa1y2",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Abscess of toe All Abscess of eyelid XE1Aa",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Cellulitis and abscess of leg XE1Ab",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Cellulitis and abscess of foot excluding toe XE1Ac",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Cellulitis and abscess of head unspecified XE1Ad",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Acute lymphadenitis XE1Ae",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Pilonidal cyst with no abscess XE1Ag",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Other specified local infection of skin or subcutaneous tissue XE1Ai",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Other specified local infection of skin and subcutaneous tissue NOS XE1Aj",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Local infection skin/subcut tissue NOS XE1Ak",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All All Boil: (face) or (external auditory) or (external ear) XE1Bg",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All (Boil -upper arm and forearm) or (axillary furunculosis) XE1Bi",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All (Cellulitis &/or abscess finger/toe) or (felon -whitlow) XE1BJ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All Superficial folliculitis XE1Bk",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All (Cellulitis -finger-paronychia) or (paronychia) XE1Bm",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All (Cellulitis/abscess: [NOS] or [other]) or (abscess NOS) XE1Bo",
            "cite_spans": [
                {
                    "start": 25,
                    "end": 30,
                    "text": "[NOS]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Definitions of common infections w ith R ead code lists."
        },
        {
            "text": "All (Cellulitis/abscess -face) or (cellulitis -lips) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 53,
                    "end": 282,
                    "text": "1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60",
                    "ref_id": "TABREF11"
                }
            ],
            "section": "Definitions of common infections w ith R ead code lists."
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Overview of alopecia areata",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "K"
                    ],
                    "last": "Hordinsky",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Investig Dermatol Symp Proc",
            "volume": "16",
            "issn": "1",
            "pages": "13--18",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alkhalifah",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alsantali",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Mcelwee",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shapiro",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "62",
            "issn": "2",
            "pages": "89--90",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Alopecia areata update",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Madani",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shapiro",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Journal of the American",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Overview of alopecia areata",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "K"
                    ],
                    "last": "Hordinsky",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Investig Dermatol Symp Proc",
            "volume": "16",
            "issn": "1",
            "pages": "13--18",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alkhalifah",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alsantali",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Mcelwee",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shapiro",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "62",
            "issn": "2",
            "pages": "89--90",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Alopecia areata update",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Madani",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shapiro",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "42",
            "issn": "4",
            "pages": "67--70",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Mirzoyev",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Schrum",
                    "suffix": ""
                },
                {
                    "first": "Mdp",
                    "middle": [],
                    "last": "Davis",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "R"
                    ],
                    "last": "Torgerson",
                    "suffix": ""
                }
            ],
            "year": 1990,
            "venue": "J Invest Dermatol",
            "volume": "134",
            "issn": "4",
            "pages": "1141--1143",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Epidemiology and burden of alopecia areata: a systematic review",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Villasante Fricke",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Miteva",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Clin Cosmet Investig Dermatol",
            "volume": "8",
            "issn": "",
            "pages": "397--403",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Sex-and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the << OBJECTIFS PEAU >> study",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Richard",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Corgibet",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Beylot-Barry",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Barbaud",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Bodemer",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Chaussade",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Eur Acad Dermatol Venereol",
            "volume": "32",
            "issn": "11",
            "pages": "1967--71",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Management of alopecia areata",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Harries",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Paus",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "E"
                    ],
                    "last": "King",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "BMJ",
            "volume": "341",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Treatments for alopecia aerate, alopecia totalis and alopecia universalis",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Cochrane",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Comorbidities in alopecia areata: A systematic review and meta-analysis",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "S"
                    ],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "80",
            "issn": "2",
            "pages": "466--77",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "P"
                    ],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mullangi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Qureshi",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "JAMA Dermatol",
            "volume": "149",
            "issn": "7",
            "pages": "789--94",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "A mixed methods survey of social anxiety, anxiety, depression and wig use in alopecia",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Montgomery",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "White",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Thompson",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "BMJ open",
            "volume": "7",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "The psychological impact of alopecia",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Hunt",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mchale",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "BMJ",
            "volume": "331",
            "issn": "7522",
            "pages": "951--954",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Safavi",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "Arch Dermatol",
            "volume": "128",
            "issn": "5",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Profile of alopecia areata in Northern India",
            "authors": [
                {
                    "first": "V",
                    "middle": [
                        "K"
                    ],
                    "last": "Sharma",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Dawn",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Kumar",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Int J Dermatol",
            "volume": "35",
            "issn": "1",
            "pages": "22--29",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Chin Giam Y. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "K"
                    ],
                    "last": "Tay",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "L"
                    ],
                    "last": "Goh",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Int J Dermatol",
            "volume": "41",
            "issn": "11",
            "pages": "748--53",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "The genetic epidemiology of alopecia areata in China",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "Y"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Br J Dermatol",
            "volume": "151",
            "issn": "1",
            "pages": "16--23",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "A clinical study of alopecia areata in Mexico",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Guzm\u00e1n-S\u00e1nchez",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "D"
                    ],
                    "last": "Villanueva-Quintero",
                    "suffix": ""
                },
                {
                    "first": "Alfaro",
                    "middle": [],
                    "last": "Alfaro",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Mcmichael",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Int J Dermatol",
            "volume": "46",
            "issn": "12",
            "pages": "1308--1318",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospitalbased study",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Furue",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yamazaki",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Jimbow",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tsuchida",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Amagai",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tanaka",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Dermatol",
            "volume": "38",
            "issn": "4",
            "pages": "310--330",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Association of alopecia areata with hospitalization for mental health disorders in US adults",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Singam",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "H"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rastogi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "I"
                    ],
                    "last": "Silverberg",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "80",
            "issn": "3",
            "pages": "792--796",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "The relationship between alopecia areata and alexithymia, anxiety and depression: a case-control study",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Sellami",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Masmoudi",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Ouali",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Mnif",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Amouri",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Turki",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Indian J Dermatol",
            "volume": "59",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Alopecia areata: psychiatric comorbidity and adjustment to illness",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ruiz-Doblado",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Carrizosa",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Garc\u00eda-Hern\u00e1ndez",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Int J Dermatol",
            "volume": "42",
            "issn": "6",
            "pages": "434--441",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Severity of Depression and Anxiety in Patients with",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Baghestani",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zare",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Seddigh",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Overview of alopecia areata",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "K"
                    ],
                    "last": "Hordinsky",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Investig Dermatol Symp Proc",
            "volume": "16",
            "issn": "1",
            "pages": "13--18",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alkhalifah",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alsantali",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Mcelwee",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shapiro",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "62",
            "issn": "2",
            "pages": "89--90",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Alopecia areata update",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Madani",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shapiro",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "42",
            "issn": "4",
            "pages": "67--70",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Mirzoyev",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Schrum",
                    "suffix": ""
                },
                {
                    "first": "Mdp",
                    "middle": [],
                    "last": "Davis",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "R"
                    ],
                    "last": "Torgerson",
                    "suffix": ""
                }
            ],
            "year": 1990,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Epidemiology and burden of alopecia areata: a systematic review",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Villasante Fricke",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Miteva",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Clin Cosmet Investig Dermatol",
            "volume": "8",
            "issn": "",
            "pages": "397--403",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Sex-and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the << OBJECTIFS PEAU >> study",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Richard",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Corgibet",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Beylot-Barry",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Barbaud",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Bodemer",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Chaussade",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Eur Acad Dermatol Venereol",
            "volume": "32",
            "issn": "11",
            "pages": "1967--71",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Management of alopecia areata",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Harries",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Paus",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "E"
                    ],
                    "last": "King",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "BMJ",
            "volume": "341",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Treatments for alopecia aerate, alopecia totalis and alopecia universalis",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Cochrane",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Comorbidities in alopecia areata: A systematic review and meta-analysis",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "S"
                    ],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "80",
            "issn": "2",
            "pages": "466--77",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "A mixed methods survey of social anxiety, anxiety, depression and wig use in alopecia",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Montgomery",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "White",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Thompson",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "BMJ open",
            "volume": "7",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "P"
                    ],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mullangi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Qureshi",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "JAMA Dermatol",
            "volume": "149",
            "issn": "7",
            "pages": "789--94",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "The psychological impact of alopecia",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Hunt",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mchale",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "BMJ",
            "volume": "331",
            "issn": "7522",
            "pages": "951--954",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Safavi",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "Arch Dermatol",
            "volume": "128",
            "issn": "5",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Profile of alopecia areata in Northern India",
            "authors": [
                {
                    "first": "V",
                    "middle": [
                        "K"
                    ],
                    "last": "Sharma",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Dawn",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Kumar",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Chin Giam Y. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "K"
                    ],
                    "last": "Tay",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "L"
                    ],
                    "last": "Goh",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Int J Dermatol",
            "volume": "41",
            "issn": "11",
            "pages": "748--53",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "The genetic epidemiology of alopecia areata in China",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "Y"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Br J Dermatol",
            "volume": "151",
            "issn": "1",
            "pages": "16--23",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "A clinical study of alopecia areata in Mexico",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Guzm\u00e1n-S\u00e1nchez",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "D"
                    ],
                    "last": "Villanueva-Quintero",
                    "suffix": ""
                },
                {
                    "first": "Alfaro",
                    "middle": [],
                    "last": "Alfaro",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Mcmichael",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Int J Dermatol",
            "volume": "46",
            "issn": "12",
            "pages": "1308--1318",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Furue",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yamazaki",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Jimbow",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tsuchida",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Amagai",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tanaka",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Dermatol",
            "volume": "38",
            "issn": "4",
            "pages": "310--330",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Association of alopecia",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Singam",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "H"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rastogi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "I"
                    ],
                    "last": "Silverberg",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "Current service utilisation and management patterns",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Mental health treatment, sick day, and unemployment burden",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "22 References 1. Hordinsky MK. Overview of alopecia areata",
            "authors": [
                {
                    "first": "",
                    "middle": [
                        "............ ."
                    ],
                    "last": "References",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Investig Dermatol Symp Proc",
            "volume": "16",
            "issn": "1",
            "pages": "13--18",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alkhalifah",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Alsantali",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Mcelwee",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shapiro",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "62",
            "issn": "2",
            "pages": "89--90",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "Alopecia areata update",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Madani",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shapiro",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "42",
            "issn": "4",
            "pages": "67--70",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "A"
                    ],
                    "last": "Mirzoyev",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Schrum",
                    "suffix": ""
                },
                {
                    "first": "Mdp",
                    "middle": [],
                    "last": "Davis",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "R"
                    ],
                    "last": "Torgerson",
                    "suffix": ""
                }
            ],
            "year": 1990,
            "venue": "J Invest Dermatol",
            "volume": "134",
            "issn": "4",
            "pages": "1141--1143",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Epidemiology and burden of alopecia areata: a systematic review",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "C"
                    ],
                    "last": "Villasante Fricke",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Miteva",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Clin Cosmet Investig Dermatol",
            "volume": "8",
            "issn": "",
            "pages": "397--403",
            "other_ids": {}
        },
        "BIBREF61": {
            "ref_id": "b61",
            "title": "Sex-and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the << OBJECTIFS PEAU >> study",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Richard",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Corgibet",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Beylot-Barry",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Barbaud",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Bodemer",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Chaussade",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J Eur Acad Dermatol Venereol",
            "volume": "32",
            "issn": "11",
            "pages": "1967--71",
            "other_ids": {}
        },
        "BIBREF62": {
            "ref_id": "b62",
            "title": "Management of alopecia areata",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Harries",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Paus",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "E"
                    ],
                    "last": "King",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "BMJ",
            "volume": "341",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF63": {
            "ref_id": "b63",
            "title": "Treatments for alopecia aerate, alopecia totalis and alopecia universalis",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Cochrane",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF64": {
            "ref_id": "b64",
            "title": "Comorbidities in alopecia areata: A systematic review and meta-analysis",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "S"
                    ],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "80",
            "issn": "2",
            "pages": "466--77",
            "other_ids": {}
        },
        "BIBREF65": {
            "ref_id": "b65",
            "title": "Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "P"
                    ],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mullangi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Qureshi",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "JAMA Dermatol",
            "volume": "149",
            "issn": "7",
            "pages": "789--94",
            "other_ids": {}
        },
        "BIBREF66": {
            "ref_id": "b66",
            "title": "A mixed methods survey of social anxiety, anxiety, depression and wig use in alopecia",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Montgomery",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "White",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Thompson",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "BMJ open",
            "volume": "7",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF67": {
            "ref_id": "b67",
            "title": "The psychological impact of alopecia",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Hunt",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mchale",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "BMJ",
            "volume": "331",
            "issn": "7522",
            "pages": "951--954",
            "other_ids": {}
        },
        "BIBREF68": {
            "ref_id": "b68",
            "title": "Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Safavi",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "Arch Dermatol",
            "volume": "128",
            "issn": "5",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF69": {
            "ref_id": "b69",
            "title": "Profile of alopecia areata in Northern India",
            "authors": [
                {
                    "first": "V",
                    "middle": [
                        "K"
                    ],
                    "last": "Sharma",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Dawn",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Kumar",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Int J Dermatol",
            "volume": "35",
            "issn": "1",
            "pages": "22--29",
            "other_ids": {}
        },
        "BIBREF70": {
            "ref_id": "b70",
            "title": "Chin Giam Y. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "K"
                    ],
                    "last": "Tay",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "L"
                    ],
                    "last": "Goh",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Int J Dermatol",
            "volume": "41",
            "issn": "11",
            "pages": "748--53",
            "other_ids": {}
        },
        "BIBREF71": {
            "ref_id": "b71",
            "title": "The genetic epidemiology of alopecia areata in China",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "Y"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Br J Dermatol",
            "volume": "151",
            "issn": "1",
            "pages": "16--23",
            "other_ids": {}
        },
        "BIBREF72": {
            "ref_id": "b72",
            "title": "A clinical study of alopecia areata in Mexico",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Guzm\u00e1n-S\u00e1nchez",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "D"
                    ],
                    "last": "Villanueva-Quintero",
                    "suffix": ""
                },
                {
                    "first": "Alfaro",
                    "middle": [],
                    "last": "Alfaro",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Mcmichael",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Int J Dermatol",
            "volume": "46",
            "issn": "12",
            "pages": "1308--1318",
            "other_ids": {}
        },
        "BIBREF73": {
            "ref_id": "b73",
            "title": "Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospitalbased study",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Furue",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yamazaki",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Jimbow",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tsuchida",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Amagai",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Tanaka",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "J Dermatol",
            "volume": "38",
            "issn": "4",
            "pages": "310--330",
            "other_ids": {}
        },
        "BIBREF74": {
            "ref_id": "b74",
            "title": "Association of alopecia areata with hospitalization for mental health disorders in US adults",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Singam",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Patel",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "H"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Rastogi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "I"
                    ],
                    "last": "Silverberg",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "80",
            "issn": "3",
            "pages": "792--796",
            "other_ids": {}
        },
        "BIBREF75": {
            "ref_id": "b75",
            "title": "The relationship between alopecia areata and alexithymia, anxiety and depression: a case-control study",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Sellami",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Masmoudi",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Ouali",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Mnif",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Amouri",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Turki",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Indian J Dermatol",
            "volume": "59",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF76": {
            "ref_id": "b76",
            "title": "Alopecia areata: psychiatric comorbidity and adjustment to illness",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ruiz-Doblado",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Carrizosa",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Garc\u00eda-Hern\u00e1ndez",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Int J Dermatol",
            "volume": "42",
            "issn": "6",
            "pages": "434--441",
            "other_ids": {}
        },
        "BIBREF77": {
            "ref_id": "b77",
            "title": "Severity of Depression and Anxiety in Patients with",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Baghestani",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zare",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Seddigh",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF78": {
            "ref_id": "b78",
            "title": "Alopecia Areata in Bandar Abbas",
            "authors": [],
            "year": 2015,
            "venue": "Iran. Dermatol Reports",
            "volume": "7",
            "issn": "3",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF79": {
            "ref_id": "b79",
            "title": "Psychiatric comorbidities in patients with alopecia areata in Taiwan: a case-control study",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "Y"
                    ],
                    "last": "Chu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "J"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "C"
                    ],
                    "last": "Tseng",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "W"
                    ],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Hwang",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Br J Dermatol",
            "volume": "166",
            "issn": "3",
            "pages": "525--556",
            "other_ids": {}
        },
        "BIBREF80": {
            "ref_id": "b80",
            "title": "Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata",
            "authors": [
                {
                    "first": "I",
                    "middle": [
                        "A"
                    ],
                    "last": "Vallerand",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "T"
                    ],
                    "last": "Lewinson",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Parsons",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hardin",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Haber",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "W"
                    ],
                    "last": "Lowerison",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "JAMA Dermatol. 2019. 25. Paus R",
            "volume": "8",
            "issn": "2",
            "pages": "188--94",
            "other_ids": {}
        },
        "BIBREF81": {
            "ref_id": "b81",
            "title": "History of atopy or autoimmunity increases risk of alopecia areata",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Barahmani",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "B"
                    ],
                    "last": "Schabath",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Duvic",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "61",
            "issn": "4",
            "pages": "581--91",
            "other_ids": {}
        },
        "BIBREF82": {
            "ref_id": "b82",
            "title": "Follow-up study on the relationship between alopecia areata and risk of autoimmune diseases",
            "authors": [
                {
                    "first": "C-H",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "K-H",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "H-C",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "S-D",
                    "middle": [],
                    "last": "Chung",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "The Journal of Dermatology",
            "volume": "43",
            "issn": "2",
            "pages": "228--237",
            "other_ids": {}
        },
        "BIBREF83": {
            "ref_id": "b83",
            "title": "Practice gaps. Alopecia areata and comorbid conditions",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Tosti",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "JAMA Dermatol",
            "volume": "149",
            "issn": "7",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF84": {
            "ref_id": "b84",
            "title": "A clinical study of childhood alopecia areata in Singapore",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "K"
                    ],
                    "last": "Tay",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "C"
                    ],
                    "last": "Giam",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF86": {
            "ref_id": "b86",
            "title": "Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Jagielska",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Redler",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "F"
                    ],
                    "last": "Brockschmidt",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Herold",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Pasternack",
                    "suffix": ""
                },
                {
                    "first": "Garcia",
                    "middle": [],
                    "last": "Bartels",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "J Invest Dermatol",
            "volume": "132",
            "issn": "9",
            "pages": "2192--2199",
            "other_ids": {}
        },
        "BIBREF87": {
            "ref_id": "b87",
            "title": "Acute diffuse and total alopecia of the female scalp associated with borrelia-infection",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "K"
                    ],
                    "last": "Bhardwaj",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "M"
                    ],
                    "last": "Tr\u00fceb",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "International journal of trichology",
            "volume": "7",
            "issn": "1",
            "pages": "26--34",
            "other_ids": {}
        },
        "BIBREF88": {
            "ref_id": "b88",
            "title": "Vitiligo and alopecia areata in patients with human immunodeficiency virus infection",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Cho",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "R"
                    ],
                    "last": "Cohen",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Duvic",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "Southern medical journal",
            "volume": "88",
            "issn": "4",
            "pages": "489--91",
            "other_ids": {}
        },
        "BIBREF89": {
            "ref_id": "b89",
            "title": "Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia",
            "authors": [
                {
                    "first": "Gil",
                    "middle": [],
                    "last": "Montoya",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Cutando",
                    "middle": [],
                    "last": "Soriano",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Jimenez",
                    "middle": [],
                    "last": "Prat",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Medicina Bucal",
            "volume": "7",
            "issn": "4",
            "pages": "303--311",
            "other_ids": {}
        },
        "BIBREF90": {
            "ref_id": "b90",
            "title": "Alopecia areata triggered or exacerbated by swine flu virus infection",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Ito",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Tokura",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "The Journal of dermatology",
            "volume": "39",
            "issn": "10",
            "pages": "863--867",
            "other_ids": {}
        },
        "BIBREF91": {
            "ref_id": "b91",
            "title": "Alopecia areata and cytomegalovirus infection in twins: genes versus environment",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Jackow",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Puffer",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hordinsky",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Nelson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Tarrand",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Duvic",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "38",
            "issn": "3",
            "pages": "418--443",
            "other_ids": {}
        },
        "BIBREF92": {
            "ref_id": "b92",
            "title": "Role of cytomegalovirus replication in alopecia areata pathogenesis",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Offidani",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Amerio",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "L"
                    ],
                    "last": "Bernardini",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Feliciani",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Bossi",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Journal of cutaneous medicine and surgery",
            "volume": "4",
            "issn": "2",
            "pages": "63--68",
            "other_ids": {}
        },
        "BIBREF93": {
            "ref_id": "b93",
            "title": "Prevalence and clinical features of skin diseases in chronic HCV infection. A prospective study in 96 patients",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Paoletti",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mammarella",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Basili",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Paradiso",
                    "suffix": ""
                },
                {
                    "first": "Di",
                    "middle": [],
                    "last": "Franco",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "De",
                    "middle": [],
                    "last": "Matteis",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Panminerva medica",
            "volume": "44",
            "issn": "4",
            "pages": "349--52",
            "other_ids": {}
        },
        "BIBREF94": {
            "ref_id": "b94",
            "title": "Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "T"
                    ],
                    "last": "Richardson",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "S"
                    ],
                    "last": "Gilmore",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Poligone",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "American journal of clinical dermatology",
            "volume": "19",
            "issn": "1",
            "pages": "119--145",
            "other_ids": {}
        },
        "BIBREF95": {
            "ref_id": "b95",
            "title": "Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "D"
                    ],
                    "last": "Kartal",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "N"
                    ],
                    "last": "Alpat",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Ozgunes",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Usluer",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "European journal of gastroenterology & hepatology",
            "volume": "19",
            "issn": "9",
            "pages": "817--837",
            "other_ids": {}
        },
        "BIBREF96": {
            "ref_id": "b96",
            "title": "Alopecia areata is not associated with Helicobacter pylori",
            "authors": [
                {
                    "first": "Abdel",
                    "middle": [],
                    "last": "Hafez",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "Z"
                    ],
                    "last": "Mahran",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Hofny",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "M"
                    ],
                    "last": "Attallah",
                    "suffix": ""
                },
                {
                    "first": "Daa",
                    "middle": [],
                    "last": "Sayed",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Rashed",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Indian journal of dermatology",
            "volume": "54",
            "issn": "1",
            "pages": "17--26",
            "other_ids": {}
        },
        "BIBREF97": {
            "ref_id": "b97",
            "title": "Impact of Historic Migrations and Evolutionary Processes on Human Immunity",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Dom\u00ednguez-Andr\u00e9s",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "G"
                    ],
                    "last": "Netea",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Trends in Immunology",
            "volume": "40",
            "issn": "12",
            "pages": "1105--1124",
            "other_ids": {}
        },
        "BIBREF98": {
            "ref_id": "b98",
            "title": "Multiple common variants for celiac disease influencing immune gene expression",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "C"
                    ],
                    "last": "Dubois",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Trynka",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Franke",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Hunt",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Romanos",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Curtotti",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Nat Genet",
            "volume": "42",
            "issn": "4",
            "pages": "295--302",
            "other_ids": {}
        },
        "BIBREF99": {
            "ref_id": "b99",
            "title": "Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Hung",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Hou",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "W"
                    ],
                    "last": "Qiao",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "T"
                    ],
                    "last": "Chow",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "J Immunol",
            "volume": "202",
            "issn": "9",
            "pages": "2558--69",
            "other_ids": {}
        },
        "BIBREF100": {
            "ref_id": "b100",
            "title": "Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zhernakova",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "C"
                    ],
                    "last": "Elbers",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Ferwerda",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Romanos",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Trynka",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "C"
                    ],
                    "last": "Dubois",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Am J Hum Genet",
            "volume": "86",
            "issn": "6",
            "pages": "970--977",
            "other_ids": {}
        },
        "BIBREF101": {
            "ref_id": "b101",
            "title": "Infections and Chronic Inflammatory Bowel Disease",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Kucharzik",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Maaser",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF103": {
            "ref_id": "b103",
            "title": "Risk factors for opportunistic infections in patients with inflammatory bowel disease",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Toruner",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "V"
                    ],
                    "last": "Loftus",
                    "suffix": ""
                },
                {
                    "first": "Jr",
                    "middle": [],
                    "last": "Harmsen",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "S"
                    ],
                    "last": "Zinsmeister",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "R"
                    ],
                    "last": "Orenstein",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Sandborn",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "J"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Gastroenterology",
            "volume": "134",
            "issn": "4",
            "pages": "929--965",
            "other_ids": {}
        },
        "BIBREF104": {
            "ref_id": "b104",
            "title": "Oral Corticosteroids and the Risk of Serious Infections in Patients With Elderly-Onset Inflammatory Bowel Diseases",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Brassard",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bitton",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Suissa",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Sinyavskaya",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Patenaude",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Suissa",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "The American journal of gastroenterology",
            "volume": "109",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF105": {
            "ref_id": "b105",
            "title": "Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clinical gastroenterology and hepatology : the official clinical practice journal of the",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "R"
                    ],
                    "last": "Lichtenstein",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "G"
                    ],
                    "last": "Feagan",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "D"
                    ],
                    "last": "Cohen",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "A"
                    ],
                    "last": "Salzberg",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "H"
                    ],
                    "last": "Diamond",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "American Gastroenterological Association",
            "volume": "4",
            "issn": "5",
            "pages": "621--651",
            "other_ids": {}
        },
        "BIBREF106": {
            "ref_id": "b106",
            "title": "Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "R"
                    ],
                    "last": "Lichtenstein",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "G"
                    ],
                    "last": "Feagan",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "D"
                    ],
                    "last": "Cohen",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "A"
                    ],
                    "last": "Salzberg",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "H"
                    ],
                    "last": "Diamond",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Price",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "The American journal of gastroenterology",
            "volume": "107",
            "issn": "9",
            "pages": "1409--1431",
            "other_ids": {}
        },
        "BIBREF107": {
            "ref_id": "b107",
            "title": "Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Fardet",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Petersen",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Nazareth",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "PLOS Medicine",
            "volume": "13",
            "issn": "5",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF108": {
            "ref_id": "b108",
            "title": "Haematological abnormalities in new-onset rheumatoid arthritis and risk of common infections: a population-based study",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Nikiphorou",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "De Lusignan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Mallen",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Khavandi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Roberts",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Buckley",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Rheumatology",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF110": {
            "ref_id": "b110",
            "title": "Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Olsen",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "F"
                    ],
                    "last": "Bergfeld",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Cotsarelis",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "H"
                    ],
                    "last": "Price",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shapiro",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Sinclair",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "48",
            "issn": "1",
            "pages": "103--113",
            "other_ids": {}
        },
        "BIBREF111": {
            "ref_id": "b111",
            "title": "Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Correa",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Hinton",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mcgovern",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Van Vlymen",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Yonova",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jones",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "BMJ open",
            "volume": "6",
            "issn": "4",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF112": {
            "ref_id": "b112",
            "title": "Defining datasets and creating data dictionaries for quality improvement and research in chronic disease using routinely collected data: an ontology-driven approach",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "De Lusignan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "T"
                    ],
                    "last": "Liaw",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Michalakidis",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jones",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Informatics in primary care",
            "volume": "19",
            "issn": "3",
            "pages": "127--161",
            "other_ids": {}
        },
        "BIBREF113": {
            "ref_id": "b113",
            "title": "International Statistical Classification of Diseases and Related Health Problems 10th",
            "authors": [],
            "year": 2016,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF114": {
            "ref_id": "b114",
            "title": "Case-finding for common mental disorders of anxiety and depression in primary care: an external validation of routinely collected data",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "John",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Mcgregor",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Fone",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Dunstan",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cornish",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Lyons",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "BMC Medical Informatics and Decision Making",
            "volume": "16",
            "issn": "1",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF115": {
            "ref_id": "b115",
            "title": "Ethnicity Recording in Primary Care Computerised Medical Record Systems: An Ontological Approach",
            "authors": [
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Tippu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Correa",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Liyanage",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Burleigh",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mcgovern",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Van Vlymen",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Ministry of Housing CLG. English indices of deprivation 2015: technical report2015 2nd",
            "volume": "23",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF116": {
            "ref_id": "b116",
            "title": "Realizing the Mass Public Benefit of Evidence-Based Psychological Therapies: The IAPT Program",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Clark",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Annu Rev Clin Psychol",
            "volume": "14",
            "issn": "",
            "pages": "159--83",
            "other_ids": {}
        },
        "BIBREF117": {
            "ref_id": "b117",
            "title": "OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "G"
                    ],
                    "last": "Dean",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "M"
                    ],
                    "last": "Sullivan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "M"
                    ],
                    "last": "Soe",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF118": {
            "ref_id": "b118",
            "title": "Methods in Observational Epidemiology 2nd Edition, Table 12-15",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Kelsey",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Whittemore",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Evans",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "D"
                    ],
                    "last": "Thompson",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF119": {
            "ref_id": "b119",
            "title": "Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of general psychiatry",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "C"
                    ],
                    "last": "Kessler",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "T"
                    ],
                    "last": "Chiu",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Demler",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "R"
                    ],
                    "last": "Merikangas",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "E"
                    ],
                    "last": "Walters",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "",
            "volume": "62",
            "issn": "",
            "pages": "617--644",
            "other_ids": {}
        },
        "BIBREF120": {
            "ref_id": "b120",
            "title": "Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "Y"
                    ],
                    "last": "Chu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "J"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "C"
                    ],
                    "last": "Tseng",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "W"
                    ],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Hwang",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Journal of the American Academy of Dermatology",
            "volume": "65",
            "issn": "5",
            "pages": "949--56",
            "other_ids": {}
        },
        "BIBREF121": {
            "ref_id": "b121",
            "title": "Nonparametric Preprocessing for Parametric Causal Inference",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Ho",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Imai",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "King",
                    "suffix": ""
                },
                {
                    "first": "Stuart",
                    "middle": [
                        "E"
                    ],
                    "last": "Matchit",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Journal of Statistical Software, Articles",
            "volume": "42",
            "issn": "8",
            "pages": "1--28",
            "other_ids": {}
        },
        "BIBREF122": {
            "ref_id": "b122",
            "title": "Cancer incidence: life table risk versus cumulative risk",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "J"
                    ],
                    "last": "Schouten",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Straatman",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "A"
                    ],
                    "last": "Kiemeney",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Verbeek",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "J Epidemiol Community Health",
            "volume": "48",
            "issn": "6",
            "pages": "596--600",
            "other_ids": {}
        },
        "BIBREF123": {
            "ref_id": "b123",
            "title": "Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Kumar",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "De Lusignan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mcgovern",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Correa",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hriskova",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gatenby",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Bmj",
            "volume": "360",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF124": {
            "ref_id": "b124",
            "title": "The impact of therapy on the risk of asthma in type 2 diabetes",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "H"
                    ],
                    "last": "Rayner",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mcgovern",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Sherlock",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Gatenby",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Correa",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Creagh-Brown",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "XaDtl All Legionnaire's disease XE0YJ All Bronchopneumonia due to unspecified organism",
            "volume": "13",
            "issn": "",
            "pages": "299--305",
            "other_ids": {}
        },
        "BIBREF125": {
            "ref_id": "b125",
            "title": "Development and Validation of an Algorithm to Accurately Identify Atopic Eczema Patients in Primary Care Electronic Health Records from the UK",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Abuabara",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Magyari",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Hoffstad",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [
                        "K"
                    ],
                    "last": "Jabbar-Lopez",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Smeeth",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "C"
                    ],
                    "last": "Williams",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Journal of Investigative Dermatology",
            "volume": "137",
            "issn": "8",
            "pages": "1655--62",
            "other_ids": {}
        },
        "BIBREF126": {
            "ref_id": "b126",
            "title": "Determinants of inter-practice variation in childhood asthma and respiratory infections: crosssectional study of a national sentinel network",
            "authors": [
                {
                    "first": "U",
                    "middle": [],
                    "last": "Hoang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Liyanage",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Coyle",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Godden",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jones",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Blair",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "BMJ open",
            "volume": "9",
            "issn": "1",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF128": {
            "ref_id": "b128",
            "title": "An algorithm to identify rheumatoid arthritis in primary care: a Clinical Practice Research Datalink study",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Muller",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "L"
                    ],
                    "last": "Hider",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Raza",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Stack",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Hayward",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "D"
                    ],
                    "last": "Mallen",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "BMJ open",
            "volume": "5",
            "issn": "12",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "The epidemiology, management, and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: Protocol for an observational study series",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "2 million) from the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database, exploring four themes: AA epidemiology, mental health comorbidities, autoimmune/atopic associations and common infections.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "of AA; ii) the prevalence and incidence of psychiatric comorbidities in people with AA; iii) the prevalence and incidence of autoimmune and atopic conditions in people with AA; iv) the incidence of common infections in people with AA.Current knowledgeEpidemiology Population studies in the USA using the Rochester Epidemiology Project database estimate the lifetime risk of AA to be 2.1%.(4) The database contained information from all patients registered with a healthcare provider in Olmsted County, Minnesota from 1990-2009. Previous studies using this database from 1971-1974 estimated the overall prevalence of AA to be 0.1-0.2%,(13) with no published studies reporting prevalence estimates since this. Other epidemiological studies have assessed the incidence of AA in patients referred to dermatology services.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "AA onset occurs before the age of 40 in 82-86% of cases.(5) To date, there have been no large population-based studies of AA epidemiology in UK populations.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "A central theory in AA pathogenesis is that it is an autoimmune phenomenon resulting from a disruption of hair follicle 'immune privilege', where numerous",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "of studies have reported autoimmune conditions to occur more frequently in those with AA than in the general population, however results are conflicting and studies have been limited by potential recruiting, recall and reporting biases.(26) A Taiwanese retrospective cohort study found individuals with AA to have an overall increased risk of developing an autoimmune condition when compared with matched controls (HR 1.86, 95%CI 1.32-2.63). In particular, greater risks of incident systemic lupus erythematosus (SLE) (HR 5.02; 95%CI",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "when compared with controls.(9) It is not however surprising from a pathogenesis perspective in terms of shared pathways of autoimmune susceptibility; IL-13 loci have been associated with autoimmune and atopic",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": "of particular importance with the emergence of Janus kinase inhibitors as a potential treatment option.(52) Whilst this medication class can produce impressive hair regrowth results even in long-standing AA their use is associated with some increased infection risk; in particular, urinary tract infections, viral gastroenteritis fungal infections, and varicella zoster infection.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "January 2009 to 1 st January 2019) exploring AA in four theme areas: epidemiology, mental health, autoimmune and atopic comorbidities and common infections.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "onset atopic and autoimmune conditions in the first five years after diagnosis in people with AA compared with matched controls.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF14": {
            "text": "will use routinely collected and collated data from the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database to provide a broadly representative sample of the population of England. The RCGP RSC incorporates pseudonymised primary care records from over 200 GP practices distributed across England. Details of the cohort included in the database have been published previously.(53) At the current time, the database contains data from 2.6 million actively registered people and the historic records of up to 5.2 million people over the last 20 years.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF17": {
            "text": "defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD10) classification; depressive episodes (F32), recurrent depressive disorder (F33), and non-phobia related anxiety disorders (F41). These conditions have been chosen as they represent the most common mental health conditions presenting to primary care.(63) Conditions will be",
            "latex": null,
            "type": "figure"
        },
        "FIGREF18": {
            "text": "algorithms validated in UK primary care. We selected the algorithms to be used in the study to optimise the positive predictive value of case identification. In brief, we will use a concurrent diagnosis and treatment code to identify acute depression episodes and for recurrent depressive disorder either a historical code for any depression and current treatment or a recurrent depressive disorder specific diagnosis code (Supplementary Tables S2.1, S2.2 and S2.3, Additional file 2). Anxiety disorder will be identified using a concurrent diagnosis of an anxiety episode and treatment code(Supplementary Table S2.4, Additional file 2).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF20": {
            "text": "myasthenia gravis, and systemic vasculitides.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF21": {
            "text": "dermatology review [Study 1], psychiatrist referral and counselling [Study 2]).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF23": {
            "text": "compare infection incidence in cases and controls up to five years.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF25": {
            "text": ", analysing associations between AA and common infections may provide evidence to support the prescribing of immune modulating medications for the treatment of AA.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF31": {
            "text": "S, van Weel C. The use of routinely collected computer data for research in primary care: opportunities and challenges. Family practice.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF33": {
            "text": "abbreviations .......................................................................................................................................... 4 1. Introduction ..................................................................................................................................................... 5 1.1 Background ...............................................................................................................................................5 1.2. Purposes of analyses ............................................................................................................................ 5 Study 1: Epidemiology of AA ................................................................................................................ 5 Study 2: Mental health comorbidities in patients with AA ....................................................... 5 Study 3: Autoimmune and atopic conditions in people with AA ............................................ 6 Study 4: Common infections in people withAA ............................................................................ 6 2. Study objectives and endpoints ................................................................................................................ 7 2.1 Study objectives ....................................................................................................................................... 7 2.1.1 Study 1 ................................................................................................................................................ 7 2.1.2 Study 2 ................................................................................................................................................ 7 2.1.3 Study 3 ................................................................................................................................................ 7 2.1.4 Study 4 ................................................................................................................................................ 7 2.2 Primary objectives ................................................................................................................................. 8 2.2.1 Study 1 ................................................................................................................................................ 8 2.2.2 Study 2 ................................................................................................................................................ 8 2.2.3 Study 3 ................................................................................................................................................ 8 2.2.4 Study 4 ................................................................................................................................................ 8 2.3 Secondary objectives: ............................................................................................................................ 9 2.3.1 Study 1 ................................................................................................................................................ 9 2.3.2 Study 2 ................................................................................................................................................ 9 2.3.3 Study 3 ................................................................................................................................................ 9 2.3.4 Study 4 ................................................................................................................................................ 9 2.4 Primary endpoint ................................................................................................................................ 10 2.5 Secondary endpoints .......................................................................................................................... 11 2.6 Other exploratory analyses .............................................................................................................. 11 3 General Study Design and Plan ............................................................................................................... 11 3.1 Study Design .......................................................................................................................................... 11 3.1.1 Study 1: ............................................................................................................................................ 11 3.1.2 Study 2: ............................................................................................................................................ 11 3.1.3 Study 3: ............................................................................................................................................ 11 3.1.4 Study 4: ............................................................................................................................................ 12 3.2 Data source and Read codes ............................................................................................................ 12 3.3 Data extraction ..................................................................................................................................... 12 3.4 Inclusion-Exclusion Criteria and General Study Population ............................................... 12 3.4.1 AA definition ................................................................................................................................. 12 3.5 Baseline socio-economic characteristics .................................................................................... 13",
            "latex": null,
            "type": "figure"
        },
        "FIGREF34": {
            "text": "of AA ............................................................................................................................ 13 3.7 Current service utilisation and management patterns .........................................................133.8 Mental health treatment, sick day, and unemployment burden ........................................ 13 4 Sample size calculations ............................................................................................................................ 14 4.1.1 Study 1 .................................................................................................................................................. 14 4.1.2 Study 2 .................................................................................................................................................. 14 4.1.3Study 3 .................................................................................................................................................. 14 4.1.4 Study 4 .................................................................................................................................................. 15 5 Populations to be analysed ....................................................................................................................... 15 5.1 Inclusion Criteria ................................................................................................................................. 15 5.2 Exclusion Criteria ........................................................................................................................... 15 5.3 Matching process ................................................................................................................................. 16 5.4 AA definition exploratory analyses ............................................................................................... 16 6 Statistical Analysis ....................................................................................................................................... 17 6.1 Statistical principles ........................................................................................................................... 17 6.2 Primary Endpoint Analysis .............................................................................................................. 17 6.2.1 Study 1 ............................................................................................................................................. 17 6.2.2 Study 2 ............................................................................................................................................. 18 6.2.3 Study 3 ............................................................................................................................................. 19 6.2.4 Study 4 ............................................................................................................................................. 19 6.3 Secondary Objective Analysis ......................................................................................................... 19 6.2.1 Study 1 ............................................................................................................................................. 19 6.2.2 Study 2 ............................................................................................................................................. 19 6.2.3 Study 3 ............................................................................................................................................. 20 6.2.4 Study 4 ............................................................................................................................................. 20 6.4 Sensitivity analysis .............................................................................................................................. 20 6.5 Missing data ........................................................................................................................................... 20 7 Study Limitations ......................................................................................................................................... 21 8 Statistical software ...................................................................................................................................... 21 9 Ethics ................................................................................................................................................................ 21 10 Acknowledgements .................................................................................................................................. 21 References ..........................................................................................................................................................",
            "latex": null,
            "type": "figure"
        },
        "FIGREF48": {
            "text": "2 million) from the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database, exploring four themes: AA epidemiology, mental health comorbidities, autoimmune/atopic associations and common infections.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF49": {
            "text": "(AA) is a common cause of immune-mediated, non-scarring hair loss.(1) Clinical presentations of AA are heterogeneous, ranging from welldemarcated patches of hair loss on the scalp to total loss of hair on the scalp (alopecia areata totalis) or entire scalp and body (alopecia areata universalis).(2)    Active AA is estimated to affect approximately 0.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF50": {
            "text": "(7)A number of treatment options can induce hair growth in people with AA, but none have been shown to have a durable impact on remission.(8)    AA has been associated with a number of autoimmune conditions, supporting the theory of an underlying autoimmune aetiology.(9) Atopic conditions and mental health disorders have also been demonstrated to be more common in people with AA,(9)(10)(11) although the temporal relationship between psychiatric conditions and AA remains poorly researched.(12)  The association between AA and common infections is not well studied.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF51": {
            "text": "of AA; ii) the prevalence and incidence of psychiatric comorbidities in people with AA; iii) the prevalence and incidence of autoimmune and atopic conditions in people with AA; iv) the incidence of common infections in people with AA.Current knowledgeEpidemiology Population studies in the USA using the Rochester Epidemiology Project database estimate the lifetime risk of AA to be 2.1%.(4) The database contained information from all patients registered with a healthcare provider in Olmsted County, Minnesota from 1990-2009. Previous studies using this database from 1971-1974 estimated the overall prevalence of AA to be 0.1-0.2%,(13) with no published studies reporting prevalence estimates since this. Other epidemiological studies have assessed the incidence of AA in patients referred to dermatology services.Clinic-based studies from around the world have estimated the incidence of AA to be in the region of 0.57-3.8%.(14)(15)(16)(17)(18) Worldwide, the majority of studies on AA have not found a significant difference in incidence between males and females.(5) AA onset occurs before the age of 40 in 82-86% of cases.(5) To date, there have been no large population-based studies of AA epidemiology in UK populations.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF52": {
            "text": "(9,(31)(32)(33)(34)(35)(36)(37)(38) Some case reports have suggested improvement or resolution of AA with treatment of the associated infection.(33,39). However, early small-scale studies have failed to find convincing evidence to support associations.(35, 36,40) Multiple genetic loci have been identified to be both protective from infection but increase the risk for autoimmune disease.(41) Examples include the HLA variants HLA-DQ2 and HLA-DQ8 which confer protection against viral infections including influenza but are associated with inflammatory bowel disease,(42, 43) and SH2B3 rs3184504*A gene variant protective against Escherichia coli infection but also detrimental for inflammatory bowel disease.(44) These loci which, in the past have conferred a genetic advantage, may still confer a reduced infection risk.(41) It is currently unclear if the genetic predisposition for AA is caused by genetic factors which also confer protection against any common infections. In other autoimmune conditions infection risk is often increased as a result of the pathological changes resulting from the condition itself, the effects of immune-modulatory treatment, or through increased exposure to pathogens through healthcare contact.(45-51) An understanding of the relative infection rates in people with AA compared to those Page 10 of 215 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open",
            "latex": null,
            "type": "figure"
        },
        "FIGREF53": {
            "text": "of particular importance with the emergence of Janus kinase inhibitors as a potential treatment option.(52) Whilst this medication class can produce impressive hair regrowth results even in long-standing AA their use is associated with some increased infection risk; in particular, urinary tract infections, viral gastroenteritis fungal infections, and varicella zoster infection.(52)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF54": {
            "text": "onset atopic and autoimmune conditions in the first five years after diagnosis in people with AA compared with matched controls.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF55": {
            "text": "College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database to provide a broadly representative sample of the population of England. The RCGP RSC incorporates pseudonymised primary care records from over 200 GP practices distributed across England. Details of the cohort included in the database have been published previously.(53) At the current time, the database contains data from 2.6 million actively registered people and the historic records of up to 5.2 million people over the last 20 years. The RCGP RSC database includes patient demographics, diagnoses, laboratory test results, primary care issued prescriptions and processes of care such as clinic visits and specialist referrals. These data are coded using the Read code system. UK general practice records provide several advantages for this study type; UK primary care is a registration-based system (a patient can only register with a single GP), records have been computerised since the 1990s, and pay-forperformance targets (introduced in 2004 through The Quality and Outcomes Framework; QOF) have resulted in consistent high-quality clinical data entry about chronic disease.(54, 55) Studies in many chronic diseases such as atopic dermatitis, rheumatoid arthritis, diabetes, inflammatory bowel disease, and chronic obstructive pulmonary disease have been published using RCGP RSC data.(51, 56-59) RCGP RSC practices get feedback on their data quality, with a particular",
            "latex": null,
            "type": "figure"
        },
        "FIGREF56": {
            "text": "defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD10) classification; depressive episodes (F32), recurrent depressive disorder (F33), and non-phobia related anxiety disorders (F41). These conditions have been chosen as they represent the most common mental health conditions presenting to primary care.(63) Conditions will be Page 16 of 215 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open",
            "latex": null,
            "type": "figure"
        },
        "FIGREF57": {
            "text": "algorithms validated in UK primary care. We selected the algorithms to be used in the study to optimise the positive predictive value of case identification. In brief, we will use a concurrent diagnosis and treatment code to identify acute depression episodes and for recurrent depressive disorder either a historical code for any depression and current treatment or a recurrent depressive disorder specific diagnosis code (Supplementary Tables S2.1, S2.2 and S2.3, Additional file 2). Anxiety disorder will be identified using a concurrent diagnosis of an anxiety episode and treatment code(Supplementary Table S2.4, Additional file 2).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF59": {
            "text": "Additional file 2). These forms are completed by GPs when their patients are accessing incapacity benefits (historically) or employment and support allowance (current) because of a disability or health condition affecting their ability to work. Time off work will be assessed by reporting the rates of issue of Med 3 (Statement of Fitness for Work) certification from primary care (Supplementary",
            "latex": null,
            "type": "figure"
        },
        "FIGREF60": {
            "text": "2) will be evaluated by calculation of annual primary care attendance rates, treatment rates (prescriptions per person per year), and the total proportion of people with one or more referral for additional services (dermatology review [Study 1], psychiatrist referral and counselling [Study 2]).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF61": {
            "text": "A greater understanding of the prevalence of mental health conditions associated with AA and the directionality of these relationships may help with the development of psychological interventions in AA, as the approach required would likely differ if the symptoms patients are experiencing are pervasive or reactive to an episode of hair loss.(12,68) Awareness of AA as a potential risk factor or associated comorbidity for certain autoimmune and atopic conditions may help reduce delays in diagnosis for these conditions and increase vigilance of GPs and dermatologists when reviewing their patients with AA in detecting co-existent conditions. Future work may focus upon whether improved control of an underlying autoimmune or atopic condition may improve chances of achieving remission in AA.Finally, analysing associations between AA and common infections may provide evidence to support the prescribing of immune modulating medications for the treatment of AA.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF62": {
            "text": "24. Vallerand IA, Lewinson RT, Parsons LM, Hardin J, Haber RM, Lowerison MW, et al. Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata. JAMA Dermatol. 2019. 25. Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J Investig Dermatol Symp Proc. 2003;8(2):188-94. 26. Barahmani N, Schabath MB, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. Journal of the American Academy of Dermatology. 2009;61(4):581-91. 27. Chen C-H, Wang K-H, Lin H-C, Chung S-D. Follow-up study on the relationship between alopecia areata and risk of autoimmune diseases. The Journal of Dermatology. 2016;43(2):228-9. 28. Tosti A. Practice gaps. Alopecia areata and comorbid conditions. JAMA Dermatol. 2013;149(7):794. 29. Tan E, Tay YK, Giam YC. A clinical study of childhood alopecia areata in Singapore. Pediatr Dermatol. 2002;19(4):298-301. 30. Jagielska D, Redler S, Brockschmidt FF, Herold C, Pasternack SM, Garcia Bartels N, et al. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genomewide significance. J Invest Dermatol. 2012;132(9):2192-7. 31. Bhardwaj EK, Tr\u00fceb RM. Acute diffuse and total alopecia of the female scalp associated with borrelia-infection. International journal of trichology. 2015;7(1):26-8. 32. Cho M, Cohen PR, Duvic M. Vitiligo and alopecia areata in patients with human immunodeficiency virus infection. Southern medical journal. 1995;88(4):489-91. 33. Gil Montoya JA, Cutando Soriano A, Jimenez Prat J. Alopecia areata of dental origin. Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal. 2002;7(4):303-8. 34. Ito T, Tokura Y. Alopecia areata triggered or exacerbated by swine flu virus infection. The Journal of dermatology. 2012;39(10):863-4. 35. Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment? Journal of the American Academy of Dermatology. 1998;38(3):418-25. 36. Offidani A, Amerio P, Bernardini ML, Feliciani C, Bossi G. Role of cytomegalovirus replication in alopecia areata pathogenesis. Journal of cutaneous medicine and surgery. 2000;4(2):63-5.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF63": {
            "text": "..................................................................................................................................................... 5 1.1Background ............................................................................................................................................... 5 1.2. Purposes of analyses ............................................................................................................................ 5 Study 1: Epidemiology of AA ................................................................................................................ 5 Study 2: Mental health comorbidities in patients with AA ....................................................... 5 Study 3: Autoimmune and atopic conditions in people with AA ............................................ 6 Study 4: Common infections in people with AA ...",
            "latex": null,
            "type": "figure"
        },
        "FIGREF64": {
            "text": ".... 6 2. Study objectives and endpoints ................................................................................................................ 7 2.1 Study objectives ....................................................................................................................................... 7 2.1.1 Study1 ................................................................................................................................................ 7 2.1.2 Study 2 ................................................................................................................................................ 7 2.1.3 Study 3 ................................................................................................................................................ 7 2.1.4 Study4 ................................................................................................................................................ 7 2.2 Primary objectives ................................................................................................................................. 8 2.2.1 Study 1 ................................................................................................................................................ 8 2.2.2 Study 2 ................................................................................................................................................ 8 2.2.3 Study 3 ................................................................................................................................................ 8 2.2.4 Study 4 ................................................................................................................................................ 8 2.3 Secondary objectives: ............................................................................................................................ 9 2.3.1 Study 1 ................................................................................................................................................ 9 2.3.2 Study 2 ................................................................................................................................................ 9 2.3.3 Study 3 ................................................................................................................................................ 9 2.3.4 Study 4 ................................................................................................................................................ 9 2.4 Primary endpoint ................................................................................................................................ 10 2.5 Secondary endpoints .......................................................................................................................... 11 2.6 Other exploratory analyses .............................................................................................................. 11 3 General Study Design and Plan ............................................................................................................... 11 3.1 Study Design .......................................................................................................................................... 11 3.1.1 Study 1: ............................................................................................................................................ 11 3.1.2 Study 2: ............................................................................................................................................ 11 3.1.3 Study 3: ............................................................................................................................................ 11 3.1.4 Study 4: ............................................................................................................................................ 12 3.2 Data source and Read codes ............................................................................................................ 12 3.3 Data extraction ..................................................................................................................................... 12 3.4 Inclusion-Exclusion Criteria and General Study Population ............................................... 12 3.4.1 AA definition ................................................................................................................................. 12 3.5 Baseline socio-economic characteristics .................................................................................... 13",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "urinary tract infection, genital infections, gastrointestinal infection, herpes simplex, herpes zoster, meningitis, COVID-19) in people with AA compared with matched controls.",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": ".1, Additional file 2) and alopecia extent if recorded (Supplementary Table S1.2, Additional file 2).",
            "latex": null,
            "type": "table"
        },
        "TABREF5": {
            "text": "Astra Zeneca, GSK, Seqirus and Takeda -all through his Universities and none related to this study. WSC and WRG are employees of Pfizer Ltd. SH and CT are investigators on the Pfizer funded Allegro clinical trial. AEM, ART, CT, MH and AGM declare that they have no competing interests.",
            "latex": null,
            "type": "table"
        },
        "TABREF6": {
            "text": ", Additional file 2",
            "latex": null,
            "type": "table"
        },
        "TABREF11": {
            "text": "Primary endpoints. *Exclusion diagnoses are; any form of scarring alopecia,",
            "latex": null,
            "type": "table"
        },
        "TABREF13": {
            "text": "(Supplementary Table S2.10, Additional file 2).",
            "latex": null,
            "type": "table"
        },
        "TABREF16": {
            "text": "Medical writing support was provided by Louise Jordan at Momentum Data and was funded by Pfizer. Editorial support was provided by Anita Lynam, Andrew McGovern, and John Dennis at Momentum Data and was funded by Pfizer. The authors would like to acknowledge project management support from Filipa Ferreira of the University of Oxford and University of Surrey. Matthew Harries was supported by the NIHR Manchester. Lewinson RT, Parsons LM, Hardin J, Haber RM, Lowerison MW, et al. Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata. JAMA Dermatol. 2019. 25. Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J Investig Dermatol Symp Proc. 2003;8(2):188-94. 26. Barahmani N, Schabath MB, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. Journal of the American Academy of Dermatology. Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol. Cohen PR, Duvic M. Vitiligo and alopecia areata in patients with human immunodeficiency virus infection. Southern medical journal. 1995;88(4):489-91. 33. Gil Montoya JA, Cutando Soriano A, Jimenez Prat J. Alopecia areata of dental origin. Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal. Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment? Journal of the American Academy of Dermatology. 1998;38(3):418-25. 36. Offidani A, Amerio P, Bernardini ML, Feliciani C, Bossi G. Role of cytomegalovirus replication in alopecia areata pathogenesis. Journal of cutaneous medicine and surgery. Mammarella A, Basili S, Paradiso M, Di Franco M, De Matteis A, et al. Prevalence and clinical features of skin diseases in chronic HCV infection. A prospective study in 96 patients. Panminerva medica. 2002;44(4):349-52. 38. Richardson CT, Hayden MS, Gilmore ES, Poligone B. Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. American journal of clinical dermatology. Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. European journal of gastroenterology & hepatology. 2007;19(9):817-20. 40. Abdel Hafez HZ, Mahran AM, Hofny EM, Attallah DAA, Sayed DS, Rashed H. Alopecia areata is not associated with Helicobacter pylori. Indian journal of dermatology. Andr\u00e9s J, Netea MG. Impact of Historic Migrations and Evolutionary Processes on Human Immunity. Trends in Immunology. 2019;40(12):1105-19. 42. Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet. 2010;42(4):295-302. Elbers CC, Ferwerda B, Romanos J, Trynka G, Dubois PC, et al. Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection. Am J Hum Genet. Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Suissa A, Sinyavskaya L, Patenaude V, Suissa S. Oral Corticosteroids and the Risk of Serious Infections in Patients With Elderly-Onset Inflammatory Bowel Diseases. The American journal of gastroenterology. 2014;109:1795. 48. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. The American journal of gastroenterology. 2012;107(9):1409-22. 50. Fardet L, Petersen I, Nazareth I. Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study. PLOS Medicine. 2016;13(5):e1002024. 51. Nikiphorou E, de Lusignan S, Mallen C, Khavandi K, Roberts J, Buckley CD, et al. Haematological abnormalities in new-onset rheumatoid arthritis and risk of common infections: a population-based study. Rheumatology. 2019. 52. Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata. The Lancet. Bergfeld WF, Cotsarelis G, Price VH, Shapiro J, Sinclair R, et al. Summary of North American Hair Research Society (NAHRS)-sponsored Workshop on Cicatricial Alopecia, Duke University Medical Center, February 10 and 11, 2001. Journal of the American Academy of Dermatology. 2003;48(1):103-10. 54. Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, et al. Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ open. 2016;6(4):e011092. 55.de Lusignan S, Liaw ST, Michalakidis G, Jones S. Defining datasets and creating data dictionaries for quality improvement and research in chronic disease using routinely collected data: an ontology-driven approach. Informatics in primary care. 2011;19(3):127-34. 56. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems 10th Revision2016 2nd January 2020. Available from: http://apps.who.int/classifications/icd10/browse/2016/en. 57. John A, McGregor J, Fone D, Dunstan F, Cornish R, Lyons RA, et al. Case-finding for common mental disorders of anxiety and depression in primary care: an external validation of routinely collected data. BMC Medical Informatics and Decision Making. 2016;16(1):35. 58. Office for National Statistics. Ethnicity2018 2nd January 2020. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity. 59. Tippu Z, Correa A, Liyanage H, Burleigh D, McGovern A, Van Vlymen J, et al. Ethnicity Recording in Primary Care Computerised Medical Record Systems: An Ontological Approach. J Innov Health Inform. 2017;23(4):920. 60. Ministry of Housing CLG. English indices of deprivation 2015: technical report2015 2nd Jan 2020. Available from: https://www.gov.uk/government/publications/english-indices-ofdeprivation-2015-technical-report. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open",
            "latex": null,
            "type": "table"
        },
        "TABREF17": {
            "text": "61. Clark DM. Realizing the Mass Public Benefit of Evidence-Based Psychological Therapies: The IAPT Program. Annu Rev Clin Psychol. 2018;14:159-83. 62. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version [updated 06/04/2013. Available from: www.OpenEpi.com. 63. Kelsey JL, Whittemore AS, Evans AS, Thompson WD. Methods in Observational Epidemiology 2nd Edition, Table 12-15. New York: Oxford University Press; 1996. 64. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Chen YJ, Tseng WC, Lin MW, Chen TJ, Hwang CY, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. Journal of the American Academy of Dermatology. haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. Bmj. 2018;360:k342. 69. Rayner LH, Mcgovern A, Sherlock J, Gatenby P, Correa A, Creagh-Brown B, et al. The impact of therapy on the risk of asthma in type 2 diabetes. Clin Respir J. 2019;13(5):299-305. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open",
            "latex": null,
            "type": "table"
        },
        "TABREF19": {
            "text": "Supplementary table S1.1. Read codes to be used to identify cases of alopecia areata, non-specified alopecia and alternative diagnoses (exclusion diagnoses).",
            "latex": null,
            "type": "table"
        },
        "TABREF24": {
            "text": "Supplementary table S1.2. Read codes to identify the extent of alopecia. The extent of disease will be considered to be that of the category recorded with the greatest extent",
            "latex": null,
            "type": "table"
        },
        "TABREF25": {
            "text": "Supplementary table S1.3. Read codes to identify dermatology referrals.",
            "latex": null,
            "type": "table"
        },
        "TABREF27": {
            "text": "table S2.1. Algorithms used to identify anxiety (non-phobia",
            "latex": null,
            "type": "table"
        },
        "TABREF28": {
            "text": "Supplementary table S2.2.Read codes used to identify depression episodes.",
            "latex": null,
            "type": "table"
        },
        "TABREF30": {
            "text": "Supplementary table S2.5.Read codes used to identify adjustment disorder.",
            "latex": null,
            "type": "table"
        },
        "TABREF44": {
            "text": "Supplementarytable S2.10. Read codes used to identify non-medication based treatments for depression or anxiety.",
            "latex": null,
            "type": "table"
        },
        "TABREF47": {
            "text": "table S3.1. Read codes used to identify unemployment.",
            "latex": null,
            "type": "table"
        },
        "TABREF48": {
            "text": "table S4.1. The case definitions for included atopic and autoimmune conditions. Supplementary table S4.2. Read codes used to identify allergic rhinitis.",
            "latex": null,
            "type": "table"
        },
        "TABREF49": {
            "text": "Page 128 of 214 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.4. Read codes used to identify Ulcerative colitis. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.5. Read codes used to identify Coeliac disease. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.6. Read codes used to identify pernicious anaemia. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.7. Read codes used to identify Hashimoto's thyroiditis. This will be defined as either a code for Hashimoto's thyroiditis or a non-specific code for hypothyroidism and no codes for any non-autoimmune hypothyroidism. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF50": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF51": {
            "text": "Page 136 of 214 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.8. Read codes used to identify Grave's disease. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.9. Read codes used to identify psoriatic arthritis. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.10. Read codes used to identify ankylosing spondylitis. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.11. Read codes used to identify systemic lupus erythematosus. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.12. Read codes used to identify polymyalgia rheumatica. Supplementary table S4.13. Read codes used to identify Sj\u00f6gren's syndrome. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.14. Read codes used to identify psoriasis. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.15. Read codes used to identify vitiligo. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S4.16. Read codes used to identify multiple sclerosis.",
            "latex": null,
            "type": "table"
        },
        "TABREF52": {
            "text": "Page 144 of 214 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF53": {
            "text": "table S5.1. The case definitions for included Upper Respiratory Tract Infections.",
            "latex": null,
            "type": "table"
        },
        "TABREF54": {
            "text": "Page 146 of 214For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF55": {
            "text": "Page 147 of 214For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF56": {
            "text": "Page 148 of 214For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF58": {
            "text": "Page 149 of 214For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF59": {
            "text": "Page 150 of 214 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S5.2. The case definitions for included Lower Respiratory Tract Infections.",
            "latex": null,
            "type": "table"
        },
        "TABREF60": {
            "text": "Page 152 of 214 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF61": {
            "text": "Page 156 of 214 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S5.3. The case definitions for included Pneumonia and Pneumonitis.",
            "latex": null,
            "type": "table"
        },
        "TABREF62": {
            "text": "Page 158 of 214 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S5.4. The case definitions for included Acute Bronchitis For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF63": {
            "text": "Supplementarytable S5.5. The case definitions for included influenza and cases of influenza-like illness. Supplementary table S5.6. The case definitions for included Skin infections.",
            "latex": null,
            "type": "table"
        },
        "TABREF64": {
            "text": "Supplementarytable S5.8. The case definitions for included Genital infections.",
            "latex": null,
            "type": "table"
        },
        "TABREF65": {
            "text": "Supplementarytable S5.10. The case definitions for included Herpes simplex. Supplementary table S5.11. The case definitions for included Herpes zoster. Magyari AM, Hoffstad O, Jabbar-Lopez ZK, Smeeth L, Williams HC, et al. Development and Validation of an Algorithm to Accurately Identify Atopic Eczema Patients in Primary Care Electronic Health Records from the UK. Journal of For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtmlThe epidemiology, management, and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: Protocol for an observational study series",
            "latex": null,
            "type": "table"
        },
        "TABREF66": {
            "text": "infection, genital infections, gastrointestinal infection, herpes simplex, herpes zoster, meningitis, COVID-19) in people with AA compared with matched controls. The Health Research Authority decision tool classed this a study of usual practice, ethics approval was not required. Study approval was granted by the RCGP RSC Study Approval Committee. Results will be disseminated through peer reviewed publications.",
            "latex": null,
            "type": "table"
        },
        "TABREF67": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF68": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF69": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtmlIt is well-recognised by clinical experts in AA that the condition can have a profound psychological impact and a possible comorbid burden of mental health conditions. A recent USA cross-sectional database study comparing 5,605 patients with AA with matched controls found a higher prevalence of mental health diagnoses in the AA group (32.8% vs 20.0%).(19) In particular, higher rates of 95%CI 1.59-15.35) were observed when compared with controls.(19) These findings concur with previous work and a similar pattern is seen in other countries.(20-23) Recently a British study identified a bi-directional positive association between major depressive disorder and AA.(24) In a sample of over 400,000 participants, major depressive disorder was seen to increase the risk of incident AA by 90% [HR 1.90, 95%CI 1.67-2.15] and AA was found to increase the risk of incident major depressive disorder by 34% [HR 1.34, 95%CI 1.23-1.46].(24) The association of other common mental health conditions with AA however was not assessed.",
            "latex": null,
            "type": "table"
        },
        "TABREF70": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml immunological mechanisms fail to prevent cytotoxic immune attack on cells and antigens present at that site.(25) A number of studies have reported autoimmune conditions to occur more frequently in those with AA than in the general population, however results are conflicting and studies have been limited by potential recruiting, recall and reporting biases.(26) A Taiwanese retrospective cohort study found individuals with AA to have an overall increased risk of developing an autoimmune condition when compared with matched controls (HR 1.86, 95%CI 1.32-2.63). In particular, greater risks of incident systemic lupus erythematosus (SLE) (HR 5.02; 95%CI 2.08-12.51), psoriasis (HR 2.01; 95%CI 1.06-3.83) and rheumatoid arthritis (RA) (HR 1.79; 95%CI 1.07-3.00) were observed.(27) There was no relationship between AA and Hashimoto's thyroiditis or type 1 diabetes (T1DM). A recent systematic review and meta-analysis found AA to be significantly associated with Graves' Disease (OR 2.07, 95%CI 1.80-2.38) and Hashimoto's Thyroiditis (OR 2.15; 95%CI 1.71-2.72) but not with SLE, RA, Psoriasis or T1DM.(9)",
            "latex": null,
            "type": "table"
        },
        "TABREF71": {
            "text": "14, 28, 29) A large meta-analysis found patients with AA had higher odds of having atopic dermatitis (OR 2.36; 95%CI 1.80-3.09) or allergic rhinitis (OR 1.33;95%CI 1.19-1.47) when compared with controls.(9) It is not however surprising from a pathogenesis perspective in terms of shared pathways of autoimmune susceptibility; IL-13 loci have been associated with autoimmune and atopic For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open",
            "latex": null,
            "type": "table"
        },
        "TABREF72": {
            "text": "Page 11 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF73": {
            "text": "Page 12 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF74": {
            "text": "Page 13 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF75": {
            "text": "Page 14 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 14 emphasis on \"episode typing\" -designating cases first, new, or ongoing, which helps differentiate incidence from prevalence.(60)",
            "latex": null,
            "type": "table"
        },
        "TABREF76": {
            "text": "2, Additional file 2).For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF77": {
            "text": "Page 17 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF78": {
            "text": "Page 18 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml -fold difference in prevalence (Additional file 1). Excluded autoimmune conditions due to low prevalence are Addison's disease, autoimmune haemolytic anaemia, immune thrombocytopenic purpura, autoimmune hepatitis, systemic sclerosis, myasthenia gravis, and systemic vasculitides.",
            "latex": null,
            "type": "table"
        },
        "TABREF79": {
            "text": "Page 19 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF80": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Study 4 will compare infection incidence in cases and controls up to five years.",
            "latex": null,
            "type": "table"
        },
        "TABREF81": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF82": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF83": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml management are robust and reliable, and the \"episode typing\" functionality of the RCGP RSC database will ensure incident and prevalent cases are appropriately assigned. The RCGP RSC database has been shown to be a representative sample of the UK population (53) and hence our results are broadly generalisable to the UK as a whole but should not be extended to populations which are dissimilar.There are also other several limitations of the study design that are worthy of consideration. Whilst a previous study has shown the ethnic breakdown in primary care data is similar to the UK census and suitable for research,(71) 86% of people in the UK are from white ethnic groups, limiting power to evaluate people of nonwhite ethnicity despite the large sample size. Findings may not be generalisable to countries with a substantially different ethnicity mix to the UK. This study does not attempt to detect cases of AA (or the comorbidities of interest) that do not present to medical attention and hence may underestimate the true burden of disease.",
            "latex": null,
            "type": "table"
        },
        "TABREF84": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 25 estimate unemployment prevalence but is likely to be suitable for providing a comparison with controls.",
            "latex": null,
            "type": "table"
        },
        "TABREF85": {
            "text": "Study approval has been granted by the RCGP RSC Study Approval Committee. The study does not require formal research ethics committee (REC) approval as it will use anonymised routinely collected healthcare data; as defined by the NHS Health",
            "latex": null,
            "type": "table"
        },
        "TABREF87": {
            "text": "is Director of RCGP RSC, he has received funding for projects from Eli Lilly, Astra Zeneca, GSK, Seqirus and Takeda -all through his Universities and none related to this study. WSC and WRG are employees of Pfizer Ltd. SH and CT are investigators on the Pfizer funded Allegro clinical trial. AEM, ART, CT, MH and AGM declare that they have no competing interests.",
            "latex": null,
            "type": "table"
        },
        "TABREF89": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Mammarella A, Basili S, Paradiso M, Di Franco M, De Matteis A, et al. Prevalence and clinical features of skin diseases in chronic HCV infection. A prospective study in 96 patients. Panminerva medica. 2002;44(4):349-52. 38. Richardson CT, Hayden MS, Gilmore ES, Poligone B. Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. American journal of clinical dermatology. Qiao SW, Chow IT, et al. Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense. J Immunol. 2019;202(9):2558-69.44. Zhernakova A, Elbers CC, Ferwerda B, Romanos J, Trynka G, Dubois PC, et al. Evolutionary and functional analysis of celiac risk loci reveals SH2B3 as a protective factor against bacterial infection. Am J Hum Genet. Bitton A, Suissa A, Sinyavskaya L, Patenaude V, Suissa S. Oral Corticosteroids and the Risk of Serious Infections in Patients With Elderly-Onset Inflammatory Bowel Diseases. The American Journal Of Gastroenterology. 2014;109:1795. 48. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. The American journal of Haematological abnormalities in new-onset rheumatoid arthritis and risk of common infections: a population-based study. Rheumatology. 2019. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Prognostic value of comorbidity indices and lung diseases in early rheumatoid arthritis: a UK population-based study. Rheumatology. 2019. 58. de Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, et al. Epidemiology and management of atopic dermatitis in England: an observational cohort study protocol. BMJ Open. 2020;10(9):e037518. 59. Galloway J, Barrett K, Irving P, Khavandi K, Nijher M, Nicholson R, et al. Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. RMD Open. Uptake of a Dashboard Designed to Give Realtime Feedback to a Sentinel Network About Key Data Required for Influenza Vaccine Effectiveness Studies. Stud Health Technol Inform. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. Bmj. 2018;360:k342. 74. Behr MA, Divangahi M, Lalande J-D. What's in a name? The (mis)labelling of Crohn's as an autoimmune disease. The Lancet. 2010;376(9736):202-3. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml The autoimmune and atopic conditions to be explored. For full definitions see Supplementary Tables S4.1 -S4.16, Additional file 2 All infections of the upper respiratory tract including rhinitis, pharyngitis, sinusitis, and the common cold Lower respiratory tract infection All infection of the lower respiratory tract including pneumonia and acute bronchitis. Dr Matthew Harries, Dr Abby E. Macbeth, Dr Susan Holmes, Professor Andrew R Thompson, Dr Wing Sin Chiu, Dr William Romero Gallardo, Professor Andrew G Messenger, Dr Christos Tziotzios, Professor Simon de Lusignan For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Contents List of abbreviations ...",
            "latex": null,
            "type": "table"
        },
        "TABREF93": {
            "text": "Describe the epidemiology of AA: Incidence of AA over time and by age, sex, ethnicity, and sociodemographic factors, and point prevalence by age and sex.",
            "latex": null,
            "type": "table"
        },
        "TABREF97": {
            "text": "Diagnosis of AA is the date of the first diagnosis code in the record and no alternative diagnosis that merits exclusion* diagnosed in the subsequent 365 days from date of AA diagnosis (seeSupplementary Table S1.1, Additional file 2).",
            "latex": null,
            "type": "table"
        },
        "TABREF98": {
            "text": "Primary",
            "latex": null,
            "type": "table"
        },
        "TABREF138": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF139": {
            "text": "Page 110 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF140": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF141": {
            "text": "Page 112 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF142": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF143": {
            "text": "[X]Intentional self poisoning by and exposure to psychotropic drugs, occurrence at homeU2041 All [X]Intentional self poisoning by and exposure to psychotropic drugs, occurrence in residential institution U2042 All [X]Intentional self poisoning by and exposure to psychotropic drugs, occurrence at school, other institution and public administrative area U2043 All [X]Intentional self poisoning by and exposure to psychotropic drugs, occurrence at sports and athletics area U2044 All [X]Intentional self poisoning by and exposure to psychotropic drugs, occurrence on street and highway U2045 All [X]Intentional self poisoning by and exposure to psychotropic drugs, occurrence at trade and service area U2046 All [X]Intentional self poisoning by and exposure to psychotropic drugs, occurrence at industrial and construction area For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF144": {
            "text": "Intentional self poisoning by and exposure to sedative hypnotics, occurrence at school, other institution and public administrative area U2023 All [X]Intentional self poisoning by and exposure to sedative hypnotics, occurrence at sports and athletics area U2024 All [X]Intentional self poisoning by and exposure to sedative hypnotics, occurrence on street and highway U2025 All [X]Intentional self poisoning by and exposure to sedative hypnotics, occurrence at trade and service area U2026 All [X]Intentional self poisoning by and exposure to sedative hypnotics, occurrence at industrial and construction area For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF145": {
            "text": "Page 116 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF146": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF147": {
            "text": "Page 118 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF148": {
            "text": "Supplementarytable S2.10. Read codes used to identify non-medication based treatments for depression or anxiety. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF149": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF150": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF151": {
            "text": "Page 122 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF153": {
            "text": "table S3.1. Read codes used to identify unemployment. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF154": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF155": {
            "text": "Supplementarytable S3.2. Read codes used to identify time off work via the issuing of Med 3 (\"fit notes\") certificates. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF156": {
            "text": "Definitions of atopic and autoimmune conditions w ith R ead code lists.table S4.1. The case definitions for included atopic and autoimmune conditions. Crohn's disease A diagnosis code for Crohn's and no conflicting code for ulcerative colitis (where conflicted codes occur the most recent diagnosis code is used to define the condition) (Supplementary table S4.3) Ulcerative colitis A diagnosis code for ulcerative colitis and no conflicting code for Crohn's disease (where conflicted codes occur the most recent diagnosis code is used to define the condition) (Supplementary table S4.4) Coeliac disease A diagnosis code for Coeliac disease (Supplementary table S4.5) Pernicious anaemia A diagnosis code for pernicious anaemia (Supplementary table S4.6) Endocrine conditions Type 1 diabetes Defined using the RCGP RSC diabetes type algorithm(3) Hashimoto's thyroiditis Either: \u2022 A code for Hashimoto's thyroiditis (Supplementary table S4.7) OR \u2022 A code for \"non-specific hypothyroidism\" AND no code for \"non-autoimmune hypothyroidism\" Grave's disease A diagnosis code for Grave's disease (Supplementary table S4.8) Rheumatological conditions Rheumatoid arthritis Defined using the validated algorithm by Muller et al. (2015)(4) Psoriatic arthritis A diagnosis code for psoriatic arthritis (Supplementary table S4.9) Ankylosing spondylitis A diagnosis code for ankylosing spondylitis (Supplementary table S4.10) Systemic lupus erythematosus A diagnosis code for systemic lupus erythematosus (Supplementary table S4.11) Polymyalgia rheumatica A diagnosis code for polymyalgia rheumatica (Supplementary table S4.12) Sj\u00f6gren's syndrome A diagnosis code for Sj\u00f6gren's syndrome (Supplementary table S4.13) Dermatological conditions Psoriasis A diagnosis code for psoriasis (Supplementary table S4.14) Vitiligo A diagnosis code for vitiligo (Supplementary table S4.15) For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF157": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF158": {
            "text": "Supplementary table S4.5. Read codes used to identify Coeliac disease.For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF159": {
            "text": "Supplementarytable S4.6. Read codes used to identify pernicious anaemia. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF160": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF161": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF162": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF164": {
            "text": "Page 137 of 215For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF165": {
            "text": "Supplementarytable S4.8. Read codes used to identify Grave's disease. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF166": {
            "text": "Supplementarytable S4.9. Read codes used to identify psoriatic arthritis. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF167": {
            "text": "Supplementarytable S4.10. Read codes used to identify ankylosing spondylitis. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF168": {
            "text": "Supplementarytable S4.11. Read codes used to identify systemic lupus erythematosus. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF169": {
            "text": "Supplementarytable S4.12. Read codes used to identify polymyalgia rheumatica. Supplementary table S4.13. Read codes used to identify Sj\u00f6gren's syndrome. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF170": {
            "text": "Supplementarytable S4.15. Read codes used to identify vitiligo. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF171": {
            "text": "Supplementarytable S4.16. Read codes used to identify multiple sclerosis. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF172": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF174": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF175": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF176": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF177": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF178": {
            "text": "For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Read CTV3 Code Term ID Description For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Dermatophytosis of the body) or (herpes circinatus) or (tinea corporis) For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF179": {
            "text": "Skin area excluding digits of hand or foot: [abscess] or [acute lymphangitis of skin] or [cellulitis]) or (other cellulitis and abscess) M030. For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Infection: [toe] or [foot] or [finger] or [other specified local infection of skin and subcutaneous tissue NOS] M07z. All (Septic spots) or (sinus) or (infected skin: [insect bite] or [ulcer] or [dermatitis] or [local infection skin/subcutaneous tissue NOS]) Cellulitis: [of thumb] or [[X] of finger and toe]) or (nail bed infection) or For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Abscess of other site M0y.. All Other specified infections of skin or subcutaneous tissue M0z.. All Infected: [sebaceous cyst] or [skin and subcut tissue NOS] For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF180": {
            "text": "Page 188 of 215 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        },
        "TABREF181": {
            "text": "[X]Cellulitis of finger and toe XE1AlAll Skin and subcut tissue infection NOS",
            "latex": null,
            "type": "table"
        },
        "TABREF182": {
            "text": "Page 191 of 215 For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml Supplementary table S5.12. The case definitions for included Meningitis. Herpes zoster For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "All Seasonal allergic rhinitis XE2QI All Allergic rhinitis due to pollens Hyu20All [X]Other seasonal allergic rhinitis X00l8All Hay fever -other allergen X00l9All Hay fever -unspecified allergen X1020All Hay fever with asthma X00lAAll Perennial allergic rhinitis X00lBAll Perennial allergic rhinitis with seasonal variation H17z.All Allergic rhinitis NOS Hyu21All ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Supplementary"
        },
        {
            "text": "Term ID Description J40.. All Regional enteritis-Crohn's disease J400.All Regional enteritis of the small bowel J4000All Regional enteritis of the duodenum J4001All Regional enteritis of the jejunum J4002 All Crohn's disease of the termnal ileum J4003 All Crohn's disease of the ileum unspecified J4004 All Crohn's disease of the ileum NOS J4005All Exacerbation of Crohn's disease of small intestine J400zAll Crohn's disease of the small bowel NOS J40.. All Crohn's disease J4010All Regional enteritis of the colon J4011All Regional enteritis of the rectum J4012All Exacerbation of Crohn's disease of large intestine J401zAll Crohn's disease of the largel bowel NOS J40z.All Crohn's disease NOS Read CTV3 CodeAll Crohn's disease Xa0lhAll Regional enteritis X302rAll Crohn's jejunitis X302tAll Crohn's ileitis J4003 All Crohn's disease of the ileum unspecified J4004 All Crohn's disease of the ileum NOS J4002 All Crohn's disease of terminal ileum J400.All Regional enteritis of small bowel XaK6CAll Exacerbation of Crohn's disease of small intestine J400zAll Crohn's disease of the small bowel NOS J401.All Regional enteritis of the large bowel XE0afAll Crohn's disease of the large bowel NOS XaK6DAll Exacerbation of Crohn's disease of large intestine J40z.All Regional enteritis NOS J4010 All Crohn's colitis J4011 All Crohn's proctitis X3050All Perianal Crohn's disease Jyu40All [X]Other Crohn's disease J4001Y30FyRegional enteritis of the jejunum All Acute non suppurative otitis media F5100All Acute otitis media with effusion F5101All Acute serous otitis media F5102All Acute mucoid otitis media F5103All Acute sanguinous otitis media F5104All Acute allergic serous otitis media F5105All Acute allergic mucoid otitis media F5106All Acute allergic sanguinous otitis media F510zAll Acute nonsuppurative otitis media NOS F52..All Suppurative and unspecified otitis media F520.All Acute suppurative otitis media F5200All Acute suppurative otitis media tympanic membrane intact F5201All Acute suppurative otitis media tympanic membrane ruptured F5203All Acute suppurative otitis media due to disease EC F520zAll Acute suppurative otitis media NOS F526.All Acute left otitis media F527.All Acute right otitis media F528.All Acute bilateral otitis media F52z.All Otitis media NOS H00..All Acute nasopharyngitis H01.. All Acute sinusitis H010.All Acute maxillary sinusitis H011.All Acute frontal sinusitis H012.All Acute ethmoidal sinusitis H013.All Acute sphenoidal sinusitis H014.All Acute rhinosinusitis H01y.All Other acute sinusitis H01y0All Acute pansinusitis H01yzAll Other acute sinusitis NOS H01z.All Acute sinusitis NOS H02.. All Acute pharyngitis H020.All Acute gangrenous pharyngitis H021.All Acute phlegmonous pharyngitis H022.All Acute ulcerative pharyngitis H023. All Acute bacterial pharyngitis H0230All Acute pneumococcal pharyngitis H0231All Acute staphylococcal pharyngitis H023zAll Acute bacterial pharyngitis NOS H024.All Acute viral pharyngitis H025.All Allergic pharyngitis H02z.All Acute pharyngitis NOS H03..All Acute tonsillitis H030.All Acute erythematous tonsillitis H031.All Acute follicular tonsillitis H032.All Acute ulcerative tonsillitis H033.All Acute catarrhal tonsillitis H034.All Acute gangrenous tonsillitis H035.All Acute bacterial tonsillitis H0350All Acute pneumococcal tonsillitis H0351All Acute staphylococcal tonsillitis H035zAll Acute bacterial tonsillitis NOS H036.All Acute viral tonsillitis H037.All Recurrent acute tonsillitis H03z.All Acute tonsillitis NOS H04..All Acute laryngitis and tracheitis H040.All Acute laryngitis H0400All Acute oedematous laryngitis H0401All Acute ulcerative laryngitis H0402All Acute catarrhal laryngitis H0403All Acute phlegmonous laryngitis H0404All Acute haemophilus influenzae laryngitis H0405All Acute pneumococcal laryngitis H0406All Acute suppurative laryngitis H040wAll Acute viral laryngitis unspecified H040xAll Acute bacterial laryngitis unspecified H040zAll Acute laryngitis NOS H041.All Acute tracheitis H0410All Acute tracheitis without obstruction H0411All Acute tracheitis with obstruction H041zAll Acute tracheitis NOS H042.All Acute laryngotracheitis H0420All Acute laryngotracheitis without obstruction H0421All Acute laryngotracheitis with obstruction H042zAll Acute laryngotracheitis NOS H043.All Acute epiglottitis (non strep) H0430All Acute epiglottitis without obstruction H0431 All Acute epiglottitis with obstruction H0432All Acute obstructive laryngitis H043zAll Acute epiglottitis NOS H044.All Croup H04z.All Acute laryngitis and tracheitis NOS H05..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "Other acute upper respiratory infections H050.All Acute laryngopharyngitis H051.All Acute upper respiratory tract infection H052.All Pharyngotracheitis H053.All Tracheopharyngitis H054.All Recurrent upper respiratory tract infection H055.All Pharyngolaryngitis H05y.All Other upper respiratory infections of multiple sites H05z.All Upper respiratory infection NOS H0y..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "Other specified acute respiratory infections H0z..All Acute respiratory infection NOS Read CTV3 Code Term ID Description",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "All Streptococcal laryngitis A3403All Streptococcal tonsillitis A740.All Herpangina AA12.All Vincent's angina -pharyngitis F51..All Non-suppurative otitis media with eustachian tube disorders F510.All Acute non-suppurative otitis media F5100All Acute otitis media: [with effusion] or [secretory] F5101All Acute non-suppurative otitis media -serous F5102All Acute non-suppurative otitis media -mucoid F5103All Acute non-suppurative otitis media -sanguinous F5104All Acute allergic serous otitis media F5105All Acute allergic mucoid otitis media F5106All Acute allergic sanguinous otitis media F510zAll Acute non-suppurative otitis media NOS F52..All Suppurative and unspecified otitis media F520.All Acute suppurative otitis media F5200All Acute suppurative otitis media -tympanic membrane intact F5201All Acute suppurative otitis media -tympanic membrane ruptured F5203All Acute suppurative otitis media due to disease EC F520zAll Acute suppurative otitis media NOS F526.All Acute left otitis media F527.All Acute right otitis media F528.All Acute bilateral otitis media F52z.All Ear infection &/or otitis media NOS FyuP0All [X]Other acute non-suppurative otitis media H00.. All (Acute nasopharyngitis or rhinitis) or (common cold) H01.. All Sinusitis (& acute) H010.All Acute maxillary sinusitis H011.All Acute frontal sinusitis H012.All Acute ethmoidal sinusitis H013.All Acute sphenoidal sinusitis H014.All NULL H01y.All Other acute sinusitis H01y0All Acute pansinusitis H01yzAll Other acute sinusitis NOS H01z.All Acute sinusitis NOS H02.. All Acute gangrenous pharyngitis H021.All Acute phlegmonous pharyngitis H022.All Acute ulcerative pharyngitis H023.All Acute bacterial pharyngitis H0230All Acute pneumococcal pharyngitis H0231All Acute staphylococcal pharyngitis H023zAll Acute bacterial pharyngitis NOS H024.All Acute viral pharyngitis H025.All Allergic pharyngitis H02z.All Acute pharyngitis NOS H03..All Tonsillitis (& acute) H030.All Acute erythematous tonsillitis H031.All Acute follicular tonsillitis H032.All Acute ulcerative tonsillitis H033.All Acute catarrhal tonsillitis H034.All Acute gangrenous tonsillitis H035.All Acute bacterial tonsillitis H0350All Acute pneumococcal tonsillitis H0351All Acute staphylococcal tonsillitis H035zAll Acute bacterial tonsillitis NOS H036.All Acute viral tonsillitis H037.All Recurrent acute tonsillitis H03z.All Acute tonsillitis NOS H04..All NULL H040.All Acute laryngitis H0400All Acute oedematous laryngitis H0401All Acute ulcerative laryngitis H0402All Acute catarrhal laryngitis H0403All Acute phlegmonous laryngitis H0404All Acute haemophilus influenzae laryngitis H0405All Acute pneumococcal laryngitis H0406 All Acute suppurative laryngitis H040wAll Acute viral laryngitis unspecified H040xAll Acute bacterial laryngitis unspecified H040zAll Acute laryngitis NOS H041.All Acute tracheitis H0410All Acute tracheitis without obstruction H0411All Acute tracheitis with obstruction H041zAll Acute tracheitis NOS H042.All Laryngotracheitis (& acute) H0420All Acute laryngotracheitis without obstruction H0421All Acute laryngotracheitis with obstruction H042zAll Acute laryngotracheitis NOS H043.All Epiglottitis: [viral] or [acute non streptococcal] H0430All Acute epiglottitis without obstruction H0431All Acute epiglottitis with obstruction H0432All NULL H043zAll Acute epiglottitis NOS H044.All NULL H04z.All Acute laryngitis and tracheitis NOS H05..",
            "cite_spans": [
                {
                    "start": 3173,
                    "end": 3180,
                    "text": "[viral]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "A3401"
        },
        {
            "text": "Other acute upper respiratory infections H050.All Acute laryngopharyngitis H051.All NULL H052.All NULL H053.All Tracheopharyngitis H054.All Recurrent upper respiratory tract infection H055.All Pharyngolaryngitis H05y.All Other upper respiratory infections of multiple sites H05z.All Upper respiratory tract infection (& viral) NOS H0y..",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "Other specified acute respiratory infections H0z..All Acute respiratory infection NOS X00iqAll Recurrent acute suppurative otitis media X00m1All Pott's puffy tumour X00mHAll Acute herpes simplex pharyngitis X00mIAll Acute herpes zoster pharyngitis X00mJAll Enteroviral lymphonodular pharyngitis X00mLAll Glandular fever pharyngitis X00mqAll Vincent's tonsillitis X00n1All Acute simple laryngitis X00n2All Vincent's laryngitis X00n4All Acute membranous laryngitis X00n5All Acute subglottic laryngitis X00n6All Recurrent allergic croup",
            "cite_spans": [],
            "ref_spans": [],
            "section": "All"
        },
        {
            "text": "Tract Infections.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Supplementary table S5.2. The case definitions for included Lower Respiratory"
        },
        {
            "text": "Term ID Description H20.. All Viral pneumonia H200.All Pneumonia due to adenovirus H201.All Pneumonia due to respiratory syncytial virus H202.All Pneumonia due to parainfluenza virus H203.All Pneumonia due to human metapneumovirus H20y.All Viral pneumonia NEC H20y0All Severe acute respiratory syndrome H20z.All Viral pneumonia NOS H21.. All Lobar (pneumococcal) pneumonia H22.. All Other bacterial pneumonia H220.All Pneumonia due to klebsiella pneumoniae H221.All Pneumonia due to pseudomonas H222.All Pneumonia due to haemophilus influenzae H223.All Pneumonia due to streptococcus H2230All Pneumonia due to streptococcus, group B H224.All Pneumonia due to staphylococcus H22y.All Pneumonia due to other specified bacteria H22y0All Pneumonia due to escherichia coli H22y1All Pneumonia due to proteus H22y2All Pneumonia -Legionella H22y3All Pneumonia due to Gram negative bacteria H22yXAll Pneumonia due to other aerobic gram-negative bacteria H22yzAll Pneumonia due to bacteria NOS H22z.All Bacterial pneumonia NOS H23.. All Pneumonia due to other specified organisms H230.All Pneumonia due to Eaton's agent H231.All Pneumonia due to mycoplasma pneumoniae H232.All Pneumonia due to pleuropneumonia like organisms H233.All Chlamydial pneumonia H23z.All Pneumonia due to specified organism NOS H24.. All Pneumonia with infectious diseases EC H240.All Pneumonia with measles H241.All Pneumonia with cytomegalic inclusion disease H242.All Pneumonia with ornithosis H243.All Pneumonia with whooping cough H244.All Pneumonia with tularaemia H245.All Pneumonia with anthrax H246.All Pneumonia with aspergillosis All NULL H22yXAll NULL H22yzAll Pneumonia due to bacteria NOS H22z.All Bacterial pneumonia NOS H23..All Pneumonia due to other specified organisms H230.All NULL H231.All NULL H232.All Pneumonia due to pleuropneumonia-like organism H233.All NULL H23z.All ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        },
        {
            "text": "Term ID Description H20.. All Viral pneumonia H200.All Pneumonia due to adenovirus H201.All Pneumonia due to respiratory syncytial virus H202.All Pneumonia due to parainfluenza virus H203.All Pneumonia due to human metapneumovirus H20y.All Viral pneumonia NEC H20y0All Severe acute respiratory syndrome H20z.All Viral pneumonia NOS H21.. All Lobar (pneumococcal) pneumonia H22.. All Other bacterial pneumonia H220.All Pneumonia due to klebsiella pneumoniae H221.All Pneumonia due to pseudomonas H222.All Pneumonia due to haemophilus influenzae H223.All Pneumonia due to streptococcus H2230All Pneumonia due to streptococcus, group B H224.All Pneumonia due to staphylococcus H22y.All Pneumonia due to other specified bacteria H22y0All Pneumonia due to escherichia coli H22y1All Pneumonia due to proteus H22y2All Pneumonia -Legionella H22y3All Pneumonia due to Gram negative bacteria H22yXAll Pneumonia due to other aerobic gram-negative bacteria H22yzAll Pneumonia due to bacteria NOS H22z.All Bacterial pneumonia NOS H23.. All Pneumonia due to other specified organisms H230.All Pneumonia due to Eaton's agent H231.All Pneumonia due to mycoplasma pneumoniae H232.All Pneumonia due to pleuropneumonia like organisms H233.All Chlamydial pneumonia H23z.All Pneumonia due to specified organism NOS H24.. All Pneumonia with infectious diseases EC H240.All Pneumonia with measles H241.All Pneumonia with cytomegalic inclusion disease H242.All Pneumonia with ornithosis H243.All Pneumonia with whooping cough H244.All Pneumonia with tularaemia H245.All Pneumonia with anthrax H246.All Pneumonia with aspergillosis H247.All All Cellulitis of hand excluding finger Xa3gGAll Cellulitis of leg, excluding foot Xa3gHAll Cellulitis of foot excluding toe Xa40bAll Cellulitis -digit NOS Xa6qCAll Perineal wart Xa6qDAll Female perineal wart Xa7HtAll Cellulitis of heel Xa7HwAll Axillary abscess Xa7I2All Periorbital cellulitis Xa7lcAll Infected nail bed Xa7ldAll Cellulitis of scalp Xa7lvAll Infected face Xa7lzAll Infected heel Xa7m0All Infected thumb Xa7m3All Septic finger Xa7m4All Infected hand Xa7nfAll Intertrigo of abdominal skin fold Xa7NiAll Infection toe Xa7NjAll Infection foot Xa7NkAll Infection finger Xa7ywAll Abscess of finger Xa82gAll Perineal abscess Xa83lAll Cellulitis of elbow Xa83mAll Abscess of elbow Xa83WAll Abscess of foot Xa85WAll All Cholera -Vibrio cholerae A001.All Cholera -Vibrio cholerae El Tor A00z.All Cholera NOS A01.. All Typhoid and paratyphoid fevers A010.All Typhoid fever A011.All Paratyphoid fever A A012.All Paratyphoid fever B A013.All Paratyphoid fever C A01z.All Paratyphoid fever NOS A02.. All Other salmonella infections A020.All Salmonella gastroenteritis A021.All Salmonella septicaemia A022.All Localised salmonella infection A0220All Local salmonella infection unspecified A0221All Salmonella meningitis A0222 All Salmonella pneumonia A0223 All Salmonella arthritis A0224 All Salmonella osteomyelitis A022zAll Other local salmonella infection A023.All Salmonella sepsis A02y.All Other specified salmonella infection A02z.All Salmonella infection NOS A03.. All Shigellosis A030.All Shigella dysenteriae (group A) A031.All Shigella flexneri (group B) A032.All Shigella boydii (group C) A033.All Shigella sonnei (group D) A03y.All Other specified shigella infection A03z.All Shigellosis NOS A04.. All Other bacterial food poisoning A040.All Staphylococcal food poisoning A041.All Botulism A042.All Clostridium perfringens food poisoning A043.All Other clostridia causing food poisoning A044.All Vibrio parahaemolyticus food poisoning A04y.All Other specified bacterial food poisoning A04y0 All Foodborne Bacillus cereus intoxication A04z.All Food poisoning NOS A05.. All Amoebiasis A050.All Acute amoebic dysentery A051.All Chronic intestinal amoebiasis A052.All Amoebic nondysenteric colitis A053.All Amoebic liver abscess A054.All Amoebic lung abscess A055.All Amoebic brain abscess A056.All Amoebic skin ulceration A05y.All Amoebic infection of other sites A05y0All Amoebic appendicitis A05y1All Amoebic balanitis A05y2All Amoeboma A05yzAll Amoebic infection of other sites NOS A05z.All All Ophthalmic herpes simplex NOS A545.All Herpes simplex septicaemia A546.All Herpes simplex whitlow A548.All NULL A54x.All Herpes simplex with other specified complication A54x0All Visceral herpes simplex A54x1All NULL A54x2All NULL A54x3All Herpesviral vesicular dermatitis A54x4All NULL A54xzAll Herpes simplex with other specified complication NOS A54y.All Herpes simplex with unspecified complication A54z. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Read V2 Code"
        }
    ]
}